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Why do some patients, who should survive their breast 
cancer, die from their disease? 
 
 
This question was posed by my consultant during a breast review clinic. Our current 
knowledge of predictive markers and prognostic indexes go some way to stratify 
patients into groups of likely outcome but there are always patients who “buck the 
trend,” the patient who doesn’t follow the prediction. This patient is an indication that, 
despite our predictive models some tumours do not behave in the way we expect; 
small tumours sometimes metastasise, low grade tumours sometime recur and some 
estrogen receptor (ER) positive tumours don’t respond to endocrine therapy. This 
clinical problem raised the question behind this study. Could we identify certain 
biological markers in breast cancer samples that would improve our stratification of 
those tumours?  
 
The fact that some ER positive cancers do not respond to endocrine therapy suggests 
that other proliferative pathways are driving that tumour’s growth. The end points of 
these pathways are the DNA transcription factors. Some of these transcription factors 
have been shown to have a role in increased proliferation of cancer cells. It was for 
this reason that the transcription factors STAT3, SP1 and NFKB were selected for 
further study in my research work.       
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Abstract of submitted thesis.  
Title: A Study of Transcription Factors STAT3, SP1 and NFkB in Breast Cancer. 
 
Supervisors: Dr B. Shenton, Mr D Browell, Professor T Lennard. 
 
Background and Aims: Breast cancer is the second most common cause of cancer 
deaths in women. It is a tumour which has been extensively studied at a molecular 
level and, compared to other solid tissue tumours, our understanding of its biology is 
extensive. There are however some patients who are considered to have good 
prognostic feature of their tumours who go on to die from their disease.  
 
Transcription factors are the end point of many cell signalling pathways. They form 
the link between exogenous hormones and growth factors and DNA transcription. For 
the purpose of this study 3 different transcription factors have been selected for 
investigation.  
 
STAT3 is activated by various growth factors and cytokines including EGF. It is 
classified as an oncoprotein as its activation can mediate tumorgenisis in nude mice. 
STAT3 has been shown to confer resistance to apoptosis in breast cancer cells and it 
is associated with poor outcome in high risk breast cancers. SP1 is a transcription 
factor which is essential in the expression and the action of estrogen receptors (ER). It 
is known to be over expressed in other solid tissue tumours but there has been little 
work into its role in breast cancer. NFkB is activated in many cell survival settings. It 
is involved in the transcription of anti-apoptotic genes and also plays a role in cell 
proliferation, angiogenisis and cell adhesion. It is associated in breast cancers with an 
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over expression of the oncogene Bcl-2. It has not been show to be a marker of 
prognosis but does appear to identify breast cancers with a poor response to 
chemotherapy.    
 
The aim of this study is to investigate the role of these transcription factors in the 
behaviour of breast cancers and the outcome of the disease. It will also investigate the 
affect of EGF and estogen stimulation on STAT3 activation in breast cancer cell lines.  
 
Methods: This study consists of 2 elements. Firstly an assessment of transcription 
factor expression in breast cancer samples and secondly a cell model experiment to 
investigate the stimulation of STAT3 activation.  
 
A cohort of 213 patients who presented to the Queen Elizabeth Hospital with invasive 
breast cancer in 1999 was selected. Tumour samples from these patients were 
retrieved and using immunohistochemistry were tested for the expression of STAT3, 
SP1 and NFkB. These results were then correlated with pathological features of the 
tumours, tumour receptor status (ER, PR HER2 and EGFR) and outcome of the 
disease.    
 
Two cell lines, MCF7 and SKBr3, were cultured in depleted medium. These cells 
were then stimulated with estrogen and EGF alone and in combination. Flow-
cytometry was then used to quantify the levels of phosphorylated STAT3 in the 2 cell 
lines over a 3 day time course. The level of phosphorylation was then compared to the 
control lines to asses the effect of stimulation.  
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Results: 209 breast cancers were successfully analysed for the expression of STAT3, 
27% of these cancers expressed nuclear STAT3. The results demonstrated a 
significant correlation of STAT3 expression with cancers of a high grade (p=<0.001), 
increasing tumour size (p=0.004), vessel space invasion (p=0.034) and lymph node 
metastases (p=0.015). STAT3 expression was shown to be significantly correlated to 
high Nottingham prognostic index (NPI) scores. With regards to receptor status it was 
show that STAT3 expression was significantly associated with ER negative and PR 
negative cancers (p=0.003), whereas there was no relationship with HER2 status. The 
results did show that there was a significant relationship between STAT3 expression 
and EGFR positive cancers (p=0.007). When disease outcome was investigated it was 
shown that there was a trend towards improved survival in the STAT3 negative group 
and a significant relationship between STAT3 expression and disease recurrence at 5 
years (p=0.04).  
 
SP1 expression was determined in 208 of the cancer samples with 33% of the tumours 
having strong nuclear staining. There was no significant relationship between SP1 
expression and any of the pathological features mentioned. SP1 expression was 
related to ER positive tumours (p=0.015). Though there was no relationship with 5 
year survival it appears that SP1 expression does reduce the risk of late (>2yr) disease 
recurrence (p=0.005).  
 
NFkB was over expressed in 15% of the 208 cancers samples. Again a significant 
correlation was shown with high grade tumours (p=0.001) and large tumours 
(p=0.014). NFkB expression was also shown to be more prevalent in ER negative 
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cancers (p=0.006) and EGFR positive tumours (p=0.007). There was no significant 
relationship between NFkB expression and disease outcome.  
 
The cell model results showed that in the EGFR positive ER negative cell line 
(SKBr3), EGF stimulation resulted in a biphasic response of STAT3 phosphorylation, 
whereas estrogen had no effect on phosphorylation. In the ER positive MCF7 cells, 
which express low levels of EGFR, again EGF stimulation resulted in a biphasic 
response curve. Estrogen stimulation does cause an increase in activation but when 
estrogen is added to EGF stimulation there is an inhibition of STAT3 
phosphorylation. 
 
Conclusions: This study has demonstrated that STAT3 and SP1 expression is 
important in disease outcome in breast cancer patients. Though there are differences 
in levels of expression, NFkB does not appear to have a role in breast cancer outcome. 
The cell model has show that EGF stimulation of EGFR positive cell lines results in 
increased STAT3 activation and also that this effect is inhibited by the addition of 
estrogen stimulation.  
 
These results raise important questions which are discussed in the study and suggest 
areas for further investigation.   
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1 Introduction. 
In the introduction of this thesis both the subject of breast cancer as a disease and on 
the endocrine aspects of breast cancer and its relevance to current therapies will be 
discussed. The subject the of the transcription factors STAT3, SP1 and NFKB will be 
introduced with a review of the current understanding of their role in breast cancer.  
1.1. An Introduction to Breast Cancer. 
This section is written as a background of breast cancer as a disease. It will review the 
anatomy and functional physiology of the breast and give a historical perspective of 
our changing understanding of breast cancer. It will then go on to outline the 
histological basis of breast cancer and its staging. The section will finish with a 
review of the current epidemiology of breast cancer and its aetiology.  
1.1.1 The gross and functional anatomy of the breast. 
The class of Mammalia is distinguished from other animals by the possession of 
mammae, breasts. These glands evolved for the feeding of offspring by the production 
of milk, termed lactation. Though only functional in the female sex they are present in 
a rudimentary form in the male. In the adult female the breast lies within the 
superficial fascia on the anterior chest wall. The base of the breast is attached to the 
chest wall longitudinally from the 2
nd
 or 3
rd
 rib to the 6
th
 rib. In the transverse plane it 
extends from the sternal edge to almost the mid axillary line. The superolateral 
quadrant of the breast extends towards the axilla (the axillary tail of Spence.) The 
arterial blood supply to the breast arises from the axillary artery suppling blood to the 
breast via the superior thoracic, the pectoral branch of the thoraco-acromial artery, the 
lateral thoracic and the subscapular arteries. The internal thoracic artery gives 
perforating branches to the anterior medial portion of the breast. There are also 
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perforating branches more laterally from the 2
nd
 to 4
th
 intercostal arteries. The venous 
drainage predominantly follows the arterial supply. The lymphatic drainage of the 
breast is much more variable. From a subareolar plexus there are lymphatic vessels 
draining to the following regions; the contra lateral breast, the internal mammary 
chain and the ipsilateral axilla. The axilla is the predominant site of lymphatic 
drainage. There are usually between 20 and 40 nodes in the axilla and these may be 
grouped into level 1 nodes, below pectoralis minor muscle, level 2 nodes, behind 
pectoralis minor and level 3 or apical nodes which are between pectoralis minor and 
the clavicle.(Grey, 1999) 
 
The substance of the breast is composed of epithelial glandular tissue, fibrous 
connective tissue (stroma) surrounding the glandular tissue and interlobular adipose 
tissue.(Cowie, 1974) The glandular tissue of the breast consists of branching ducts 
connecting the terminal secretory lobules to larger lactiferous ducts which in turn end 
with an opening on the apex of the nipple. Just prior to this opening the duct dilates 
and forms the lactiferous sinus. Each breast contains 15-25 of these functional units 
(lobes.) The branching ducts eventually form terminal ducts each connected to a 
lobule. The lobule consists of multiple excretory acini. The lobules are separated by 
moderately dense collagenous interlobular tissue, whereas the supporting tissue within 
the lobule, the intralobular tissue, is less collagenous and more vascular. Ducts and 
acini are lined with 2 layers of cells, a luminal layer of epithelia cells and a basal layer 
of myoepithelial cells which rest on a basement membrane. The epithelial cells are 
columnar in the larger ducts and cuboidal in the smaller ducts and acini.(Wheater, 
2000)  
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Fig. 1.1: The gross anatomy of the breast. (courtesy of the breastsite.com)  
 
 
 
 
 
 
 
Fig. 1.2: The breast lobe. (http://www.kbsplit.hr/rakdojke/images/fig9.) 
 
The embryological origins of the breasts develop in the 4
th
 week of gestation as a pair 
of epidermal thickenings, mammary ridges. These run from the axilla to the inguinal 
region as what are known as the milk lines. These lines usually disappear apart from a 
remnant on the anterior chest wall which becomes the primary bud of the mammary 
gland by the 5
th
 week. This primary bud grows down into the dermis beginning to 
branch by the 12
th
 week forming several secondary buds. During the rest of gestation 
these buds lengthen, branch and canalize forming the 15-25 lactiferous ducts opening 
at the nipple. It is not unusual for more than one nipple to be formed along the milk 
line (polythelia,) due to accessory remnants of the mammary ridge. (Larsen, 2001)  
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Fig. 1.3: The mammary ridge line. http://www.kbsplit.hr/rakdojke/images/fig1. 
 
 
The next stage in breast development in the female commences with puberty. There 
are 4 described stages of this pubertal breast development; Stage 1. Breast bud 
elevation, Stage 2. Growth and protrusion of the nipple, Stage 3. Elevation of the 
secondary areolar mound, Stage 4. Regression of the areolar mound to form the 
general breast contour.(Zacharias and Schatzoff, 1970, Rees, 1995)  This development 
is driven by increasing estradiol levels which during the first anovulatory cycles 
induce duct sprouting, and branching. Estrogen also stimulates the connective tissue 
and vascular growth required to support the developing breast. On the commencing of 
ovulatory cycles there is an increased production of progesterone which causes the 
differentiation of the terminal ductular bud to form the adult lobules (Graham and 
Clarke, 1997).  
  
27 
 
 
 
 
 
 
 
 
 
Fig. 1.4: The stages of breast development at puberty. 
www.teenpuberty.com/images/puberty/breastdev. 
 
Following puberty the breast is subject to a fluctuating hormone environment during 
the menstrual cycle leading to changes in the nature and structure of the breast tissue.  
In the follicular phase of menstruation (days 3-14) the stroma of the breast becomes 
less dense and there is an expansion of the lumen of the ducts. During the luteal phase 
the ducts fill with secretions as the stromal tissue density increases. There is an 
increase cellular proliferation until day 26 when apoptosis of the epithelial cells 
returns the breast to its resting state (Fanger and Ree, 1974).  
 
Under the influences of the increased circulating sex steroid hormones the breast 
alters during pregnancy in preparation for lactation. The stromal elements in the 
breast tissue diminish to accommodate the hyperplasia of the lobular units. At the 
time of the third trimester there is an increase in the number of acini and the overall 
size of the lobules. The ductal epithelial cells differentiate and begin to synthesise and 
secrete milk. At birth there is a dramatic fall in the levels of oestrogen and 
progesterone allowing prolactin which has risen during pregnancy to act uninhibited 
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on the breast inducing lactation. The stimulus of suckling on the nipple acts along 
with inputs from the higher centres on the hypothalamus, this produces oxytocin 
which causes milk expulsion and maintains prolactin production. On cessation of 
breast feeding there is a fall in oxytocin and prolactin levels and the breast returns to 
its normal pre-pregnancy state. 
 
During the approach of the menopause breast involution begins. The stromal tissue 
around the lobules becomes denser, there is loss of the cells of lining the acini and the 
basement membranes become thicker. This is not a uniform process throughout the 
breast and can lead to clinically palpable lumps within the breast. The major 
constituent of the remaining post menopausal breast is adipose tissue.       
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1.1.2 The history of breast cancer. 
 
Breast cancer may be defined as a malignant proliferation of a cellular constituent of 
the breast (Schnitt and Guidi, 2004). This pathology has been studied and written 
about for the past 4000 years.  
 
The Edwin Smith papyrus is thought to have been written in 1700BC based upon a 
text written in 3000BC. Within the 48 cases described there are two concerning 
tumours of the breast; the first of which feels hot under the hand is described as; 
  
"One having tumors with prominent head in his breast, (and) they produce cysts of 
pus. An ailment which I will treat with the fire-drill.”(Breasted, 1980) 
 
 An accurate description of a breast abscess and its treatment. The second case is that 
of a tumour thus described;  
 
“If thou examinest a man having tumors on his breast, (and) thou findest that swelling 
have spread over his breast; if thou puttest thy hand upon his breast upon these 
tumors, (and) thou findest them very cool, there being no fever at all therein when thy 
hand touches him; they have no granulation, they form no fluid, they do not generate 
secretions of fluid, and they are bulging to thy hand. Thou shouldst say concerning 
him: One having tumors. An ailment with which I will contend.”(Breasted, 1980) 
There is no treatment offered for this type of tumour likely to be a breast cancer. 
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The origin of the word cancer can be attributed to the Greek physician Hippocrates 
(460-370 B.C.) Hippocrates used the term “Karkinos” or “Karkinoma” for tumorous 
growths probably relating to the crab like invasion of a tumour. Hippocrates 
considered that these hidden cancers should not be treated as treatment hastened 
death. Celsus, first century AD, although better known for his description of 
inflammation (calor, dolor, rubor, tumor) described an operation for early breast 
cancer but advised against surgery for more advanced disease. Galen (A.D. 130-203) 
considered that the most common cancers arose in the female breast and were due to 
an excess of black bile again he recognised the need for surgery to control local 
disease. Following this period medicine along with the rest of intellectual thinking 
entered the dark ages, it was not until the renaissance that there were any further 
advances in medical science.  
 
The 16
th
 and 17
th
 century saw a rebirth of the study of anatomy and surgery. Andreas 
Vesalius (1514 – 1564) published the first comprehensive anatomy text, De Humani 
Corporis Fabrica, in 1543. This replaced Galen’s writings which were based on the 
dissections of apes. Ambroise Paré (1510 – 1590) contributed to the advancement of 
surgery in numerous ways including the introduction of ligation of vessels during 
operations as opposed to cautery. These advances lead to the description of a number 
of breast operations for cancers. Based upon the work by Thomas Bartholin (1616 – 
1680) on the lymphatic system and the introduction of the microscope to medicine, 
Henry François LeDran (1685 -1780) proposed in 1757 that breast cancer commenced 
as a local disease that then spread via the lymphatics to the rest of the body, hence 
early surgery may be curative. This centrifugal theory of metastatic spread was the 
basis of the treatment of breast cancer into the 20
th
 century (Zenon Rater, 2003). 
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In 1867 Charles Moore published a paper describing local recurrences of breast 
cancer following inadequate operations (Moore, 1867). He stressed the importance of 
adequate resection and that the tumour should not be cut into or even seen during the 
operation. Following work in Germany during the 1880’s by Kuster, Schmid and 
Heidenman on the value of mastectomy and en-bloc removal of the axilliary lymph 
nodes William Stewart Halsted (1852 – 1922) published his first description in 1898 
of what was later to become known as the radical mastectomy bearing his name 
(Halsted, 1898).  
 
 
 
 
 
 
 
Fig. 1.5: William Stewart Halsted. http://www.hopkinsmedicine.org/hmn/W02/photos/Halsted.jpg. 
 
Advances in the understanding and treatment of breast cancer during the last 100 
years now underpin its current management. The surgical therapy has become less 
aggressive with an improved understanding of cancer biology. There is now an 
important role for radiotherapy in combination with surgery. Chemotherapy is an 
important adjuvant in advanced or metastatic disease and with advances in molecular 
biology endocrine manipulation is now one of the core elements of the treatment of 
breast cancers.  
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1.1.3 The histological basis of breast cancer. 
 
Carcinoma of the breast may be considered as a heterogeneous group of diseases. The 
formal histological typing of breast cancer has been established by the World Health 
Organization (1982). This classification is based upon the histological properties of 
the cancer. It is not an indication of the origin of the tumour within the breast. The 
majority of invasive carcinomas originate from the terminal duct lobular unit 
irrespective of its histological type (Schnitt S.J., 2004)  
 
Cancers of the breast may be divided in to invasive and non invasive or in situ lesions. 
The in situ lesions are defined as abnormal proliferation of cells that are not invading 
the basement membrane that the cells are attached to, whereas invasive lesions are 
those in which the cells transgress this membrane. For the purpose of this study we 
will consider only the invasive breast cancer  
 
The prevalence of the different histological types of breast cancer is well documented.  
The most common type of invasive breast cancer is the default diagnosis of ductal 
carcinoma of no special type (NST) This is followed by lobular carcinoma, then the 
rarer special types of breast cancer (see table 1.1). 
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Histological Type % of presenting lesions 
Ductal 70% 
Lobular 10% 
Medullary 5% 
Mucinous 2% 
Tubular 3% 
Mixed 2% 
Other 8% 
 
Table 1.1: Histological types of breast cancer(Schnitt S.J., 2004).  
 
1.1.3.1 Ductal Carcinoma of no special type. 
Ductal carcinoma of no special type (NST) is diagnosed when the lesion does not 
exhibit any histological features of the other breast cancer types. They commonly 
present with a mass or on screening mammography, rarely they can present as Paget’s 
disease of the nipple (more commonly due to DCIS). Macroscopically they are 
commonly a hard mass with a grey or white surface on sectioning and a gritty texture. 
The lesion itself may be spiculated or stellate in nature infiltrating the surrounding 
tissue though some lesion may be more circumscribed. Fig 1.6 illustrates a classical 
ductal carcinoma with a white surface and an infiltrating stellate appearance. 
Microscopic examination of invasive ductal cancers can show marked variation 
between both individual cases and within a single tumour. Histologically the cells can 
be seen as glandular structures, sheets, cords or trabeculae. This may be associated 
with or without necrotic areas. The tumour cells themselves can exhibit a range of 
cytological features in the nucleus, cytoplasm and the mitotic rate. 
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Fig. 1.6: Ductal cancer of the Breast.  (Courtesy of Loyola University Chicago Stritch School of 
Medicine. Chicago.) 
 
 
 
1.1.3.2 Special types of Breast Cancers. 
As shown in table 1.1 lobular carcinoma of the breast is the most common type of 
special cancers. Clinically they may not present with a classical hard mass but more 
of a non discrete thickening, they are more commonly found to be multifocal and 
bilateral compared to the other types of breast cancers. On imaging, both 
mammographical and on ultrasound, the appearances may be quite subtle. These 
features of lobular cancer can present a challenge when diagnosed pre-operatively. It 
is well recognised that both clinical examination and classical imaging may undersize 
the pathological lesion and this can cause a higher rate of involved margins when the 
lesions are excised with breast conserving surgery. In the Queen Elizabeth Hospital 
Gateshead, women with a preoperative diagnosis of lobular carcinoma will, as 
standard practice, have a breast MRI scan which is considered to be more accurate 
guide to the overall size of the lesion than mammography or USS and diagnose 
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mammographically invisible multi focal disease. Histologically lobular carcinomas 
classically appear as an infiltration of the stroma with relatively uniform small cells 
with small nuclei. The cells usually appear loosely cohesive and some may have a 
signet ring appearance. There are a number of described variants of lobular 
carcinomas including the signet cell subtype but also the solid, alveolar, 
tubulolobular, pleomorphic and histocytoid variations. The lobular carcinoma may be 
less likely to metastasise to the classical site of lung, liver and brain though compared 
to ductal carcinoma but can be found as metastasis in unusual sites, such as the 
ovaries, many years after the primary disease. Its outcome is not as advantageous as 
some of the other special types of breast cancer. 
 
Medullary carcinoma, now called medullary like carcinoma, is a cancer of the breast 
which presents commonly with a palpable mass or with mammographic appearances 
similar to a ductal cancer. Histologically it has a well circumscribed margin with an 
infiltration of lymphocytes and plasma cells. It is considered to have a lower rate of 
axillary metastases and an improved survival compare to ductal cancers. 
  
Mucinous (colloid) carcinomas tend to present with poorly defined lobular masses. 
They consist of neoplastic cells in pools of mucin. They have lower rates of 
metastasis and an improved survival compared to ductal cancers.  
 
Tubular carcinomas more commonly present as screening abnormalities rather than 
palpable lesions. They are characterised by the presence of well differentiated glands 
or tubules and have an excellent prognosis.   
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More recently has been the identification of the basal phenotype of breast cancer. 
These cancers are identified by the expression of CK5/14 on IHC. They are 
commonly associated with BRCA1 positive cancers and tend to be ER and HER2 
negative (Jumppanen et al., 2007). These cancers tend to be more aggressive and have 
a poorer outcome than non-basal type cancers of the same grade (Rakha et al., 2006, 
Fulford et al., 2007). The ER and HER2 negative status of these cancers obviously 
have an impact on the use of adjuvant therapies available for their treatment.  
 
There are also a number of much rarer cancers of the breast including cribiform 
carcinomas, papillary carcinomas, metaplastic carcinomas, and adenoid cystic 
carcinomas to mention but a few. 
1.1.3.3 Tumour Grading. 
This heterogeneous group of tumours are classified in a grading system. The grading 
of a cancer is a microscopic description of how similar the tumour is to normal breast 
tissue. The most commonly recommended histological grading system in use is the 
Elston and Ellis modification of the Bloom and Richardson system (Elston and Ellis, 
1991). This grading system scores a tumour on three components; tubule formation, 
nuclear pleomorphism and mitotic rate. These three components are allocated a score 
(1-3) and the total score determines the overall histological grade: The scoring is 
determined as followed; 
 
Tubule formation, % of the tumour forming normal duct structures >75% = 1 point, 
10-75% = 2 points and <10% = 3 points.  
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Nuclear pleomorphism, this parameter is based upon whether the nucleus of the cell is 
of a normal shape, size and staining or an abnormal shape size and staining 
(pleomorphic.) minimal pleomorphic = 1 point, moderate pleomorphic = 2 points and 
marked pleomorphic 3 points.  
 
Mitotic rate, this is a measure of the rate of division within the tumour and is assessed 
by counting the number of dividing cells in a field of view under the microscope. 
These mitotic figures are only counted at the periphery of the tumour in the most 
mitotically active areas seen. The score per count is dependent on the microscopic 
field used but again is allocated a 1,2 or 3 score as the number of mitotic cells 
increases.   
 
Grade Description Score 
I Well differentiated 3-5 
II Moderately differentiated 6-7 
III Poorly differentiated 8-9 
 
Table 1.2: Table showing the Elston and Ellis modification of the Bloom and Richardson grading of 
breast cancer(Elston and Ellis, 1991). 
 
The grade of the ductal cancer has implications for the survival of the patient and 
treatment decisions may be based partly upon this grade. There are some issues with 
regards to this method of allocating a grade to the tumour as it is obviously dependent 
on the observer and it is known that there will be some intra observer variation or 
discordance. In a recent study it was shown that there was a discordance rate of 28% 
(195 of 689 samples) in the grade assigned the same tumour but 2 different pathology 
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centres (Bueno-de-Mesquita et al., 2009). These discordance rates can be reduced by 
using standardised protocols between units. It has to be remembered that despite this 
discordance rate grade is still a significant prognostic factor in the outcome of the 
disease.  .  
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1.1.3.4 Molecular Classification of breast cancers.  
With the advent of gene expression profiling in breast cancer tumours can now be 
classified based upon their genetic signature rather than histological phenotype. Using 
cDNA microarrays thousands of candidate genes in many archived breast cancers 
sample have been assessed for the significance of expression up and down regulation 
(Hyman et al., 2002). By the hierarchal analysis of gene expression in multiple 
tumours distinct sub-types of cancers have become apparent (SÃ¸rlie et al., 2001). In 
some of the latest work a sub-set of 306 gene micro array has been used to distinguish 
5 and a possible 6
th
 subtype of breast cancers (Hu et al., 2006) see fig 1.5.5. 
The following subtypes have been identified and now validated in many other studies; 
 
The Luminal (ER positive) type.  
Luminal A, an ER positive predominantly lower grade cancer expressing the highest 
level of ER α, GATA binding protein A,, X-box binding protein 1, Trefoil factor 3, 
Hepatocyte nuclear factor 3 α and estrogen-regulated LIV-1.  
Luminal B, again an ER positive tumour but lower expression of the luminal type 
genes with a higher overall grade and poorer outcome than Luminal B cancers.  
Lumina C, a subdivision of luminal B but showing expression of a gene subset similar 
to the Basal and ERBB2+ subtypes. 
 
Non-luminal types (low to absent of ER α and other luminal cluster factors.)  
Basal like subtype, characterised by high expression of keratin 5 and 17 and fatty acid 
binding protein. 
ERBB2+ subtype, characterised by high expression of the genes in the ERBB2+ 
amplicon at 17q22.24 including ERBB2 and GRB7 
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Normal Breast like subtype, showing high expression of gene associated with adipose 
and other nonepithelial cell types. They also showed high expression of basal type 
genes with low expression of luminal epithelial genes. (Perou et al., 2000, SÃ¸rlie et 
al., 2001) 
 
This molecular classification of breast cancer looking at the alterations in gene 
expression driving the cancer is important in two particular areas. Firstly the 
classification into these subtypes has been shown to have important prognostic 
significances beyond the traditional prognostic indexes discussed later and secondly it 
is now being realised that these subtype groups are important in predicting the 
response to adjuvant therapies including chemotherapy (Rouzier et al., 2005). These 
studies have shown that there is a greater response to chemotherapy in the non-
luminal types of breast cancers rather that the luminal types. Factors such as the 
subtype group are now being taken into account when planning patients adjuvant 
treatment.          
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Fig 1.5.5 Gene expression patterns of 85 experimental samples representing 78 carcinomas, three 
benign tumors, and four normal tissues, analyzed by hierarchical clustering using the 476 cDNA 
intrinsic clone set. (A) The tumor specimens were divided into five (or six) subtypes based on 
differences in gene expression. The cluster dendrogram showing the five (six) subtypes of tumors are 
colored as: luminal subtype A, dark blue; luminal subtype B, yellow; luminal subtype C, light blue; 
normal breast-like, green; basal-like, red; and ERBB2+, pink. (B) The full cluster diagram scaled 
down (the complete 456-clone cluster diagram is available as Fig. 4). The colored bars on the right 
represent the inserts presented in C–G. (C) ERBB2 amplicon cluster. (D) Novel unknown cluster. (E) 
Basal epithelial cell-enriched cluster. (F) Normal breast-like cluster. (G) Luminal epithelial gene 
cluster containing ER(SÃ¸rlie et al., 2001). 
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1.1.4 The staging of breast cancer. 
The staging of all types of cancers has a similar aim, that is to group patients 
according to their disease burden. This grouping of patients allows for prediction of 
clinical outcome, comparison of like for like patients for the purpose of research and 
provides a guide for treatment of their disease. To this extent breast cancer is no 
different. The staging of breast cancer is based on the TNM (tumour, nodes and 
metastases) system. Once the TNM status has been assessed the patients are placed in 
a Stage Group. The TNM staging is based on both clinical (examination and imaging) 
findings and on the pathological findings.   
 
The T stage is based upon the size of the cancer or its invasion of local structures. The 
size primarily is taken from the pathological excision but, if not available, from the 
imaging results. The involvement of local structures may be seen on clinical 
examination, imaging or pathology specimen. There are 4 major groups T1-T4 with 
subset of both the T1 and T4 groups. See table 1.3.The T stage is also used in the 
Nottingham Prognostic Index (NPI) discussed later.  
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Major Heading Subset Descritpion. 
T1  Tumour 2cm or less. 
 T1is In situ disease only. 
 T1mic Microinvasion < 0.1cm 
 T1a Tumour >0.1cm <0.5cm 
 T1b Tumour >0.5cm <1cm 
 T1c Tumour >1cm <2cm 
T2  Tumour >2cm <5cm 
T3  Tumour >5cm 
T4  Tumour with extension. 
 T4a Chest wall extension not 
including pectoralis. 
 T4b Oedema or ulceration of the 
skin. 
 T4c Both T4a and T4b 
 T4d Inflammatory carcinoma. 
 
Table 1.3: The Tumour staging groups for breast cancer 
 
The lymph node stage again may be assessed clinically with examination and imaging 
but more commonly determined after surgical excision of a sample of lymph nodes. In 
the UK there has been a shift in the staging of the axillary lymph nodes. Traditionally 
a sample of nodes was excised during the operation on the breast cancer. This sample 
may have been a random 4 node sample or a formal level 1 or level 2 dissection. Due 
to the results of the ALMANAC trial (Mansel et al., 2006), the staging of the axillary 
lymph nodes is now a more targeted exercise. Pre-operatively the axilla is imaged 
with USS and any large or structurally abnormal lymph nodes sampled with FNA or 
core biopsy. If the preoperative staging of the axilla is negative the patient will then 
go on to a targeted sentinel node sample. This approach reduces the morbidity 
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associated with lymphoedema in the arm which was seen with axillary clearance 
(Mansel et al., 2006).  
 
The sentinel node is identified intra-operatively with a combination of blue dye and 
radioactive isotope injection. The sentinel node or nodes are excised and examined 
pathologically. If positive sentinel nodes are identified, the axilla is managed with 
further surgery, an axillary clearance, and radiotherapy. Table 1.4 shows the 3 major 
pathological lymph node (N) groups and the relevant sub groups.  
 
Distant metastasis (M) may be clinically apparent either on physical examination at 
the point of diagnosis or on staging imaging such as CT scans of the chest and 
abdomen or isotope bone scans. Routine staging imaging tends to be restricted to 
patients who are lymph node positive or are going on to chemotherapy. These results 
of the staging imaging are valid if carried out within 4 months of the diagnosis of the 
primary disease if no neo-adjuvant treatment has been used. There are only 3 major M 
groups; MX metastasis not assessed, M0 no distant metastasis and M1 distant 
metastasis present. 
 
The TNM groups are then combined to place the patient into one of the overall 
staging groups see table 1.5. These stages of disease range from Stage 0 to Stage 4. It 
is more common for the disease stage to be used for the comparison of patient group 
response to treatment rather than the more involved TNM classification.  
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Major Heading Subset Description 
pNX  Regional nodes not available 
for assessment 
pN0  No regional lymph node 
metastasis. 
pN1  Metastasis in 1-3 axillary 
nodes or internal mammary 
nodes (not clinically 
apparent. 
 pN1mi Micro metastasis >0.2mm 
<2mm.  
 pN1a Metastasis in 1-3 axillary 
nodes. 
 pN1b Metastasis in internal 
mammary nodes. 
 pN1c pN1a and pN1b 
pN2  Metastasis in 4-9 axillary 
nodes or clinically apparent 
internal mammary nodes. 
 pN2a Metastasis in 4-9 axillary 
nodes (at least 1 deposit 
>2.0mm.  
 pN2b Clinically apparent internal 
mammary  metastasis in 
absence of axillary 
metastasis. 
pN3  10 or more involved axillary 
nodes or internal mammary 
nodes; or 1 or more 
ipsilateral supraclaviclar 
nodes.  
 
Table 1.4: The Lymph node staging groups for breast cancer 
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Stage Group Tumour Nodes Metastasis 
Stage 0 Tis N0 M0 
Stage I T1 N0 M0 
Stage II A T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
Stage II B T2 N1 M0 
 T3 N0 M0 
Stage III A T0 N2 M0 
 T1 N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
Stage III B T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
Stage III C Any T group N3 M0 
Stage IV Any T group Any N group M1 
 
Table 1.5: The Stage group of breast cancer. 
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1.1.4.1 Prognostic Indices.  
There is an obvious need to be able to stratify patients into prognostic groups. The 
TNM staging is, as can be seen in table 1.5, cumbersome and difficult to interpret. 
Using factors which, independently are of important prognostic value and when 
combined into a prognostic index and subjected to multi-variant analysis still remain 
significant, a prognostic tool can be developed. The Nottingham prognostic index 
(NPI) uses this method to score patients and place them into prognostic group. The 
three factors which are used in the NPI are tumour size, tumour grade and lymph node 
status. They are combined in the following formula;  
 
NPI = Tumour size (cm) x0.2 + histological grade (1-3) + Lymph node status*  
(* 1= node negative, 2= 1-3 nodes positive, 3= >3 nodes positive)  
 
This formula produced a range of values from 2.08 upwards. Arbitrary cut off points 
were made at 3.4 and 5.4 to create 3 prognostic groups. Now 6 prognostic groups are 
recognised. These are; an Excellent Prognostic group (EPG) with an observed NPI 
score of 2.08–2.4, Good (GPG) 2.42 to 3.4; Moderate I (MPG I) 3.42 to 4.4, 
Moderate II (MPG II) 4.42 to 5.4, Poor (PPG) 5.42 to 6.4 and very poor (VPG) 
6.5–6.8 (Blamey et al., 2007).    
 
Table 1.6 shows the 10 year breast cancer specific survival of patients from 1990. 
This index has been well validated in many studies and is robust and widely used 
(Balslev et al., 1994).    
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Table 1.6: Table showing the 10 yr survival depending on NPI group(Blamey et al., 2007) . 
 
There are a number of other tools used in the breast clinic to aid decision making on 
an individual patient basis. One of these used extensively by oncologists is “Adjuvant 
Online.” (https://www.adjuvantonline.com.) This online program uses patient details 
(age and co-morbidities) tumour details (size, grade, lymph node status and hormone 
receptor status) and proposed adjuvant treatment to provide specific predicted survival 
and the survival benefit of adjuvant treatment.   
  
NPI Group 10 year survival (%) 
EPG 96 
GPG 93 
MPG I 81 
MPG II 74 
PPG 50 
VPG 38 
All 80 
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1.1.5 An overview on the treatment of breast cancer.  
This section gives a brief overview of the current treatment of breast cancer. Some 
areas will be further discussed in the relevant sections later in the thesis. The 
treatment of breast cancer is based upon five modalities; surgery, radiotherapy, 
chemotherapy, endocrine manipulation and biological inhibitors. These modalities can 
all be used in both the curative and the palliative setting. For simplicity  this section  
will consider the treatment of curable (early) breast cancers.  
 
1.1.5.1. Surgery.     
The role of surgery in breast cancer if twofold, firstly it is for the excision of the 
primary tumour and secondly for the staging and control of the axilla. Primary surgery 
on the breast can be considered a 2 therapeutic options either a simple mastectomy or 
breast conserving surgery (BCS) the choice between mastectomy and BCS is 
dependent on a number of tumour and patient specific factors. Traditionally a 
mastectomy is advised if the tumour is greater than 40mm in size or is multi-focal (in 
more than one area of the breast). Some units will have a lower size threshold for 
mastectomy but what is probably more valid is the consideration of tumour volume to 
whole breast volume. When BCS is performed then the patient will require whole 
breast radiation. The combination of BCS and whole breast radiation has been shown 
in many meta-analysis studies to have an equivalent 10 year overall survival as a 
mastectomy (EBCTCG, 1995). The introduction of oncoplastic techniques using 
breast reduction surgery now is pushing the boundaries of what is possible to safely 
remove whilst preserving the breast. It is now recognised that neo-adjuvant 
chemotherapy may render some tumours suitable for BCS that were only operable 
with a simple mastectomy. There has been much discussion over the distance of clear 
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excision margin required in BCS but it is now generally accepted that >2mm is 
adequate (Singletary, 2002).  
 
As mentioned earlier the staging of the axilla now involves targeted sentinel lymph 
node biopsy using blue dye and radio-isotopes. This is usually carried out at the time 
of the primary breast surgery but may be used alone prior to this if considering neo-
adjuvant chemotherapy. The level III axillary clearance is now reserved for the patient 
who have been identified pre-operatively to have positive lymph nodes or as a second 
procedure following a positive sentinel node biopsy.  
 
1.1.5.2 Radiotherapy. 
Radiotherapy has a key role in the reduction of locoregional recurrence. It is used in 
the post operative or adjuvant setting commonly in BCS but also to the skin flaps and 
chest wall in mastectomies with a high risk of recurrence ie large tumours close to the 
chest wall. Radiotherapy is also used in the axilla and supra-clavicular regions in 
patients with lymph node involvement. The whole breast radiotherapy is given 
following CT planning and patent marking and the current regime locally is a dose of 
40 Gy given over 3 weeks (15 sessions). Following radiotherapy the reported local 
recurrence rates in BCS vary from 6-20% at 10 years but it is however accepted that 
the use of radiotherapy in BCS leads to an 18.5% reduction in local recurrence at 10 
years (Fisher et al., 1995) 
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1.1.5.3. Chemotherapy.   
 It is now recognised that the use of chemotherapy in the adjuvant setting reduced the 
risk of recurrence and death in breast cancers (EBCTCG, 2005). The important 
consideration in the use of this therapy which has a significant morbidity and 
mortality if the selection of patients who are likely to gain the most with a reduction 
in the over treatment of low risk patients. The St Gallen meeting 2007 categorised 
operable breast cancer into risk groups.  
 
Based upon this risk group categorisation recommendations were then made upon the 
adjuvant treatment. These recommendations were not only for chemotherapy but also 
for the use of endocrine therapies (tamoxifen and AIs) and Trastuzumab (Herceptin). 
The consensus suggested that all HER2 positive case chemotherapy was considered. 
In HER2 negative cases patients of in the high risk group were offered chemotherapy, 
patients in the low risk group should not be offered chemotherapy. In the intermediate 
group the hormone receptor negative and the low receptor expressing tumours should 
be considered for chemotherapy (Goldhirsch et al., 2007). 
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Table 1.7 Definition of risk categories (adapted from 2007 St Gallen Meeting (Goldhirsch et al., 2007))  
Some Panel members view pT1a and pT1b (i.e. pT <1 cm) tumors with node-negative disease as 
representing low risk even if higher grade and/or younger age b Extensive peritumoral vascular 
invasion (i.e. neoplastic emboli seen in two or more blocks of the tumor) was recognized as a 
discriminatory feature of increased risk; its presence defined intermediate risk for node-negative 
disease, but did not influence risk category for node-positive disease c Some cases such as medullary 
carcinoma and apocrine carcinoma may be regarded as low risk despite the absence of steroid 
hormone receptor expression.d HER2/neu gene overexpression or amplification must be determined by 
quality-controlled assays using immunohistochemistry or FISH analysis.e Note that the intermediate 
risk category includes both node-negative and node-positive 1-3 disease.* pT, pathological tumor size 
(i.e. size of the invasive component); **histologic and/or nuclear grade; ***ER, estrogen receptor; 
PgR, progesterone receptor.  
Risk category 
Low risk
a
  Node negative AND all of the following features: 
pT* ≤2 cm, AND 
Grade 1**, AND 
Absence of extensive peritumoral vascular invasion
b
, AND 
ER and/or PgR*** expressed
c
, AND 
HER2/neu gene neither overexpressed nor amplified
d
, AND 
Age ≥5 years 
Intermediate risk
e
  Node negative AND at least one of the following features: 
pT* >2 cm, OR 
Grade 2-3**, OR 
Presence of extensive peritumoral vascular invasion
b
, OR 
ER and PgR absent
c
, OR 
HER2/neu gene overexpressed or amplified
d
, OR 
Age <35 years 
Node positive (1-3 involved nodes) AND 
ER and/or PgR expressed, AND 
HER2/neu gene neither overexpressed nor amplified
d
  
High risk Node positive (1-3 involved nodes) AND 
ER and PgR absent, OR 
HER2/neu gene overexpressed or amplified
d
  
Node positive (4 or more involved nodes)  
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The types of chemotherapy prescribed predominantly now fall into two groups, 
Anthracycline based chemotherapy and Taxane based chemotherapy. The 
anthracycline agents have largely superseded the older CMF regimes as they have 
been show to be superior in randomised control trials such as the UK National 
Epirubicin Trial (NEAT). This trial compares 6 cycles of cyclophosphamide, 
methotrexate and flurouracil (CMF) with 4 cycles of epirubicin combined with 4 
cycles of CMF. This showed that the epirubicin arm had a relapse free survival at 5 
years of 91% compared with 85% in the CMF alone arm (Poole et al., 2006).  
 
The taxanes paclitaxel (Taxol) and docetaxel (Taxotere) are active cytotoxic agents 
against breast cancer. In the metastatic setting they have been shown to be active 
against anthracycline resistant tumours (Ghersi et al., 2005). In the adjuvant setting 
the issue of superiority over anthracycline based chemotherapy is unclear and it is 
probably safe to say that in selected groups (HER2 positive ER negative) the taxanes 
may offer a survival advantage over anthracycline (Hayes et al., 2007). 
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1.1.5.4. Endocrine therapies. 
The use of anti-estrogen therapies in breast cancer is discussed in detail in the later 
sections of the thesis. The use of Tamoxifen and Aromatase inhibitors as adjuvant 
therapy is the mainstay of the treatment in ER positive breast cancers.  
 
1.1.5.5 Biological Modulators. 
  
The use of the anti ERB-2neu receptor antagonist Trastuzumab and other pathway 
inhibitors are again discussed later in this thesis.  
 
1.1.5.6 Neo-adjuvant treatment. 
 
Radiotherapy, endocrine treatment and chemotherapy can be employed in the neo-
adjuvant setting. The aim of this treatment is usually to render a locally advanced 
inoperable breast cancer operable. There is also the argument that neo-adjuvant 
chemotherapy and endocrine therapy may be used to move a patient from a 
mastectomy towards BCS. It has been shown that there is equivalence between neo-
adjuvant and adjuvant chemotherapy in terms of survival (Deo et al., 2003). Neo-
adjuvant treatment is now more widely accepted as a therapy for patients with 
borderline BCS of a relatively large tumour to breast volume ratio whom it is clear 
would be receiving adjuvant chemotherapy (i.e. young node positive high grade 
tumours.)  
 
There are some issue which need to be considered regarding neo-adjuvant 
chemotherapy. Firstly it is sensible to mark the location of the tumour within the 
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breast using a marker clip at time of biopsy; this is because successful neo-adjuvant 
chemotherapy could render the tumour invisible with a complete radiological 
response rendering further surgery difficult. It is recognised that patients should 
undergo pre-treatment axillary staging as the axillary sample post neo-adjuvant 
therapy is not prognositcally valid. The ongoing assessment of response to the 
chemotherapy is important and it is suggested that MRI assessment is both a measure 
of size and metabolic response (Drew et al., 2001). It has to be agree how long to give 
the neo-adjuvant therapy for and when to decide that the response is not enough to 
justify further treatment a surgery should be performed. There is also some debate 
about post operative chemotherapy regimes for both the responders and non-
responders to neo-adjuvant treatment.       
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1.1.6 The epidemiology of breast cancer. 
 
Worldwide breast cancer represents 1/10 of all new cancers diagnosed. It accounts for 
a quarter of cancers diagnosed in women which equals approximately 1.1 million 
cases per year (Ferlay, 2004).  It is the leading cause of cancer death in women and its 
incidence is increasing.  
 
 
 
 
 
 
 
 
 
Fig. 1.7: Worldwide incidence of cancer by type(both sexes). (Ferlay, 2004) 
 
 
 
 
 
 
 
 
Fig. 1.8: Worldwide incidence and mortality of breast cancer 2002 (Ferlay, 2004) 
57 
 
Breast cancer is considered to be a disease of the western or developed world. The 
families of migrants from countries with a low incidence of breast cancer will acquire 
the same risk of developing the disease as the home population within 2 generations 
of moving to a country with a higher incidence (Ziegler, 1993). There is now also a 
dramatic rise in the rates of breast cancer in countries with a historically low 
incidence (Pompe-Kirn et al., 2000, Nagata et al., 1997, Leung, 2002).  
 
In Europe breast cancer is the second most common cancer, to lung cancer, diagnosed 
with 245,000 women developing the disease in 2000. This represents ¼ of all female 
malignancies diagnosed (Becker N., 1998).  
 
 
 
 
  
 
 
 
Fig. 1.9: Estimated incidences and mortality of Breast cancer in the year 2000 per 100,000 
population.(Becker N., 1998) 
 
In the UK Breast cancer is the most common cancer diagnosed in women. In 2005 
there were 45947 new cases recorded, 99% of these cases are in women. This total 
represents 15% of all cancers diagnosed(2005a, 2005b, 2005c). In the UK due to its 
high incidence and 5 year survival rates approaching 75% there is a high prevalence 
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of women living with the diagnosis of breast cancer. It is estimated that there are 
172,000 women in the UK alive with this diagnosis(Micheli, 2002).  
 
 
 
 
 
 
 
 
Fig 1.10: UK cancers by type 2002. (Statistics, 2005)  
 
For the past 10 years there has been a fall in the mortality rates in breast cancer. 
Accounting for 12,696 deaths in 2003 breast cancer was until 1999 the leading cause 
of cancer deaths in women. It has since then been surpassed by lung cancer (1997b).  
 
 
 
 
 
 
 
 
Fig. 1.11: Breast cancer mortality since 1950 per 100,000 population (UK) (1997b).  
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The survival rates for breast cancer have also been improving. The five year survival 
for patients diagnosed from 1971 -1975 was 52% compared with the estimated five 
year survival today of 80%(Coleman, 2004). 
 
 
 
 
 
 
 
 
 
 
Fig. 1.12: Improvements in breast cancer survival (Coleman, 2004). 
 
The prevalence of breast cancer on a national and worldwide scale and the increasing 
incidence of breast cancer in the developing world is an indication of the importance 
of this disease to the global population. 
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1.1.7 The aetiology of breast cancers. 
 
The study of the epidemiological distribution of breast cancer is the basis of many of 
the declared risk factors for developing the disease. These risk factors are 
predominantly related to the breast’s life time exposure to estrogen. 
 
Breast cancer is 100 times more common in women than men, following sex age is 
the next most significant risk factor. As a woman’s age increases then so does her 
likelihood of developing cancer. Before the age of 40 the risk of developing breast 
cancer is 1/200 this increases to 1/10 by the age of 85.(Statistics, 2005) 
 
Lifetime estrogen exposure is directly related to a woman’s reproductive history. 
Estrogen production by the ovaries increases dramatically after the menarche. If 
menarche takes place at an earlier age then this estrogen exposure will be more 
significant. The average age of menarche has been falling in the 20
th
 century from 16-
17 years to 12-13 today (Rees, 1995). For every year that menarche is delayed after 
the age of 12 it is estimated that the risk of developing pre and post menopausal breast 
cancer is reduced by 7% and 3% respectively.(Clavel-Chapelon, 2002) Estrogen 
production is suppressed during pregnancy and breast feeding. It has been shown that 
the younger the age a woman starts her family the lower the risk of developing breast 
cancer. There is also a risk reduction for every month that a women breast feeds 
(2002). Nulliparous women have been shown to have a 30% greater risk of 
developing breast cancer compared to parous women.(Ewertz M, 1990) The later the 
menopause the greater the risk of breast cancer (Sweeney et al., 2004) and pre-
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menopausal women have a higher risk of breast cancer compared with post 
menopausal women of the same age (1997a).  
The prescription of exogenous hormones, in the form of the oral contraceptive pill and 
hormone replacement therapy (HRT), affect an individual’s breast cancer risk. It has 
been shown that during and immediately after taking an estrogen containing 
contraceptive pill the risk of developing breast cancer increases slightly, relative risk 
1.24 (95% CI 1.15-1.33), but this risk returns to base line after 10 year of 
cessation(1996). HRT has long been associated with an increased risk of breast 
cancer. The degree of this was more accurately quantified with the publishing of the 
Million Women Study in 2003(2003). This concluded that there was an increase in the 
development of breast cancer if combined HRT was used for more than 10 years 
following the age of natural menopause with a relative risk increase of 2.31 (C.I. 2.08-
2.56) (Collaborators, 2003). It has been estimated that there has been 15,000 extra 
cases of breast cancer due to estrogen/progesterone containing HRT over the last 10 
years.(Collaborators, 2003)  
 
In post menopausal women estrogen production predominantly occurs in adipose 
tissue but at a much reduced level than in the premenopausal women. A higher body 
mass index in post menopausal woman is associated with an increase in the risk of 
developing breast cancer (Bergstrom et al., 2001). This increase in risk is not seen in 
the pre-menopausal patient (Tehard and Clavel-Chapelon, 2006). It has also been 
demonstrated that increased physical activity is associated with a decrease in the risk 
of breast cancer (Tehard et al., 2006). 
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Alcohol has been associated with an increase in the risk of developing breast cancer. 
It has been shown that a moderate intake (2 units per day) over a life time increase the 
risk with an odds ratio of 1.33 (C.I. 1.01–1.74), this is more significant in women with 
a lower BMI.(Terry et al., 2006)   
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Diet, especially fat intake, has long thought to be important in the risk of developing 
breast cancer. The extent of its relationship is debated but it is probable safe to say 
that there is a causal link between high fat intake and breast cancer (Mattisson et al., 
2004).  
 
Unusually for most neoplastic diseases breast cancer is more common in women of a 
higher social economic group with an odds ratio of 1.2 (C.I. 1.05-1.37) (Robert et al., 
2004). This difference is probably related to some confounding risk factors such as 
reproductive history and nutritional differences. It is suggested that there is a 
relationship between breast cancer and high protein diets. It is also more likely that 
women in higher socio-economic groups are older at the time of their first child and 
have fewer children, again increasing the risk of breast cancer. 
 
Exposure to ionising radiation increases the risk of developing breast cancer. This has 
been seen in survivors of atomic bombs and those who have had therapeutic 
radiotherapy for Hodgkin’s lymphoma (Carmichael et al., 2003), this later group are 
now offered additional screening for breast cancer. It has also been noted that air 
hostesses with a higher occupational exposure to cosmic radiation have 
correspondingly higher rates of breast cancer, but there may be some confounding 
factors such as reproductive history (Kojo et al., 2005).  
 
A positive family history is associated with an increase risk of developing breast 
cancer. It is however important to recognise the over 85% of breast cancer patients 
have no family history of the disease. In women developing breast cancers aged 
below 40 who have a family history of breast cancers or other malignancies, the 
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possibility of an inherited susceptibility to malignancy should be considered.  Most 
cases of hereditary breast cancers are due to mutations in BRCA1 and BRCA2 genes. 
There are other rarer syndromes associated with the development of breast cancer 
including Li-Fraumeni syndrome, Cowdens disease, Peutz-Jeghers syndrome and 
ataxia-telangiectasia heterozygosity (Isaacs et al., 2004). There has been much debate 
over the exact risk conferred by a BRCA1 or BRCA2 mutation. Early studies in 
families selected because of their hereditary history suggested a life time risk of breast 
cancer in BRCA1 carriers was 87% (95% CI = 72-95%)(Ford et al., 1994) and 84% 
(95% CI = 43-95%)(Ford et al., 1998) in BRCA2 carriers. These studies also 
demonstrated a high risk of pre-menopausal breast cancer, contra lateral breast cancer 
and ovarian cancer in BRCA1/2 carriers compares with general population risk. It is 
however possible that the risk of breast cancer in BRCA1/2 carriers, in a less selected 
population, may be lower due to reduced penetrance (Struewing et al., 1997).    
 
It has to be remembered that prior to testing a patient for the carriage of one of the 
BRCA genes careful counselling is required. The patient needs to understand the 
impact of a positive result on both themselves and their offspring in terms of the risk 
of developing cancer and potential risk reducing strategies. These strategies may 
include increased surveillance using mammography or MRI, chemoprevention using 
tamoxifen or risk reducing surgery including prophylactic salpingo-oophorectomy and 
prophylactic mastectomy.  
 
It has been shown that screening in BRCA patients using mammography has a lower 
sensitivity than the general population and it has been suggested that MRI screening 
should be considered in these patients (Stoutjesdijk et al., 2001). Tamoxifen use has 
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been associated with a decrease in breast cancers in BRCA2 mutation carriers when 
started at the age of 35 but this effect is not seen in BRCA1 carriers, it is suggested 
that this difference is due to the finding of high rates of ER negative cancers in 
BRCA1 carriers compared to BRCA2 carriers (King et al., 2001). Salpingo-
oophorectomy is associated with a significantly statistic reduction in the development 
of breast cancers in both BRCA1/2 carriers (HR 0.47 95%CI = 0.35-0.64) as well of 
course reducing the risk of developing ovarian or fallopian tube cancers (Rebbeck et 
al., 2009).  
 
It is now not uncommon in breast clinics to be referred patients via the genetics 
services for discussion of risk reducing surgery. There is also a population of patients 
who though they do not have a documented gene abnormality may well request this 
surgery on the basis of family history alone. This risk reducing surgery is usually in 
the form of a mastectomy. This may be a standard mastectomy or a skin sparing 
mastectomy in conjunction with reconstructive surgery. The reconstructive surgery 
may be immediate or delayed. It has to be remembered that, as its name suggests, this 
is risk reducing surgery not risk eliminating surgery. Despite best intentions there will 
be residual breast tissue remaining after the surgery and breast cancer can arise in this 
residual tissue. This along with the possibility of occult tumours being discovered 
within the specimen at pathological sampling has to be discussed with the patient 
prior to surgery. 
 
 Bilateral risk reducing mastectomy has been shown to reduce the risk of breast cancer 
by 90% alone or by 95% when in conjunction with an oopherectomy (Rebbeck et al., 
2004). As the awareness of genetic screening and its use becomes more widespread it 
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is not unreasonable to expect these cases to become a more common feature in the 
breast clinic and it is likely that these patients will be best served by a combination of 
risk reducing strategies (Calderon-Margalit and Paltiel, 2004).  
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1.2. Hormones, Growth factors and Endocrine therapy in breast 
cancer. 
Breast cancer is one of the most widely studied solid tissue tumours. It is because of 
this that its molecular biology, in terms of the affect hormones have on this cancer, is 
relatively well understood. This chapter aims to give an overview of the important 
hormone receptors found in breast cancers and the different treatment modalities 
targeted at these receptors. 
   
1.2.2 Estrogen and the Estrogen Receptor (ER.) 
Estrogens (oestrogens) are a group of steroid based hormones. Though present in both 
men and women their role is predominately in the regulation of the ovulatory cycle in 
women. Produced by the developing follicles and corpus luteum in the ovary and by 
the placenta their production is under the control of follicle stimulating hormone 
(FSH) and luteinisng hormone (LH). Other secondary sources of estrogen production 
include the liver, adrenal glands adipose tissue and breasts, these secondary sources 
are important in postmenopausal women. The theca internal cells of the ovaries 
synthesise androstenedione from cholesterol, this is then converted either directly or 
indirectly via testosterone into oestrone or oestradiol. This final step is catalysed by 
the enzyme aromatase.  
      
The role of estrogen in the pathogenesis of breast cancer has been recognised for over 
100 years. Although the initial treatment of inoperable breast cancer by performing an 
oopherectomy is commonly attributed to Sir George Beatson in 1896 (Beatson, 1896), 
this treatment modality was originally described by Albert Schinzinger in 1889, in a 
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case series of 96 cases of breast cancer treated with oopherectomy (Schinzinger, 
1889). He noticed that the 23 patients who were still menstruating showed most 
benefit with regards to tumour control. He suggested that tumour growth in these 
younger patients was driven by the ovaries and hence recommended oopherectomy 
for these patients. One of the first attempted randomised control trials conducted in 
breast cancers in the Christie Hospital in 1948 was aimed at determining if ovarian 
ablation using radiation at the time of a radical mastectomy (the treatment group) was 
superior to ovarian ablation at the time of first relapse (the control group). Though the 
initial results were not significant, analysis at 15 years did show a significant increase 
in the length of time to relapse in the treatment group (p=<0.05) (Stewart, 1991). 
This, along with many other early trials into the use of ovarian ablation, noticed that 
response to treatment occurs in approximately 2/3 of patients, suggesting that there 
was a yet to be discovered difference between the tumours that responded to this 
treatment and those which did not. In the early 1960’s it was first noticed that 
estrogens when radioactively labelled concentrated in target organs. It was also 
noticed that they became especially concentrated in breast cancers (Folca et al., 1961, 
Jensen and Jacobson, 1962). This work led to the belief of the existence of an 
estrogen receptor (ER.). 
 
It is now well known that ER is over expressed in approximately 70-80% of invasive 
breast cancers at the point of diagnosis. The importance of the ER status of a breast 
cancer was quickly realised. It has been shown that ER positive cancers are of a lower 
grade, a smaller size, more likely to be node negative and have better survival 
outcome than ER negative cancers (Aaltomaa et al., 1991, Fisher et al., 1988, Grann 
et al., 2005).  
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ER is part of the nuclear hormone receptor (NHR) super family. It belongs to sub-
group III which also includes the progesterone and androgen receptors (Laudet, 
1997). All of these intracellular hormone receptor are proteins which have the ability 
to bind to DNA and regulate transcription of associated genes.  These NHRs have 5 
common domains A/B,C,D,E,F with variations within these domains determining 
function.  
 
A/B (n-
terminal 
domain) 
C (DNA 
binding 
domain) 
D (Hinge 
region) 
E (ligand 
binding 
domain) 
F (c-terminal 
domain) 
 
Fig. 1.13: Diagrammatic representation of the common domains of the NHR.  
 
 
ERα has been localised to chromosome 6. A second ER subtype (ERß) which is 
smaller than classical ERα has been localised to chromosome 14. Differences between 
these sub-types in the ligand binding domain, and the smaller size of ERß suggests 
that they have different physiological properties (Enmark, 1997). It has been show 
that ERα has a much higher affinity for 17α-estradiol compared with ERß (Kupier, 
1997). ERα and ERß are primarily confined to the nucleus with a small proportion of 
receptors expressed within the cytoplasm and a 36KDa splice variant which is 
membrane bound (Wang et al., 2006). ERα and ERß have been shown to have a wide 
variation in the tissue type and proportions in which they are expressed. These tissues 
include myocardial cells, major arteries, smooth muscle cells of the lungs, glandular 
tissue in the GI tract, the pituitary and thyroid gland, the female reproductive organs 
and of course breast tissue.    
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In its unbound state ER is a monomer found predominantly within the cytoplasm 
where it is associated with a heat shock protein, HSP90. Heat shock proteins, of 
which there are many sub types, are virtually ubiquitous in all living organisms. They 
act as a chaperone to many other proteins including the steroid receptors. They have a 
regulatory functioning on protein interactions including folding and binding.  
 
Upon activation with estrogen ER undergoes a confirmation change which involves 
the loss of the HSP. This loss of HSP and conformational change exposes two sites of 
dimerisation. The ligand binding thus allows the formation of stable ER dimers which 
may be homodimers or heterodimers depending on the sub-types involved (Smith and 
Toft, 1993).  Gene transcription is then induced when these dimers are shuttled from 
the cytoplasm to the nucleus where they interact both directly and indirectly with the 
DNA. ER activity may be up-regulated by its interactions with many receptor co-
factors.   
 
We are now beginning to understand the complexity of ER signalling and its actions. 
The complexity of this ER signalling allows fine regulation of transcription of many 
ER dependant and ER independent genes. ER can act in a genomic and non-genomic 
mechanism. 
1.2.2.1 Genomic action of ER 
 
ER’s genomic actions can be divided into estrogen response element (ERE) 
dependant and ERE independent actions. The ERE dependant or “classical 
mechanism” of ER action involves the shuttling of the ER dimer to the nucleus where 
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due conformational changes it can bind directly to the genomic ERE, recruit co-
factors and induce gene transcription (Nilsson et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.14: The classical mechanism of ER action: 1. E2 enters cell. 2. Ligand binds to ER. 3. 
Dissociated HSP allows formation of ER dimer. 4. ER dimer shuttled to nucleus where it binds directly 
to ERE inducing transcription.  (Courtesy of Dr A Davison, Department of Surgery, Newcastle 
University.)  
 
ER may exert is genomic affects without binding directly with DNA. It has been 
shown that 1/3 of the genes up-regulated by ER do not contain an ERE. ER can up-
regulate gene transcription by protein-protein interactions within the nucleus with 
other transcription factors (O'Lone et al., 2004). It has been shown the ER can directly 
bind to, phosphorylate and stabilise the AP1 genes transcription factors c-fos and c-
jun (Duan et al., 1999). Other transcription factors that have be shown to be related to 
ER in this way include Sp1 at the GC-rich promoter sequences (Porter et al., 1997).  
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1.2.2.2 The None-Genomic action of ER. 
Cross talk is a process where there are interactions between different signalling 
pathways, it is a mechanism that allows a specific ligand associated receptor to utilise 
a different signalling pathway. ER can cross talk with other cell signalling pathways 
at the non-genomic level. Studies have shown that ER exists both as a membrane and 
cytoplasmic associated receptor. They have been shown to be associated with the 
cytoplasmic scaffold protein caveolin-1 (Chambliss et al., 2000, Kim et al., 1999). At 
these locations ER may exert their non-genomic effects (Razandi et al., 2002). It is 
now recognised that estradiol stimulates signal transduction via plasma membrane 
associated ER that are G protein coupled to EGFR or insulin-like growth factor-1 
receptors (Razandi et al., 2003). This leads to initiation of the downstream cell 
signalling pathways. These cell signal pathways include an increase in the Src kinase 
cascade and hence activation of MAP-kinase signalling pathway (Wong et al., 2002a). 
It is also important to note that at this level the cross-talk is bidirectional in nature 
with ER its self being phosphorylated and activated by MAPK (Kato et al., 1995). 
This gives a possible mechanism where, using the up regulation of protein kinase 
cascades due to cross talk at a receptor level, ER can increase its own activation via 
phosphorylation by MAPK. It has been shown that up-regulation of growth factor 
signalling is associated with endocrine therapy resistance in ER +ve breast cancers 
(Gee et al., 2001). There is also an increased dependence on EGFR/MAPK mediated 
signalling in ER +ve tamoxifen resistant MCF-7 cell lines (McClelland et al., 2001).  
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Fig.1.15: Diagram representing membrane protein associated alternative ER signalling pathway. 
(Courtesy of Dr A Davison, Department of Surgery, Newcastle University.)  
 
 
 
 
 
 
 
 
 
 
 
Fig.1.16: Overview of genomic and none genomic ER cross-talk. (Courtesy of Dr A Davison, 
Department of Surgery, Newcastle University.)  
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1.2.2.3 Estrogen manipulation in breast cancer. 
Endocrine manipulation is an important treatment modality in the treatment of breast 
cancer. It is used as a primary or neo-adjuvant treatment, as an adjuvant treatment in 
early cancers and as a therapy for recurrent or metastatic disease. Until recently the 
most widely used drug of this type is tamoxifen. 
   
Tamoxifen is a selective estrogen receptor modulator (SERM). It has both an anti-
estrogenic and estrogenic action and depending on the target organ can be considered 
as a partial agonist. On binding to ER it alters the receptor’s conformational form 
affecting its interaction with nuclear transcriptional co-activators. This allows 
tamoxifen to have different actions on different tissues i.e. estrogenic action in bone, 
increasing bone density and uterine tissue, increasing the risk of endometrial 
malignancy. Tamoxifen has an anti-estrogenic action in the breast which, for ER 
positive cancers, has a cytostatic rather than cytotoxic effect (Jordan, 1998, Pace et 
al., 1997).  
 
Tamoxifen was introduced in 1969 where in advanced disease it introduced remission 
in some patients (Cole et al., 1971). Tamoxifen is used in advanced metastatic breast 
cancers, as a primary endocrine therapy and as an adjuvant therapy in early breast 
cancers. In metastatic breast cancers 50% of patients with previously untreated ER 
+ve cancers achieve an objective response or tumour stabilisation with tamoxifen 
(Jaiyesimi et al., 1995). As an adjuvant therapy in early ER positive breast cancer 
tamoxifen improves overall survival by 26% with a 47% reduction in disease 
recurrence and a 47% reduction in contralateral breast cancers. There is a four times 
increase in the incidence of endometrial cancers but in absolute numbers this is half 
75 
 
the number of the prevented cases of contralateral breast cancer (Early et al., 1998). 
Despite these benefits of tamoxifen treatment almost all the patients with metastatic 
disease and as many as 40% of patients receiving adjuvant therapy eventually relapse 
and die from their disease (Ring and Dowsett, 2004). On relapse these tumours are 
usually found to be resistant to tamoxifen and many of these recurrences remain ER 
positive on IHC testing (MacFarlane R et al., 2008).  
 
Aromatase inhibitors, now the first choice treatment for post menopausal patients, 
have an indirect action on breast cancers. As their name suggest their mechanism is to 
inhibit the conversion of androstenedione into estrone and testosterone in to estradiol. 
There are two classes of aromatase inhibitors, type I are irreversible steroidal 
inhibitors (such as exemestane ) which form a permanent bond with the aromatase 
enzyme and type II non-steroidal inhibitors (such as anastrozole and letrozole) which 
work via reversible competition. Though they have an action on the aromatase in the 
breast reducing local estrogens they also act in the liver and peripheral tissue. In the 
pre-menopausal patient the inhibition of this enzyme is “over ridden” by an increase 
in FSH and LH release increasing the amount of estrogen produced from the ovaries. 
Initial studies demonstrated that aromatase inhibitors were superior to tamoxifen in 
inducing remission in patient with advanced disease and in patients with tumour 
progression whilst on tamoxifen (Milla-Santos et al., 2000). In the adjuvant setting 
large randomised control trials have demonstrated a reduced recurrence rate compared 
to tamoxifen alone (ATAC et al., 2002) or following 2 or five year of tamoxifen when 
compared with tamoxifen alone for five years (Coombes et al., 2004, Goss et al., 
2003). These drugs to have side effects including arthralgia and myalgia and the 
increase of osteoporosis related fractures.  
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1.2.2.4 Anti-estrogen resistance. 
 
Tamoxifen resistance appears to be complex and multifactorial. There are two main 
phenotypes of tamoxifen resistance, primary resistance, where a tumour never 
responds to tamoxifen and secondary or acquired resistance. Acquired resistance is 
when an initially responsive tumour escapes tamoxifen control. Currently prediction 
of primary response to tamoxifen is based upon the expression of estrogen and 
progesterone receptors. Up to 75% of ER+/PR+ tumours will respond to tamoxifen 
(Clarke et al., 2003) showing that there is a considerable number of ER +ve tumours 
which demonstrate primary resistance. Of the ER +ve tumours which initially 
responded to tamoxifen, on relapse less than 25% had lost ER expression 
(Kuukasjarvi et al., 1996) and many of which would still be classified as ER +ve on 
IHC (Encarnacion et al., 1993). These results show that there is a population of 
tumours which whilst expressing ER do not respond as predicted to tamoxifen 
therapy. 
 
A number of mechanisms have been proposed as to the mode in which an ER +ve 
tumours becomes resistant to tamoxifen. These include the loss or alteration of ER 
expression and function (Speirs et al., 1999), the expression of the sub type of 
estrogen receptor ERβ (Speirs, 1999), alterations in pharmacological properties and 
tolerance of tamoxifen (Ring and Dowsett, 2004) and alterations in the action of co-
regulatory proteins involved in the interaction between ER and the ERE within the 
target genes (Ring and Dowsett, 2004). It has to be remembered that the tumour is a 
heterogeneous mass of cells, some of these cell may be ER positive and some may 
have lost their ER expression. The use of anti-estrogen treatments may well initially 
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cause a regression and suppression of the disease but over time it may select for the 
ER –ve cell population.  A further mechanism of estrogen resistance has been 
suggested which involves the interaction or “cross-talk” of ER with other cell 
signalling pathways. It may be this cross talk between ER and other cell signalling 
pathways, via the non-classical mechanism discussed above which gives the most 
complete mechanism for tamoxifen resistance. With the advent of novel therapies 
concerned with blocking these alternate signalling pathways an understanding of this 
mechanism may improve the prediction of disease outcome and identify patients who 
may benefit from these novel therapies. 
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1.2.3 The Progesterone Receptor. 
 
Progesterone is a steroid hormone that is important in normal development and 
reproduction. Like all steroid hormones it is synthesised from cholesterol 
predominantly from the ovaries (the corpus luteum) and from the placenta during 
pregnancy. Its action is mediated via the progesterone receptor (PR).  
 
PR is a nuclear receptor and there are 2 forms of human PR, PR-α and PR-ß. They are 
both products of the same gene loci 11q22 (Grigrande et al., 1997). Transcription of 
this gene is induced by the action of estrogen and ER (Schultz et al., 2003b). Binding 
of the hormone to the carboxy-terminal hormone binding domain induces 
conformational changes to the receptor. This causes co-repressor dissociation, co-
activator recruitment and binding to the DNA recognition sequences. The use of 
knockout mice has shown that a lack of PR causes reduced mammary development, 
uterine hyperplasia and failure to ovulate (Connely et al., 2001).   
 
Both forms of PR are expressed in breast cancers, PR-α expression predominates over 
PR-ß expression. There is a strong correlation between ER-α expression and PR-α 
expression in breast cancers with only 19% of tumour positive for only one of these 
receptors (Reiner et al., 1990). There is evidence that PR expression is associated with 
well differentiated tumours with a better overall survival (Reiner et al., 1990). Most 
evidence regarding the prognostic role of PR is based upon the assumption that PR 
expression indicates a functioning ER pathway (Ravdin et al., 1992). It therefore has 
been shown that PR positive ER positive tumours have a better response to endocrine 
therapy than ER positive PR negative cancers (Payne et al., 2008).  
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Beyond the role of PR in the prediction of response to endocrine therapy, the 
progesterone receptor has yet to be shown to be of any further prognostic or 
therapeutic value in breast cancer. Recent guidelines now suggest that PR expression 
is no longer required to be routinely assessed and only ER status is required in the 
minimum histopathological dataset as described by the Royal College of Pathologists.   
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1.2.4 Human Epidermal Growth Factor 2 (Her2/neu). 
 
HER2, also known as ErbB2-neu, is a member of the epidermal growth factor 
receptor family. This trans-membrane growth factor receptor is a product of the 
oncogene c-erbB-2. This oncogene is located at 17q21 and amplification of this 
oncogene results in over-expression of HER2 on the cell membrane (Schecter et al., 
1984, Zoll et al., 1992).  
 
HER2 is a “ligandless” or “orphan” receptor, it has no natural ligand. HER2 is 
activated when it forms a dimer with one of the other epidermal growth factor 
receptors HER-1, HER-3 or HER-4. On activation HER2 initiates a cascade of 
signalling via the MAPK, PI3K and phospholipid C pathways, this induces cell 
proliferation and resistance to apoptosis (Ciocca et al., 2006). The over expression of 
HER2 is reported to occur in 10-30% of invasive breast cancers (Ciocca et al., 1992). 
Over expression of HER2 is associated with higher grade tumours (Sjorgen et al., 
1998),  ER negative tumours (Gago et al., 2006) and poorer overall survival 
(Yamauchi et al., 2001).  
 
HER2 over expression in breast cancer is a target for systemic biological therapy. The 
monoclonal antibody trastuzumab (Herceptin; Genetech, South San Francisco, CA, 
USA.) is directed against the HER2 receptor. Large trials have shown this drug’s 
effectiveness both in the metastatic and in the adjuvant setting in disease response and 
improved recurrence rates (Slamon et al., 2001, Joensuu et al., 2006, Romond et al., 
2005, Smith et al., 2007). The National Institute of Clinical Excellent has now 
approved the use of trastuzumab in both the adjuvant and metastatic setting.   
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1.2.5 EGFR in breast cancer. 
Epidermal growth factor EGF was one of the first growth factors isolated when it was 
discovered in new born mice by Stanley Cohen in 1962 (Cohen, 1962). It was then 
later in 1975 that it was isolated in humans (Cohen and Carpenter, 1975, Gregory, 
1975) and it was not until 1980 that the EGF receptor (EGFR) was isolated (Cohen et 
al., 1980). 
 
EGFR is a receptor in the ErbB family of membrane bound receptor tyrosine kinases. 
There are four members of this family, EGFR (HER-1/ErbB1), HER-2 (ErbB2 or neu) 
HER-3 (ErbB3) and HER-4 (ErbB4). These receptors, apart from HER2, become 
activated by ligand binding. On activation these receptors form homo or hetero dimers 
with other receptors in the same class. The dimerisation causes subsequent tyrosine 
phosphorylation initiating a cascade of signalling pathways shown in fig.1.17 (Lo et 
al., 2006). Ligands which activate EGFR include EGF, Transforming growth factor α 
(TGFα) and Heparin-binding EGF-like growth factor (HB-EGF).   It has been 
proposed that EGFR has a second direct pathway of signalling when the receptor 
translocates to the nucleus where it acts as a transcriptional co-factor (Lin et al., 
2001). The action of EGFR activation is both proliferative and anti-apoptotic.   
 
The role of EGFR in breast cancer has been widely studied. It has been reported that 
the rate of expression of EGFR in breast cancers varies widely depending on the study 
from 14% to 91% (Klijn et al., 1992). This variation is due to the different methods of 
analysing the tumours for expression of EGFR and the variation in patient tumour 
samples studied.  
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Fig.1.17: The EGF signalling pathway; A the traditional pathway involving transduction cascades and 
B the direct pathway involving translocation of activated EGFR to the nucleus (Lo et al., 2006).  
 
It is suggested that EGFR expression is linked to higher grade, more aggressive 
tumours but not to lymph node involvement (Zeillinger et al., 1993). EGFR 
expression is associated with ER and PR negative breast cancers (Zeillinger et al., 
1993, Klijn et al., 1994). EGFR expression in breast cancer has also been linked to 
poorer disease outcome in respect to both disease recurrence and overall survival 
(Pawlowski et al., 2000).   
 
As EGFR plays an important role is breast cancer aetiology it is an obvious target for 
anti-cancer therapy.  Gefitinib (Iressa; Astra-Zeneca) is a selective inhibitor of the 
tyrosine kinase portion of the EGF receptor. Initially licensed for the treatment of 
advanced non small cell lung cancer it has been trialled in the treatment of breast 
cancer.  
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1.3. Transcription factors. 
1.3.1 Introduction to transcription factors. 
 
Cells alter their behaviour by responding to extra cellular signals. These signals may 
be in the form of biological molecules such as hormones. The way a cell recognises 
these signals or hormones may involve receptors for these signals both on and in the 
cell itself. Once the signal has been recognised a common mechanism for that signal 
to be translated to an affect is via the up or down regulation of transcription, 
transcription being the mechanism in which DNA is copied into mRNA prior to the 
synthesis of proteins.  
 
This transcription may be directly regulated by a receptor complex, such as the ERE 
rich genes controlled by classical ER signalling, or, in some occasions this regulation 
is carried out via an intermediary protein, a transcription factor. These transcription 
factors are small proteins which recognise and interact with specific DNA sequences 
located adjacent to the gene under its control (Latchman, 1997). They act by either 
promoting or repressing the transcription of DNA to RNA by recruiting the enzyme 
DNA polymerase. All transcription factors have at least one specific DNA binding 
domain (DBD) (Ptashne and Gann, 1997).  
 
It is thought that there are approximately 2600 coded proteins in the human genomes 
with DBD which may act as transcription factors (Babu et al., 2004). Some genes 
require a combination of transcription factors to regulate them this gives these 2600 
transcription factors the ability to uniquely regulate the large number of genes in the 
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human genome. This massive group of transcription factors are divided into 5 super 
family sub groups depending on the functional similarity of the factor.  
Transcription factors, like all proteins are a product of gene transcription themselves, 
and there are occasion when a transcription factor can control, usually inhibiting, its 
own transcription. As transcription factors play such a fundamental role in the control 
of gene transcription and hence cell behaviour it is not unreasonable to suggest that 
abnormalities in their function may result in pathological changes. As these 
pathological changes include the up regulation of pro-proliferative genes (oncogenes) 
or the down regulation of anti-proliferative genes (tumour suppressor genes) it is clear 
that some alteration in transcription factor expression or function may result in the 
development of malignancies.  
 
For the purpose of this study 3 transcription factors in different family groups have 
been selected, the reason for the selection of these 3 transcription factors is because of 
suggested properties which may make them of some importance in the biology of 
breast cancer. The transcription factors selected are; STAT3, SP1 and NFkB. The 
rational for the choice of these three transcription factors is expended on in the next 
section of the thesis but briefly, STAT3 has been studied in solid cancers and has been 
shown to act as an oncoprotein, it controls the transcription of genes important to cell 
cycle regulation and in breast cancer is associated with poor prognostic tumours. SP1 
is important to the transcription of the estrogen receptor  and ER-SP1 complexes are 
involved with the expression of other cell proliferation receptors, ER-SP1 complexes 
may also have a role in Tamoxifen resistant cancers. NFκβ have a role in proliferation 
in ER negative tumours and in metastatic behaviour of breast cancer cell lines. Other 
transcription factors were considered such as c-fos and c-jun but previous work 
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conducted at the QEH had demonstrated difficulties in showing any difference in 
levels of expression of these transcription factors in breast cancers when using IHC. It 
was felt that these 3 transcription factors were diverse enough to explore the different 
mechanism of tumour behaviour whilst also having previously been shown to be 
relevant to breast cancers.   
86 
 
1.3.2 STAT3 
Signal Transducers and Activators of Transcription (STAT) are a diverse family of 
transcription factors involved in cell cycle regulation. They are cytoplasmic proteins 
that are essential for the normal cellular responses to cytokines and growth factors. 
STATs are activated by receptor associated kinase phosphorylation (Clevenger, 2004) 
and move to the nucleus where they act as transcription factors. There are functionally 
2 different groups of STATs, firstly STAT 2, 4 and 6 which are activated by cytokines 
and play an important role in the development of T-cells and IFNγ, secondly  STAT 
1, 3 and 5 which are activated by various growth factor and are involved in mammary 
gland development. It is this second group  which are considered to be of importance 
in breast cancer biology (Calo et al., 2003). STAT1 expression in breast cancer has 
been demonstrated to be a favourable prognostic indicator relating to its role in 
growth arrest and pro-apoptotic signalling pathways (Widschwendter et al., 2002).  
 
STAT3 is classified as an oncoprotein because constitutively active STAT3 can 
mediate oncogenic transformation in cultured cells and tumorigenesis in nude mice 
(Song et al., 2004).  The inactivation of STAT3 is lethal during embryological 
development of mice (Takeda et al., 1997). Blockage of STAT3 signalling results in 
growth inhibition and apoptosis of STAT3 +ve cells in vivo and in vitro (Turkson and 
Jove, 2000, Burke et al., 2001). STAT3 is activated by phosphorylation at the tyrosine 
residue 705 (tyr705). Activation induces the formation of tyrosine phosphorylated 
STAT3 dimers which trans-locate to the nucleus. In the nucleus it binds to specific 
STAT3 DNA response elements directly controlling gene expression (Bromberg and 
Darnell, 2000, Levy and Darnell, 2002). Modulation of and maximal transcriptional 
activity of STAT3 may occur via secondary phosphorylation at a serine residue 
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(ser727) (Wen et al., 1995).  This is usually a rapid well controlled and transient 
process. STAT3 activation is predominantly via the Scr and Janus Kinase (JAK) 
pathways which occur downstream of cell membrane receptors, especially the EGFR 
and IL6/gp130 receptors (Berishaj et al., 2007, Garcia et al., 2001).  
 
     
 
 
 
 
 
 
Fig. 1.18: Diagram representing the activation of STAT3 via cytokine induced phosphorylation. 
(courtesy of Sigma Aldrich signalling)  
 
 
 
 
 
 
 
 
 
 
Fig. 1.19: Diagram showing mechanism of EGF induction of STAT3 activation. (Garcia et al., 2001) 
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Genes under the influence of STAT3 transcription include cell cycle progression and 
apoptosis control genes such as Cyclin D1, Bcl-xL and c-Myc (Bromberg et al., 
1999). STAT3 has been implicated in many of the components of malignancy 
(Aggarwal et al., 2009). STAT3 activation has a role in mediating inflammation; it 
has been shown to be an acute phase protein (the area of its initial discovery,) 
(Pfitzner E et al., 2004), it is activated by pro-inflammatory agents such as IL-6 
(Zhong et al., 1994) and has been shown to interact with NFκβ which is another 
inflammatory mediating transcription factor (Hoentjen et al., 2005). The 
transformation of cells by viruses and various oncogenes accompanies STAT3 
activation, this is seen with the Hep-C virus (Yoshida T et al., 2002) and with the T-
cell lymphotropic virus (Migone et al., 1995). As mention STAT3 activation can 
suppress apoptosis, conditional inactivation of STAT3 has a pro-apoptotic action in 
mammary gland involution (Chapman R et al., 1999), the suppression of apoptosis is 
via the products of genes including bcl-xl, bcl-2, survivn Mcl-1 and cIAP2 (Kanda et 
al., 2004). Activation of STAT3 can lead to cell proliferation due to the induction of 
cyclin D1(Masuda et al., 2002), it has also been show to upregulate the expression of 
other growth promoting genes such as myc (Kiuchi N et al., 1999). STAT3 activation 
can also mediate cellular invasion due to the regulation of matrix metalloproteinase 
(MMP1 and MMP2) which mediate cell invasion (Xie et al.). There has been shown 
to be a link between STAT3 activation and VEGF expression mediating angiogenesis 
and down regulation of STAT3 suppresses VEGF and down regulates angiogenesis 
(Li et al., 2006). Persistent or uncontrolled activation of STAT3 has been seen in solid 
tissue malignancies including myosarcomas, prostate, ovary and head and neck 
cancers (Song and Grandis, 2000, Yu and Jove, 2004).  
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Specifically in breast cancer STAT3 activation has also been shown to be involved in 
breast cancer proliferation (Li and Shaw, 2002). Persistent activation of STAT3 in 
breast cancer cell lines has been shown to induce survivin gene expression and confer 
resistance to apoptosis (Gritsko et al., 2006a). It has been shown that phosphorylation 
can be mediated by estradiol and ER via cross-talk with MAPK, Src-kinase and PI3-
kinase cascades.(Yamamoto et al., 2000b, Bjornstrom and Sjoberg, 2004). STAT3 
activation is also stimulated by EGFR and this activation contributes to growth and 
survival of breast cancer cells in culture (Garcia et al., 2001, Berclaz et al., 2001). In 
breast cancer STAT3 ser727 phosphorylation has been shown to be associated with 
ER negative tumours (Yeh et al., 2006a). STAT3 activation, in high risk breast 
cancers, is also associated with poor response to chemotherapy (Diaz et al., 2006b).  
 
There is limited evidence of the use of STAT3 as a prognostic marker with one study 
demonstrating a correlation of activated Phospho-STAT3 with improved survival in 
node negative breast cancer patients (Dolled-Filhart et al., 2003a). There are no 
studies which have assessed the correlation of STAT3 expression with tamoxifen 
resistance in ER +ve breast cancers and no large studies in unselected breast cancers 
aimed at ascertaining its role as a prognostic marker.  
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1.3.3 Sp1 
 
Sp1 is a sequence specific transcription factor that recognises GC rich promoter 
sequences. It is a product of the Sp1 gene which maps to chromosome 12q13(Dynan 
and Tjian, 1983, Kadonaga et al., 1987). Sp1 is a member of a family of Specificity 
Proteins along with Kruppel-like factors which all bind to the GC rich promoter 
genes. They are catagorised by their similar modular structure SP1-SP4 form one sub-
group with SP5-SP8 are a structurally similar but truncated group. This family of 
transcription factors playes a critical role in the normal development of tissues and 
organs (Safe and Abdelrahim, 2005). Expression of SP1 varies between tissues by at 
least 100 fold (Saffer et al., 1991). As with STAT3, Sp1 is an essential transcription 
factor controlling the expression of genes related to cell growth, survival and 
angiogenesis. On binding to these GC boxes in the promoter regions it is activated by 
phosphorylation (Jackson et al., 1990). Genes containing these regions can be 
regulated by interactions of Sp1 with ERs (Porter et al., 1997) and the number of 
genes known to be regulated by estradiol via these ER-Sp1 complexes is increasing. 
They include cyclin D1 (Castro-Rivera et al., 2001), c-fos (Duan et al., 1998), bcl2, 
IGF binding protein and DNA polymerase α (Khan et al., 2003). There is also 
evidence that these interactions between ER and Sp1 are important for the expression 
of TGFα, EGFR and progesterone receptor (Khan et al., 2003, Schultz et al., 2003a). 
It has also been shown that the Sp1 is essential for the transcription of the ERα gene 
(deGraffenried et al., 2002). It is known that ER-Sp1 complex activation does take 
place in the presence of SERMs (tamoxifen) (Saville et al., 2000). With regards to 
angiogenesis it has been shown that in some cancer cell lines Sp1 expression 
regulated the transcription of the VEGF receptor and that angiogenesis was mediated 
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by Sp1 via this induction of transcription (Shi et al., 2001). It appears that the 
transcriptional action of Sp1 is dependent on its interaction with multiple co-factors. 
These co-factors may be other transcription factors, NFκβ or c-jun, enzyme dependent 
modulation by phosphokinases etc or chemical induced modulation.  
 
 
 
Fig. 1.19: Proposed model for regulating Sp1 dependent transactivation and pathways that modulate 
this response (Safe and Abdelrahim, 2005)  
 
There is little published research into the over expression of SP1 in breast cancer 
samples, in one study 11 out of 14 breast cancers expressed SP1 compared with 1 out 
of 5 benign breast lesions (Zannetti et al., 2000). Other solid tissue tumours do 
however appear to over express Sp1 to varying degrees including 54% of gastric 
cancers (Zhang et al., 2005b), 31% of colon cancers (Maurer et al., 2007) and 45% of 
pancreatic cancers (Jiang et al., 2008). Due to its role in the transcription of the ERα 
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gene Sp1 will play an important role in the behaviour of breast cancers and may 
provide a target for future therapies. Despite this few studies have investigated its use 
as a potential prognostic marker in breast cancer. In gastric cancers there is an 
association of decreased survival in patients over expression Sp1 compared to patients 
with weak Sp1 expression (Wang et al., 2003) and it has been suggested that this may 
be an important prognostic marker. The inclusion of this prognostic marker to this 
study will allow the exploration of the use of Sp1 as a prognostic marker in breast 
cancer.      
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1.3.4 Nuclear Factor Kappa β (NFκß) 
 
NFκβ is a transcription factor first identified in 1986 named because of its binding to 
the immunoglobulin kappa light chains in B cells (Aggarwal, 2004). It was initially 
thought only to be present in B cell, later it was found to be ubiquitous in all cells.   
NFκß is a transcription factor activated in a variety of cell survival settings (Pahl, 
1999). NFκβ has many actions it is important in the inflammatory response after cell 
injury but in malignancy its predominate role is the activation of anti-apoptotic gene 
expression, it also plays a role in cell proliferation, adhesion and angiogenesis (Karin 
et al., 2002). Prior to activation NFκß exists as a hetero-dimer in the cytoplasm. It is 
bound to inhibitory sub-units known as Iκβs. The Iκβs bind to the nuclear localisation 
sequences causing its retention in the cytoplasm. It is activated via phosphorylation of 
the Iκβ and its subsequent degradation allowing translocation of NFκβ to the nucleus 
(Romashkova and Makarov, 1999). Activation of NFκβ is a tightly controlled event 
upon stimulation by various factors. Known activators of NFκβ include pro-
inflammatory cytokines such as tumour necrosis factor α (TNFα) interlukin-1β (IL-
1β), epidermal growth factor (EGF) T and B cell mitogens, viral proteins and physical 
and chemical stresses such as ionising radiation and chemotherapeutical agents. It is 
suggested that in a neoplastic setting molecular alterations may lead to loss of this 
tight control and the presence of constitutively active NFκβ (Sethi et al., 2008).  
 
Again like the other transcription factors NFκβ has been implicated in carcinogenesis 
due to its key role in cell survival, cell adhesion, inflammation differentiation and cell 
growth. NFκβ mediated the genes of growth factors including TNFα, IL-6 and IL-1β. 
These have been shown to be important in the growth of tumours such as 
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glioblastomas (TNFα) (Aggarwal et al., 1996) and head and neck cancers (IL-6) (Kato 
et al., 2000). Along with growth factors NFκβ also is important in the regulation of 
cyclin D1 a cell cycle regulatory protein (controls progression of cells from G1 into S 
phase) (Foehr et al., 2000). NFκβ activation has been shown to have anti-apoptotic 
properties in T-cell lymphomas, melanomas, pancreatic cancers (Aggarwal, 2004). It 
has also been implicated in a role of invasion of tumour cells, angiogenesis and cancer 
metastasis. See fig 1.20 
 
 
Fig 1.20 diagram showing both the multiple factors activating NKκβ and the effect of constitutive 
action leading to malignancy(Sethi et al., 2008) .  
 
Transcripts of NFκß regulated genes are found to be elevated in breast tumours when 
compared to the surrounding tissue indicating functional NFκß activity (Cogswell et 
al., 2000). Estradiol activation of Akt signalling leads to an increase in gene 
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expression containing NFκß binding sites (Kawagoe et al., 2003).NFκß expression is 
associated with the over expression of Bcl-2 in tumours with poor prognosis and may 
represent an important mechanism for the promotion of malignant behaviour in MCF7 
cells (Ricca et al., 2000). Activation of NFκß up-regulates the expression of matrix 
metalloproteinases, urokinase-type plasminogen activator and cytokines in highly 
metastatic breast cancer cell lines and may be implicated in the metatasis of breast 
cancers in vitro (Helbig et al., 2003). NFκß has been shown to have a major role in 
cell proliferation in ER –ve breast cancers (Nakshatri et al., 1997), with certain breast 
cancer cells relying on this pathway for proliferation and avoidance of apoptosis 
(Biswas et al., 2004). EGFR +ve breast cancer cells also demonstrate an increase 
basal activity of  NFκß (Biswas et al., 2000). There is some evidence that inhibition of 
NFκß can restore anti-estrogen induced apoptosis in anti-estrogen resistant breast 
cancer cells (Riggins et al., 2005). NFκß has been considered as a prognostic marker 
of disease outcome in breast cancer, though it does appear to be important in the 
prediction of response to chemotherapy (Montagut et al., 2006b) there are few papers 
describing its role in overall disease survival. 
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2. Aims of this Study. 
 
As described in the introduction and background, breast cancer in comparison with 
other solid tissue tumours, has been extensively studied at the molecular biological 
level. Despite the knowledge accumulated of the years there are still patients who 
appear to have relatively good pathological prognostic features at presentation whom 
do poorly and vice versa. This is an indication that the current understanding and 
application of prognostic pathological and molecular markers, though useful, is not 
complete.  
 
In earlier studies, the transcription factors STAT3, Sp1 and NFκß, though quite 
different in nature, have all been shown to have a possible role in breast cancer 
pathology. It may be hypothesised that as these transcription factors are so 
fundamental to the behaviour of both the normal and malignant cell they may well 
provide valuable information on the outcome of disease in breast cancer patients.  
 
There are two parts to this study; a clinical study and a cell model study. 
 
The aim of the clinical study is to identify the level of expression of the 3 
transcription factors in a cohort of unselected breast cancer patients who are 
representative of the full range of breast cancer as a disease. It is then proposed that 
the expression of these transcription factors will be correlated to the pathological 
features of the tumours.  
97 
 
The tumours will be assessed for their expression of the hormone receptors; ER, PR, 
HER2 and EGFR. This will allow correlation of the expression of these receptors to 
that of the transcription factors. The culmination of this part of the study will be the 
correlation of the expression of these transcription factors with the outcome of 
patients with respect to disease free interval and overall survival. 
 
It is proposed that the second part of this study will aim to ascertain the change in 
expression of STAT3 in breast cancers cell lines under the influence of estrogen and 
epidermal growth factor (EGF) stimulation. To do this 3 different cell models will be 
used to test the hypothesis that Estrogen and EGF not only induce STAT3 
phosphorylation but that this action may be interlinked.  
 
It if felt that it is important to understand the action of estrogen and EGF on STAT3 
activation as both of these hormones are currently targets for endocrine manipulation 
in the treatment of breast cancers. Without greater understanding of the action of these 
hormones on STAT3 activation cell behaviour may be inadvertently influenced via 
STAT3 when we use endocrine therapy in these tumours. Some of these changes in 
cell behaviour via STAT3 may adversely affect the disease outcome.       
 
To summarise the overall hypothesis for this study is; 
 
Transcription Factors STAT3, Sp1 and NFκβ are important prognostic factors in 
breast cancer survival and that STAT3 induction may change depending on 
stimulation with estrogen and EGF.  
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3 The Clinical Study 
The aim of the clinical study is to firstly ascertain the expression of the 3 transcription 
factors, STAT3 Sp1 and NFκβ, in an unselected group of breast cancers. Then it is to 
go on and correlate this expression with known prognostic factors and also to disease 
recurrence and overall survival.  
 
The hypothesis is that increased expression of STAT3, Sp1 and NFκβ is associated 
with endocrine resistance, disease recurrence and poorer survival.  
 
This section of the study was conducted with ethical approval for the retrospective 
testing of breast cancer samples with novel transcription factors. It was approved with 
an amendment to prior ethical approval via the Local Regional Ethical Committee. 
LREC ref: 52/02.  
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3.1 Methodology of Clinical Study. 
3.1.1 Selection of the patient group. 
The breast unit at the Queen Elizabeth Hospital serves a population of 200,000 people 
in the South Tyne region. It is also a regional breast screening centre. Annually the 
team of 2 consultant surgeons, breast radiologists, pathologists, oncologists and breast 
care nurses treat approximately 250 cases of screen detected and symptomatic 
invasive breast cancers. The group of patients treated represents a sample of both 
symptomatic and screen detected cancers which would be expected at any large unit 
in the UK. The treatment of these patients follows nationally agreed protocols and 
guidelines. The application of these protocols is tailored to the individual patient 
following case discussion at the weekly multi-disciplinary team meetings.  
 
To allow the collection of adequate follow-up data it was decided that a retrospective 
patient sample group should be derived from the patients diagnosed with invasive 
breast cancer in 1999. At the time of this study this would allow 7 years of survival 
data to be collected.  
 
The pathology database at the Queen Elizabeth Hospital was interrogated to generate 
a list of every sample of breast tissue received in 1999. From this list the pathology 
report for each sample was retrieved, from these reports it was possible to identify all 
the patients with a diagnosis of invasive breast cancer. As the aim of this study 
involved the retrospective testing of breast cancer samples, the patients who were 
managed non-operatively were excluded from this group due to inadequate tissue 
volume. The H&E case slides and paraffin embedded blocks of tissue were then 
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retrieved from storage. All the case slides were then reviewed by a breast pathologist 
to confirm the diagnosis of invasive breast carcinoma and select representative blocks 
for study. 
 
3.1.2 Collection of patient data. 
Patient data was obtained by a review of the hospital notes for all the patients 
identified in the study group. The following data was obtained for each patient; 
 Sex, date of birth, age at diagnosis, presentation (screening vs. symptomatic). 
 Consultant, date of operation, nature of surgery. 
 Histological type of cancer, tumour size, tumour grade, measured clearance 
margins, presence of vessel space invasion, nodal status. 
 Neo-adjuvant treatment, adjuvant chemotherapy regime, adjuvant 
radiotherapy, endocrine therapy, duration of endocrine therapy, switching of 
endocrine therapy. 
 Disease outcome, date of disease recurrence, site of recurrence, treatment for 
recurrence.  
 Survival, date of death, cause of death, length of follow up, discharge date.      
 
There were a number of patients whom were lost to hospital follow up at the Queen 
Elizabeth Hospital. Every effort was made to complete this data collection, this 
included contacting the last known general practitioners, writing to other hospitals 
when a patient had moved out of the area and contacting responsible consultants when 
a patient had been cared for in the private sector.  
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3.1.3 Principles of immunohistochemistry. 
Immunohistochemistry (IHC) is based on the principle of the specific binding of 
antibodies to antigens, usually proteins, within a tissue sample. The antibodies can be 
classified as monoclonal, recognising only one epitope of the antigen of interest, or 
polyclonal which may bind to more than one epitope. The antibodies themselves are 
not visible using light microscopy therefore they have to be attached to a dye or 
enzyme that allows visualisation. Antibodies may be primary conjugated i.e. already 
attached to a dye or enzyme (the direct method), or require a secondary antibody to be 
applied which will recognised the specific primary antibody and is attached to the 
desired dye or enzyme (the indirect method). The indirect method may be more 
sensitive than the direct method due the amplification of the reaction by more than 
one secondary antibody molecule binding to the primary antibody. 
 
In this study the IHC was performed using the indirect method. Secondary 
biotinylated antibodies couples with the enzyme streptavidin-horseradish peroxidase 
were applied as a second layer after the primary antibody. 3,3-diaminobenzidine 
(DAB) was then added which reacts with this enzyme producing a brown stain easily 
seen on light microscopy.  
 
 
 
 
 
Fig.3.1: Direct immunohistochemistry; the anti-A antibody is directly conjugated to the dye or enzyme. 
Courtesy of www.wikepedia.org  
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Fig. 3.2: Indirect Immunohistochemistry; the primary anti-A antibody is recognised by a secondary 
antibody attached to the desired dye or enzyme. Courtesy of www.wikepedia.org  
 
In this study IHC was to be carried out on archival paraffin embedded samples of 
breast tissue. In paraffin embedded blocks the antigens of interest are hidden and must 
be exposed by a process of sample retrieval. Techniques for sample retrieval included 
the use of enzyme solutions, heat treatments and microwave treatment.  
 
The optimum techniques for IHC protocols were determined by the process of 
working up an antibody using different retrieval techniques, titrations of antibodies 
and staining methods against known positive controls expressing the proteins of 
interest. Once stained the slides were then assessed with a light microscope and the 
expression of the antigen of interest scored and recorded.  
 
For this study the IHC work was performed in the Department of 
Immunohistochemistry at the Queen Elizabeth Hospital Gateshead under the 
supervision of Dr D. Hemming, Consultant cellular Pathologist. The Slides were cut 
and stained with assistance from Miss E. Scott as part of her work towards a MSc 
degree .  
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3.1.4 Preparation of samples. 
 
Following retrieval from the tissue store, paraffin embedded blocks of representative 
tumour for each case was identified. The samples were then cut with a microtome 
(LEICA RM2255 Microtome) to a thickness of 4µm. The sections were placed upon 
vecta-bonded coated glass slides and placed in an oven for 60 min at 60
0
C. Each 
section preparation was then checked with light microscope (Leitz Diaplan 
microscope). The sections were deparaffinised and rehydrated in graded ETOH. 
Following this preparation the samples were then treated with the appropriate retrieval 
method and then processed on a Techmate Horizon immunostainer (Dako 
Cytomation, Ely, Cambridgeshire UK) or a Bond Max immunostainer (Vision bio 
systems) 
 
Consumables used in processing IHC; 
Buffers - CheMate Buffer Kit No. K5006 (Dako.) 
Hydrogen Peroxide – NO.H-1009 (Sigma Aldrich Company Limited Dorset UK) 
Envision- CheMate Envision Detection Kit No.K5007 (Dako.) 
Haematoxylin – CheMate Haematoxylin No.S2020 (Dako.) 
Retrieval solution – Dakocytomation Target Retrieval Solution No. S2367 (Dako.) 
 
For the Bond Max the following reagent were used; 
Primary Antibody diluted – Bond Primary Antibody Diluent Cat No. AR932 (Vision 
BioSystems.) 
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Polymer refines Detection – Bond Polymer Refine Detection Cat No. AR9800 Anti-
NF-kB p65 CT (rabbit polyclonal IgG) Code db033 Delta biolabs, Cambridge 
Biosciences (Vision BioSystems.) 
Bond Enzyme – Bond Enzyme Pre-treatment Kit Cat No. AR9551 (Vision 
BioSystems.) 
DAB Enhancer – Bond DAB Enhancer Cat No. AR9432 (Vision BioSystems.) 
Epitope Retrieval 1 – Bond Epitope Retrieval Solution 1 Cat No. AR9961 (Vision 
BioSystems.) 
Epitope Retrieval 2 – Bond Epitope Retrieval Solution 2 Cat No. AR9640 
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3.1.5 Individual protocols used in the clinical study. 
As the antibodies for ER, PR and HER2 are routinely used in this lab the protocols for 
staining are well established. The pathology lab at the Queen Elizabeth participates in 
ICC NEQAS (an external quality assessment program). The study antibodies (EGFR, 
STAT3, SP1 and NFκß) had to be worked up and the test concentrations were 
identified after a process of optimisation. The concentrations of antibodies used were 
those which gave a consistent staining result of the positive control with the least 
background staining (i.e. clean staining).      
 
3.1.5.1 Assessment of Estrogen Receptor α (ERα) status. 
Retrieval: Dako target retrieval solution high pH, pressure cooker @121
0
C for a total 
of 2 hours 20min. 
Processor: Techmate 
TM
 Horizon Automated immunostaining Machine. 
Antibody: Dako ERα monoclonal mouse anti-human antibody M7047, concentration 
1/50 
Controls: Breast cancer ER quick score 3, 12, 18 supplied with antibody. 
 
3.1.5.2 Assessment of Progesterone receptor (PR) status. 
Retrieval: Dako target retrieval solution high pH, pressure cooker @121
0
C for a total 
of 2 hours 20min. 
Processor: Techmate 
TM
 Horizon Automated immunostaining Machine. 
Antibody: Dako M3569 Monoclonal mouse anti human PR, concentration 1/60. 
Controls: Breast cancer PR quick score 3, 12, 18 supplied. 
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3.1.5.3 Assessment of CerB-2 (HER2) status. 
Retrieval: Water bath 40min @95
0
C in Dako Epitope retrieval solution pH 9 then left 
to stand for 20 min. 
Processor: Techmate 
TM
 Horizon Automated immunostaining Machine. 
Antibody: CerbB2- Rabbit Anti-Human c-erbB-2 Oncoprotein code No. A 0485(Dako 
Cytomation, Ely Cambridgeshire, UK) concentration: 1/2500 
Control: Breast cancer controls (supplied with Hercep Test kit DAKO, Ely 
Cambridgeshire, England.) 
3.1.5.4 Assessment of EGFR.  
Retrieval: Dako target retrieval solution high pH, pressure cooker @121
0
C for a total 
of 2 hours 20min. 
Processor: Techmate 
TM
 Horizon Automated immunostaining Machine. 
Antibody: Epidermal growth factor receptor (EGFR) –Clone EGFR.25 No. NCL-
EGFR-384 (Novocastra Laboratories Limited, Newcastle – Upon –Tyne, UK) 
concentration: 1/100. 
Control: Placenta. 
3.1.5.5 Assessment of STAT3 
Retrieval: 30 mins @ 95
0
C(Bond Max Machine) Bond Epitope Retrieval Solution 1 
Cat No. AR9961 (Vision BioSystems.) 
Processor: Bond Max Automated Immunostainer. 
Antibody: Anti- STAT3 (rabbit polyclonal IgG) Code Number. 06-596 (Upstate Cell 
signalling Solutions, Hampshire, UK) concentration: 1/800 
Control: Placenta. 
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3.1.5.6 Assessment of Sp1. 
Retrieval: 30 mins @ 95
0
C(Bond Max Machine) Bond Epitope Retrieval Solution 1 
Cat No. AR9961 (Vision BioSystems.) 
Processor: Bond Max Automated Immunostainer. 
Antibody: Anti- SP1 (rabbit polyclonal IgG) Code Number. 07-645 
(Upstate Cell signalling Solutions, Hampshire, UK) concentration: 1/2000 
Control: colon. 
 
3.1.5.7 Assessment of NFkB. 
Retrieval: Dako target retrieval solution high pH, pressure cooker @121
0
C for a total 
of 2 hours 20min. 
Processor: Techmate 
TM
 Horizon Automated immunostaining Machine. 
Antibody: NFkB p65 (C20) Code Number. DB033 (Delta Biolabs, Gilroy, CA 95020) 
concentration: 1/5000 
Control: diffuse large B cell lymphoma. 
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3.1.6 Scoring of results 
The slides once stained were scored jointly by Dr D Hemming (Consultant Breast 
Pathologist) and the author. The scoring systems used varied depending on the 
receptor or protein of interest being examined. The details of the scoring systems used 
are described below. During the scoring of the slides Dr Hemming and the author 
were blind to any other details of the patient. The images shown below were taken 
with a Leica photo system in the Department of Pathology Queen Elizabeth Hospital. 
 
3.1.6.1 Scoring of ER and PR 
There are a number of systems in use for the scoring of estrogen and progesterone 
receptor in breast cancer, these include the Allred score (Allred et al., 1998) and the 
Quick score (Detre et al., 1995). Both of these methods are similar in the fact that they 
combine the proportion of stained nuclei with the intensity of the staining. 
 
 
 
 
 
 
 
 
Table 3.1: The Allred score(Allred et al., 1998). 
Score for proportion stained Score for intensity of staining  
0 = no nuclear staining 0 = no stain 
1 = <1% nuclei staining 1 = weak stain 
2 = 1-10% nuclei staining 2 = moderate staining 
3 = 11-33 % nuclei staining 3 = strong staining 
4 = 34-66% nuclei staining  
5 = 67-100% nuclei staining  
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For the Allred score the 2 values are added to give a possible score of 0-8. The cut off 
suggested for the treatment of a tumour as ER or PR positive is >3 (Leake et al., 2000, 
Harvey et al., 1999) as tumours with a score below this value were shown to be less 
likely to respond to anti-estrogen treatment.  
 
In the Quick score these 2 values are multiplied to give a score of 0-18. When the 
quick score value was compared to the quantitative Abbott enzyme immunoassay 
using a semi-quantitative H-score it was suggested that a score of 3 or greater was 
indicative of ER positive tumour (Detre et al., 1995).  
 
 
 
 
 
 
 
 
 
Table 3.2: The Quick Score(Detre et al., 1995). 
 
The histoscsore is a semiquantitative evaluation of immunocytochemical staining. It is 
performed using a histoscore which relates to the tumour ER content. Based on the 
intensity of nuclear staining a subjective integer score of 0 to 4 is given with 0 
indicating no evidence of staining. To assess the average degree of staining within a 
tumour, various regions of the tumour section are analyzed. The second parameter 
Score for proportion stained Score for intensity of staining  
0 = no nuclear staining 0 = no stain 
1 = 0-4% nuclei staining 1 = weak stain 
2 = 5-19% nuclei staining 2 = intermediate staining 
3 = 20-39 % nuclei staining 3 = strong staining 
4 = 40-59% nuclei staining  
5 = 60-79% nuclei staining  
6 = 80-100% nuclei staining  
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was the estimated proportion of stained cancer cells in percentage. The formula for 
the histoscore is:  
 
Histoscore = 2 (i + 1) x P/, where i = intensity of nuclear staining (0-4) and P, = 
percentage of stained cancer cells. 
 
In the initial studies a histoscore of >100 was considered positive for ER (Jonat et al., 
1986). Further studies showed that a histoscore of >75 correlated well with a cytosol 
analysis of 20 fmol in predicting ER sensitivity(Kinsel et al., 1989) and that a 
histoscore is equivocal if not superior to a direct cytosol binging assay in predicting 
ER response (Helle et al., 1989).   
 
These semi-quantative analyses all introduce an element of intra and inter observer 
variation. Many studies have been conducted into how to minimise that variation this 
includes the standardisation of techniques in staining, the methods of scoring and the 
use of QA programs within the pathology labs (Diaz et al., 2004). The pathology 
department here at the Queen Elizabeth Hospital is actively involved in an ongoing 
QA program as part of its role in the cancer network.  
  
In the Queen Elizabeth hospital the Quick score was routinely used for the scoring of 
ER and PR hence it is this method that was used in this study. Since this study the 
Allred scoring system has been adopted by the department. The Allred score is used 
by the majority of breast pathology units.  
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Illustrated below are examples of slides assessed for ER status; 
 
 
 
 
 
 
Fig. 3.3: Ductal carcinoma of the breast stained for ERα quick score 3. (x400)  
 
 
 
 
 
 
Fig. 3.4: Ductal carcinoma of the breast stained for ERα quick score 9. (x400) 
 
 
 
 
 
 
Fig. 3.5: Ductal carcinoma of the breast stained for ERα quick score 18. (x400) 
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Examples of staining and scoring of PR: 
 
 
 
 
 
 
Fig. 3.6: Ductal carcinoma of the breast stained for PR quick score 3. (x400) 
 
 
 
 
 
 
Fig. 3.7: Ductal carcinoma of the breast stained for PR quick score 12. (x400) 
 
 
 
 
 
 
Fig. 3.8: Ductal carcinoma of the breast stained for PR quick score 18. (x400) 
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3.1.6.2 Scoring of HER2. 
HER2 is a membrane associated receptor therefore positive results are found in 
invasive cancers with membrane staining. Membranous staining should not be seen in 
normal breast tissue. As HER2 assessment in breast cancers is now vitally important 
in planning adjuvant treatment with Trastuzumab there are widely published 
guidelines on the scoring of IHC samples. These include the American Society of 
Clinical Oncology / College of American Pathologists who recently published a 
scoring system (Wolff et al., 2007) which has been endorsed in the latest UK HER2 
testing recommendations (Walker, 2008). These guidelines score the samples negative 
if none or <10% of cell membranes are stained; 1+ (negative) if there is faint 
membrane staining in >10% of cells, 2+ (equivocal) is weak to moderate complete 
membrane staining in >10% of cells or <30% of cells with strong membrane staining 
and 3+ (positive) if >30% strong membrane staining (Walker, 2008). HER2 over 
expression can also be ascertained by the use of fluorescent in-situ hybridisation 
(FISH). This process is directed at the detection of the over amplification of the HER-
2/neu gene rather than the protein detected by IHC. The advantage of the use of ICH 
over FISH is that it is faster, more economic and easier to provide as a routine 
diagnostic IHC service (Rhodes et al., 2002). In clinical practice in the UK the use of 
FISH is limited to the confirmation of the status of the 2+ (equivocal) IHC results. 
Since this study the FISH has been superseded by the process of silver enhanced 
insitu hybridisation (SISH). This process is quicker and cheaper than FISH whilst still 
providing unequivocal results (Dietel et al., 2007). SISH has now been adopted by the 
Queen Elizabeth for the testing of its HER2 2+ ICH results. In this study the use of 
FISH was not available for these equivocal cases and a decision was made based upon 
the data in the department that the majority (80%) of IHC 2+ are FISH negative to 
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class all IHC 2+ tumours as HER2 negative. The published FISH positivity of IHC 2+ 
cancers varies from 17% (Yaziji et al., 2004) to 24% (Tubbs et al., 2007). The reason 
for the preclusion of FISH testing was limited financial funding. This decision was 
not taken without some careful consideration as it is a possible source of error within 
this part of the study. It was ascertained the proportion of cancers which were scored 
at 2+ was small, 25/213 cancers and if 80% of these cases were HER2 negative then 
20% would be wrongly classified as HER2 negative when actually being HER 2 
positive, this would equate to 5 out of 213 (2.3%) cases placed in the wrong group. It 
was felt that this was an acceptable error margin  
 
Examples of HER2 scoring.  
 
 
 
 
 
Fig. 3.9: HER2 score 0 (negative) (x400) 
 
 
 
 
 
 
Fig. 3.10: HER2 score 1+ (negative) (x400) 
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Fig. 3.11: HER2 2+ (equivocal) (x400) 
 
 
 
 
 
 
Fig. 3.12: HER2 3+ (positive) (x400). 
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3.1.6.3 Scoring of EGFR. 
 
As with HER2, EGFR is a membrane receptor and staining where positive is 
membranous. Due to the fact that EGFR is not routinely assessed on breast cancer 
samples, unlike HER2, there are no set evidenced based scoring protocols. 
Publications have included a 0-3 score similar to HER2, an H-score test or positive if 
any staining present (Walker, 2008). The studies which have used a 0-3 scoring 
system were assessing EGFR expression in high grade locally advanced cancers with 
a high overall EGFR expression(Nieto, 2007b). Our study includes cancer samples of 
all grades and stages, the overall EGFR positive cancer population was expected to be 
low. We therefore considered any membranous staining to be indicative of EGFR 
positive cancers. This scoring has been used previously in groups with lower overall 
expression (Gee et al., 2005). 
 
 
 
 
 
 
 
 
Fig. 3.13: EGFR negative, no plasma membrane staining,(x400) 
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Fig. 3.14: EGFR positive, minimal plasma membrane staining. (x400) 
 
 
 
 
 
 
 
 
Fig. 3.15: EGFR positive, florid membrane staining. (x400) 
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3.1.6.4 Scoring of STAT3. 
There have been a number of studies where IHC has been used to asses STAT3 
expression in breast cancers. The results of tumour staining have demonstrated that 
some cancer samples do not exhibit staining for STAT3, some show cytoplasmic 
staining and some strong nuclear staining. These previous studies have considered the 
nuclear staining of STAT3 to be evidence of over or up-regulated expression (Diaz et 
al., 2006b, Yeh et al., 2006a) Studies have also been published which considered the 
specificity of using nuclear staining of anti-STAT3 anti-body as a marker of activated 
STAT3 by comparing its staining to that of anti-Phospho-STAT3 antibodies in 
matched samples. These studies have shown a correlation between nuclear STAT3 
and Phospho-STAT3 staining (Yeh et al., 2006a, Dolled-Filhart et al., 2003a). It is 
based upon this published work that we graded our tissue samples as 0= no staining, 
1= cytoplasmic staining and 2= nuclear staining and considered the nuclear staining to 
be indicative of STAT3 activation.  
 
 
 
 
 
 
 
Fig. 3.16: Cytoplasmic staining of STAT3 in invasive breast cancer. (x400) 
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Fig. 3.17: Nuclear and cytoplasmic staining of STAT3 in invasive breast cancer. (x400) 
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3.1.6.5 Scoring of SP1. 
There are few studies published using IHC analysis of SP1 and none could be found 
specifically in breast cancer. The scoring of the SP1 slides in this study therefore was 
based upon methods previously described in studies looking at immunohistochemistry 
of SP1 expression in gastric carcinomas. As discussed with STAT3, nuclear staining 
is considered significant. As it appeared that the majority of samples were found to 
exhibit a degree of nuclear SP1 staining an assessment of the degree of staining has to 
be made. Based upon these previous studies the slides were assessed upon the 
percentage of the population and the intensity of the nuclear staining. Using this 
method the slides were graded into 3 groups; 0 = negative, 1= weak, and 2=strongly 
positive. For the data analysis the strongly positive group were considered to have 
over-expression of nuclear SP1 (Zhang et al., 2005b, Wang et al., 2005).  
 
 
 
      
 
 
 
 
Fig. 3.18: SP1 negative, minimal cytoplasmic staining only. (x400) 
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Fig. 3.19: SP1 weak positive score 1 (25-50% cell, moderate intensity) (x400) 
 
 
 
 
 
 
 
 
Fig. 3.20: SP1 strong positive score 2 (>50% cells moderate intensity) (x400) 
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3.1.6.6 Scoring of NFκß. 
 
NFκß is transcriptionally active when it has translocated from the cytoplasm to the 
nucleus. The scoring system for this antibody is dependent on the location of the stain 
in the cell. In this study we determined if staining was present in the sample and then 
the location of the staining. If the staining was absent or located only in the cytoplasm 
then these samples were considered to be nuclear NFκß negative. If nuclear staining 
was present irrespective of the presence of cytoplasmic staining then the sample was 
considered nuclear NFκß positive. There have been a number of published studies 
which have used a similar IHC scoring protocol which was then validated with either 
cDNA micro-arrrays looking for NFκß dependent gene products (Van Laere et al., 
2007b) or electrophoretic mobility-shift assay (Biswas et al., 2004). The assumption 
that nuclear NFκß staining indicates the transcriptions factor in its active state is now 
widely held  (Biswas et al., 2004, Montagut et al., 2006b, Ghosh and Karin, 2002). 
 
 
 
 
 
 
 
 
Fig. 3.21: Cytoplasmic staining of NFκß with no nuclear staining. (x400) 
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Fig. 3.22. Nuclear and cytoplasmic NFκß staining (x400)  
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3.1.7 Power of the Study 
Without knowing the prevalence of expression or effect of expression of the selected 
transcription factors it was not possible to calculate the sample size necessary to 
adequately power the study directly regarding these transcription factors. We did 
consider the sample size required to power the study with 80% power to detect the 
25% survival difference with an α type 1 error rate of 0.05 when considering ERα 
expression. This calculation determined that a total sample size of 140 was adequate. 
This calculation was performed using Epi Info 2000. (EpiInfo was developed by the 
Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.) with the 
kind help of Dr T Chadwick, University of Newcastle upon Tyne. (see appendix)  
 
3.1.8 Statistical analysis. 
The association between ICH results and pathological features were assessed using 
the X
2
 and Fisher exact test where indicated. Survival was plotted using the Kaplan-
Meier method. The log-rank method was used to study the correlation of possible 
prognostic variables with survival times. Multi-variant analysis of survival was 
performed using the Cox-regression model including the identified significant 
variables of tumour grade, size and lymph node involvement. All the statistical tests 
were conducted at the two-sided tailed 0.05 level of significance. Statistical analysis 
was performed with the SPSS Statistical Software, 15.0 version. (SPSS, Inc, Chicago, 
IL, USA.)      
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3.2 Results of Clinical Study.  
3.2.1 Patient group demographics. 
During 1999, 213 patients were diagnosed with invasive breast cancer and received 
surgical treatment in the Queen Elizabeth Breast unit. Of these patients 204 were 
suitable for use in the study in that there was sufficient tumour tissue and full survival 
data. This group of 204 patients presented with 206 cancers i.e. 2 patients had 
bilateral cancers. There were 2 cases of male breast cancer within the group. The age 
range of the patients was 27 - 87 years old with a mean age of 57 (fig 3.23 & 3.24).  
72 (35%) of the patients presented with asymptomatic breast cancers via the N.H.S. 
breast screening program. All the patients were discussed at the multi-disciplinary 
team meeting at the time of diagnosis. The patients’ management was directed by the 
guidelines at the time with regards to the surgical intervention and any neo-adjuvant 
or adjuvant therapy. 
 
  
 
 
 
 
 
 
 
Fig. 3.23: Bar chart showing the age at the time of diagnosis of the 204 patients in the study group. 
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Fig.3.24: Survival curve showing the effect of age group at the time of diagnosis on overall survival. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.25: Survival curve showing the significant affect of mode of presentation (screening vs 
symptomatic) on overall survival. 
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P = 0.041
Cancer type and 5 year survival.
3.2.2 Pathological features of study group. 
3.2.2.1 Histological type of breast cancer.  
The breast cancer histological type was ascertained from the initial histological report. 
Any samples without a defined histological type were re-examined by the breast 
pathologist.   
 
 
 
 
 
 
Table 3.3: Table showing the histological type of breast cancers diagnosed within the study group. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.26: Survival curve showing the significant affect of the histological type of breast cancer 
(special type vs. NST) on overall survival. 
Type  Number (%) 
Ductal  174 (85%) 
Lobular 21 (10%) 
Tubular 7 (3%) 
Mixed 2 (1%) 
Mucinous 1 (0.5%) 
Medullary 1 (0.5%) 
Total 206 (100%) 
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3.2.2.2 Tumour Grade.  
The cancers were graded according to the Elston and Ellis modification of the Bloom 
and Richardson system. Again if the initial grading was unclear the samples were re-
examined.  
 
 
 
 
 
 
Table 3.4:Table showing the grade of cancers diagnosed in the study groups.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.27: Survival curves showing the significant affect of tumour grade on overall survival. 
 
Grade Number (%) 
1 58 (28%) 
2 98 (48%) 
3 50 (24%) 
Total 206 
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3.2.2.3 Tumour size. 
The tumour size was recorded from the initial pathology report. The range of size was 
1mm to 190mm with a mean of 20.81mm. Median tumour size 18mm. The tumour 
sizes were divided into the staging groups of T1 <20mm, T2 20-50mm, T3 >50mm. 
 
 
 
 
 
Table 3.5: Table showing the distribution of tumour sizes diagnosed in the study group.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.28: Survival curves showing the significant affect of tumour size upon over all survival. 
T size Gp. Number (%) 
T1 <20mm 118 (57%) 
T2 20-50mm 80 (39%) 
T3 >50mm 8 (4%) 
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3.2.2.4 Vessel space invasion. 
The presence or absence of vessel space invasion was reported in all 206 cancer 
samples. Vessel space invasion was present in 53 (26%) of the 206 samples.   
 
 
 
 
 
 
Table 3.6 Table showing the presence of vessel space invasion in the tumour samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.29: Survival curves showing the significant affect of vessel space invasion on overall survival. 
Vessel space 
invasion Number (%) 
No 153 (74%) 
Yes 53 (26%) 
Total 206 
131 
 
Months following diagnosis.
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3.2.2.4 Lymph node status. 
The lymph node status was available on 205 out of the 206 cancers operated on. The 
missing case was an elderly lady considered not fit for axilliary surgery. 
 
 
 
 
 
 
Table 3.7: Table showing the lymph node involvement of the study group, the results have been split 
into the 3 prognostic groups used in calculating NPI. 5 yr overall survival rates are also shown.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.30: Survival curves showing the significant affect of lymph node metastases on overall survival. 
 
Nodal status Cases 5yr OS 
Negative 130 86% 
1-3 nodes involved 59 64% 
>3 nodes involved 16 44% 
Total 205  
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3.2.2.5 Nottingham Prognostic Index (NPI).  
The NPI was calculated for the 205 patients that we had the nodal status available. 
 
 
 
 
 
 
Table 3.8: Table showing the distribution of cases in the study group when NPI was calculated, 5 yr 
survival is also shown. 
 
 
 
 
 
 
 
 
 
 
     
Fig. 3.31: Survival curve showing the significant affect of NPI group on overall survival. 
 
NPI score Prognostic Gp. Number 5yr OS 
<2.4 Excellent  44 94% 
2.5 - 3.3 Good 41 88% 
3.4 – 5.4 Moderate 95 77% 
> 5.4 Poor 25 42% 
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3.2.2.6 Type of surgery performed. 
The patients’ operation type was defined as breast conserving surgery including wide 
local excisions, lumpectomies, quadrentectomies or as a total mastectomy. If a patient 
initially underwent a breast conserving procedure which following pathology results 
proceeded to a mastectomy they were placed in the mastectomy group.  
 
 
 
Table 3.9: Table showing the type of surgery performed. 
 
 
 
 
 
 
 
 
 
Fig. 3.32: A pie chart representing the mastectomy rate of 52%. 
 
 
Type of surgery Number (%) 
Breast conserving 
surgery 99 (48%) 
Mastectomy 107 (52%) 
Total 206 
134 
 
0
2
4
6
8
10
12
14
0-12 13-
24
25-
36
36-
48
49-
60
61-
72
>72
Months 
Time from Diagnosis to Recurrence  
Number of recurrences
3.2.2.7 Disease Recurrences: 
In the sample group there were recurrences of metastatic breast cancer in 50 cases. A 
number of cases had multiple sites of recurrence of the disease. The recurrences were 
recorded under the first site of recurrence.  
 
 
 
 
 
 
 
 
Table 3.10: Table showing the site of first recurrence in the 50 cases in the study group.   
 
 
 
 
 
 
 
 
 
Fig.3.33: Bar Chart to show time from diagnosis to first recurrence of disease. 
 
Site Number (%) 
Local 17 (34) 
Bone 14 (28) 
Lung 8 (16) 
Liver 7 (14) 
Brain 3 (6) 
Choroid 1 (2) 
Total 50 
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3.2.2.8 Correlation of Pathological features. 
When the pathological features had been collected the relationship between each of 
the pathological features was compared along with 5 year survival.  
 
 
Table 3.11: Summary table showing the significant correlation between the pathological features and 5 
year survival (RIP5yr).* The Chi-square statistic is significant at the 0.05 level. a:  The Chi-square test 
is not performed for this sub-table because row and column variables are identical. (Tsizegp= tumour 
size group, VSI= vessel space involvement, Nodescore=axillary lymph node stage, NPIgp= NPI 
prognostic group, RIP5yr= overall 5 yr survival.)  
 Grade Tsizegp VSI Nodescore NPIgp RIP5yr 
Grade Chi-square . 24.631 20.402 19.150 179.771 10.005 
Df . 4 2 4 6 2 
Sig. .(a) >.001(*) >.001(*) .001(*) >.001(*) .007(*) 
Tsizegp Chi-square 24.631 . 17.864 71.102 94.007 6.414 
Df 4 . 2 4 6 2 
Sig. >.001(*) .(a) >.001(*) >.001(*) >.001(*,) .040(*) 
VSI Chi-square 20.402 17.864 . 56.906 36.221 15.135 
Df 2 2 . 2 3 1 
Sig. >.001(*) >.001(*) .(a) >.001(*) >.001(*) >.001(*) 
Nodescore Chi-square 19.150 71.102 56.906 . 113.555 25.622 
Df 4 4 2 . 6 2 
Sig. .001(*) >.001(*) >.001(*) .(a) >.001(*) >.001(*) 
NPIgp Chi-square 179.771 94.007 36.221 113.555 . 27.845 
Df 6 6 3 6 . 3 
Sig. >.001(*) >.001(*) >.001(*) >.001(*,b) .(a) >.001(*) 
RIP5yr Chi-square 10.005 6.414 15.135 25.622 27.845 . 
Df 2 2 1 2 3 . 
Sig. .007(*) .040(*) >.001(*) >.001(*) >.001(*) .(a) 
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A short comment on the above table; it has to be appreciated when testing multiple 
variant against each other of the increased probability of finding a spurious correlation 
between these factors. This is due to the numbers of times the test is performed and 
the small numbers in some of the groups. To ascertain if there is a significant 
correlation each factor should be subjected to a multivariate analysis, this would 
control for the influence of the other factors on the outcome and therefore 
demonstrate if the correlation is meaningful. 
 
In the following section there are a number of discrepancies in the numbers of 
positive and negative receptor in the tables, this is due to the fact that in some of the 
cancers not all the receptor status was known i.e. one cancer may have and ER or 
EGFR known but not a PR status.  
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3.2.3 Hormone receptor expression. 
3.2.3.1 The Estrogen Receptor: 
The ER status was determined on 196 cancer samples. There were a number of 
samples in which it was not possible to stain for ER due to technical problems e.g. 
insufficient tumour samples left in the blocks.  
 
 
 
Table 3.12: Table of ER status results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.13: Table showing the distribution of ER status in for each pathological feature and for 5 year 
survival(Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary lymph node 
stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.)  
ER status Number (%) 
ER +ve 139 (71%) 
ER –ve 57 (29%) 
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Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
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Table 3.14: Table showing the correlation between ER status and pathological features, 5 year 
survival included. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.34: Survival curves showing the significant affect of ER status on overall survival.  
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3.2.3.2 Progesterone Receptor. 
The progesterone receptor status was ascertained in 195 cases within the study group. 
As with the ER status there were a number of samples where the block cut out and no 
tumour could be retrieved.  
 
 
 
Table 3.15: Table showing PR status of cases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.16: Table showing the distribution of PR status in for each pathological feature and for 5 year 
survival. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary lymph 
node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
  
PR status Number (%) 
PR +ve 132 (68%) 
PR –ve 63 (32%) 
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Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
More than 20% of  cells in this subtable have expected
cell counts less than 5. Chi-square results may  be
invalid.
a. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.17: Table showing the correlation between PR status and pathological features, 5 year 
survival included. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
 
 
 
 
 
 
 
 
 
Fig. 3.35: Survival curves showing the significant affect of PR status on overall survival 
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1.2.5 EGFR in breast cancer. 
 
The ER/PR combined expression demonstrated the following results in 194 cases. 
 
 
 
 
 
 
Table 3.18: Table showing the co-expression of ER and PR.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.36: The survival curves were plotted but the significance is limited due to the small numbers in 2 
of the groups (ER+ve/PR-ve and ER-ve/PR+ve). 
ER/PR status Number (%) 
ER+ve / PR+ve 128 (66%) 
ER+ve / PR-ve 10 (5.1%) 
ER-ve / PR+ve 3 (1.6%) 
ER-ve / PR-ve 53 (27.3%) 
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3.2.3.4 HER2 receptor. 
HER2 receptor status was successfully tested for in 200 of the sample cases. As 
discussed earlier the IHC result 2+ was not reassessed with FISH and in this study is 
considered HER2 negative. When the HER2 0, 1+ and 2+ groups were compared 
there was no statistically significant difference between the groups and pathological 
feature and survival. 
 
 
 
 
 
 
 
 
 
Table 3.19: Table showing the results of the  
HER2 for the study group.  
 
 
 
 
Table 3.20: Table showing the distribution of HER2 status in for each pathological feature and for 5 
year survival. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary lymph 
node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
  
HER2 score Number (%) 
0 90 (44%) 
1+ 33 (17%) 
2+ 25 (13%) 
3+ 55 (26%) 
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Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.21: Table showing the correlation between HER2 status and pathological features, 5 year 
survival included (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
 
 
 
 
 
 
 
 
Fig. 3.37: Survival curves showing a non significant trend towards poorer survival in the HER+ group 
When this was re-plotted for cancer specific deaths the p value was significant at 0.009.  
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3.2.3.5 HER2 and ER Status  
Following the IHC results for HER2 the co-expression between ER and HER2 could 
then be investigated. . 
 
 
 
 
 
Table 3.22: Table showing the co-expression of ER and HER2 in the study group. 
 
 
 
 
 
 
 
 
 
 
 
Fig.3.38: Survival curves of each of the ER/HER2 groups showing little additional impact of the HER2 
status over the ER status. 
ER/HER2 status Number. 
ER+ve/HER2+ve 27 (14%) 
ER+ve/HER2-ve 111 (57%) 
ER-ve/HER2+ve 23 (12%) 
ER-ve/HER2-ve 34 (17%) 
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3.2.3.6 EGF Receptor. 
EGF receptor status was determined in 203 cases of invasive breast cancers. 
 
 
 
Table 3.23: Table showing the results of the EGFR status in the study group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.24: Table showing the distribution of EGFR status in for each pathological feature and for 5 
year survival. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary lymph 
node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
 
  
EGFR status Number (%) 
EGFR +ve 19 (9.4%) 
EGFR –ve 184 (90.6%) 
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Pearson Chi-Square Tests
11.283
2
.004*
9.389
2
.009*,a
2.391
1
.122
2.214
2
.331
8.684
3
.034*,b
39.633
1
.000*
30.522
1
.000*
1.094
1
.296
12.283
1
.000*,b
Chi-square
df
Sig.
Grade
Chi-square
df
Sig.
Tsizegp
Chi-square
df
Sig.
VSI
Chi-square
df
Sig.
Nodescore
Chi-square
df
Sig.
NPIgp
Chi-square
df
Sig.
ER
Chi-square
df
Sig.
PR
Chi-square
df
Sig.
HER2
Chi-square
df
Sig.
RIP5y r
EGFRsc
Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
The minimum expected cell count in this subtable is
less than one. Chi-square results may  be invalid.
a. 
More than 20% of  cells in this subtable have expected
cell counts less than 5. Chi-square results may  be
invalid.
b. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.25: Table showing the correlation between EGFR status and pathological features, 5 year 
survival included (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival. 
 
 
 
 
 
 
 
 
 
Fig. 3.39: Survival curves showing significant poorer outcome for the EGFR+ve cancers. 
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As described earlier EGFR is one of the growth factor receptors that when activated 
form a heterodimer with the orphan receptor HER2. The results of the HER2 positive 
breast cancers split by their EGFR status were plotted below. Of the 54 HER2 
positive cancers 7 of these were EGFR positive. The survival curves for this group 
were plotted below. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.40: Survival curve showing the significant effect on EGFR status on HER2 positive cancers.  
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3.2.4 Transcription factor results. 
The overall staining results for the 3 transcription factors in the clinical study are 
shown in the appendix. 
3.2.4.1 STAT3 expression. 
209 cancer samples were successfully assessed for stat3. Overall 56 (26.8%) of the 
tumours demonstrated nuclear staining for STAT3 and were graded as STAT3 
positive.  
 
 
 
 
 
 
 
 
Table 3.26: Table showing the STAT3  
staining characteristics of all of the 209 patients. 
 
 
 
Table 3.27: Table showing the distribution of STAT3 results for other pathological features and 
hormone receptor status. (Tsizegp= tumour size group, VSI= vessel space involvement, 
Nodescore=axillary lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
  
STAT3 status Number (%) 
0 : negative 9 (4.3%) 
1 : faint 80 (38.3%) 
2 : cytoplasmic 64 (30.6%) 
3 : nuclear 56 (26.8%) 
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Pearson Chi-Square Tests
21.600
2
.000*
10.873
2
.004*
4.470
1
.034*
8.365
2
.015*
23.815
3
.000*
8.696
1
.003*
9.013
1
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1
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7.360
1
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1.799
1
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Chi-square
df
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EGFRsc
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Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.28: Table showing the correlation between STAT3 positivity and other pathological features 
and hormone receptor status. (Tsizegp= tumour size group, VSI= vessel space involvement, 
Nodescore=axillary lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
 
 
 
 
 
 
 
 
 
Fig 3.41: Survival curves showing a trend towards poorer survival in STAT3 positive cancers.  
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p = 0.04
 
 
 
 
 
 
 
 
 
 
Fig. 3.42: Survival curves demonstrating the significant relationship between STAT3 positivity and 
disease recurrence.  
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The affect of Stat3 expression on 5 year survival in HER2 
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p = 0.098
3.2.4.2 Stat3 and HER2 expression.  
As discussed earlier STAT3 has been identified as one of the end points of HER2 
related intracellular signalling. It therefore is reasonable to assess the impact of 
STAT3 status depending on HER2 expression. 
 
 
 
Table 3.29: Table showing the distribution of STAT3 and HER2 results.  
 
 
 
 
Table 3.30: Table showing the 5 year survival (%) dependent on STAT3 and HER2 expression. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.43: Survival curves showing the trend towards poorer survival in the STAT3 positive HER2 
positive cancers. 
Total cases HER2 negative HER2 positive 
Stat3 negative 115 37 
Stat3 positive 39 27 
% 5yr survival HER2 negative HER2 positive 
Stat3 negative 88% 77% 
Stat3 positive 81% 53% 
152 
 
Months following diagnosis
100806040200
C
u
m
 S
u
rv
iv
a
l
1.0
0.8
0.6
0.4
0.2
0.0
pos-censored
neg-censored
pos
neg
STAT3sc
Stat3 Expression and 5 year Survial in Node Negative Breast 
Cancer
p= 0.017
3.2.4.3 STAT3 expression in node negative breast cancers. 
One of the aims of this study was to identify the group of low risk breast cancers 
(those whom we expect good prognosis) who do poorly. To this end we analysed the 
affect of STAT3 expression in lymph node negative breast cancers.  
 
 
 
 
Table 3.31: Table showing the distribution of STAT3 positivity in node negative breast cancers and the 
5 year survival of each group (%). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.44: Survival curve showing the significant relationship between STAT3 positivity and poor 
survival in node negative breast cancers. 
 
Node negative Cancers Number 5yr DFS % 
Stat3 negative 100 94% 
Stat3 positive 23 78.3% 
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3.2.4.3 SP1 expression.  
SP1 expression was determined in a total of 208 samples in the study group. 68 
(32.7%) of these cancers demonstrated nuclear staining and were determined as SP1 
positive.  
 
 
 
Table 3.32: Table showing the results of the Sp1 staining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.33: Table showing the distribution of SP1 results for other pathological features and hormone 
receptor status. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival. 
  
SP1 Status Number (%) 
Non – nuclear (negative) 140 (67.3%) 
Nuclear (positive) 68 (32.7%) 
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Pearson Chi-Square Tests
3.382
2
.184
3.727
2
.155
.801
1
.371
1.458
2
.482
4.112
3
.250
5.892
1
.015*
1.012
1
.314
.367
1
.544
1.287
1
.257
3.559
1
.059
Chi-square
df
Sig.
Grade
Chi-square
df
Sig.
Tsizegp
Chi-square
df
Sig.
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Chi-square
df
Sig.
Nodescore
Chi-square
df
Sig.
NPIgp
Chi-square
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Sig.
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Chi-square
df
Sig.
PR
Chi-square
df
Sig.
HER2
Chi-square
df
Sig.
EGFRsc
Chi-square
df
Sig.
RIP5y r
SP1sc
Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.34: Table showing the correlation between Sp1 and other pathological features and hormone 
receptor status. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
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Fig 3.45 Survival curves showing improved disease free survival in the SP1 positive group.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.46: Survival curves showing the trend towards improved survival in the Sp1 positive group.  
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The overall survival curves (fig. 3.45) appear to show a divergence of the lines after 2 
years of follow up. To assess the significance of this we selected all the patients who 
had survived 24 months after diagnosis and re-plotted that groups survival dependent 
of Sp1 expression. 
 
 
 
 
 
 
 
 
 
 
Fig 3.47: Survival curves showing the improved outcome in the Sp1 positive group after 24 months of 
follow up.  
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3.2.4.4 NFκß. 
208 samples were successfully analysed for NFκß expression. Of these samples 31 
(14.9%) of the cancers demonstrated nuclear staining and were determined to be 
NFκß positive. 
 
 
 
 
Table 3.35: Table showing the distribution of NFκß staining in the 208 samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.36: Table showing the distribution of Nfκß for other pathological features and hormone 
receptor status. (Tsizegp= tumour size group, VSI= vessel space involvement, Nodescore=axillary 
lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.)  
NFκß status Number (%) 
No stain 93 (44.7%) 
Cytoplasmic 84 (40.4%) 
Nuclear 31 (14.9%) 
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Pearson Chi-Square Tests
13.252
2
.001*
8.472
2
.014*
.126
1
.723
.088
2
.957
8.781
3
.032*
7.590
1
.006*
10.887
1
.001*
3.218
1
.073
7.301
1
.007*,a
.086
1
.770
Chi-square
df
Sig.
Grade
Chi-square
df
Sig.
Tsizegp
Chi-square
df
Sig.
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Chi-square
df
Sig.
Nodescore
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df
Sig.
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Chi-square
df
Sig.
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Sig.
PR
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Sig.
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Chi-square
df
Sig.
EGFRsc
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df
Sig.
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Results are based on nonempty  rows and columns in each
innermost subtable.
The Chi-square statistic is signif icant at the 0.05 level.*. 
More than 20% of  cells in this subtable have expected
cell counts less than 5. Chi-square results may  be
invalid.
a. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.37: Table showing the correlation between NFκß positivity and other pathological features 
including hormone receptors status. (Tsizegp= tumour size group, VSI= vessel space involvement, 
Nodescore=axillary lymph node stage, NPIgp= NPI prognostic group, RIP5yr= overall 5 yr survival.) 
 
 
 
 
 
 
 
 
 
Fig. 3.48: Survival curves demonstrating no correlation between NFkB expression and recurrence.   
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Fig. 3.49: Survival curves demonstrating that NFκß status has no effect on overall outcome. 
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3.3 Discussion of the Clinical Study Results. 
3.3.1 The patient group demographics.  
The demographics recorded show that the patients in the study group were largely 
representative of the overall population of breast cancer patients. The age range and 
distribution correlates with the published data from 2005(Office of National Statistics, 
2008). There was a peak in the age of diagnosis in the early 50’s which corresponded 
with the commencing of screening of patients in that age group (fig 3.23). There was 
no statistically significant affect of age of diagnosis on overall survival, there was a 
trend towards an improved outcome in the 45 – 65 year old population (fig 3.24). This 
may be accounted for by the increased proportion of screen detected cancers within 
this group. The poorer survival of the younger patients is well recognised. The poorer 
outcome in overall survival of the older patients may be explained by the non-cancer 
related deaths in this group however when analysed for disease recurrences, this 
group also had a trend towards a poorer outcome. This group will contain a higher 
proportion of symptomatic rather than screen detected cancers. The NHS breast 
screening program (NHSBSP) detected 14,000 (30%) of the 46,000 breast cancers 
diagnosed nationwide in 2005(Office of National Statistics, 2008). Local provision of 
the NHSBSP with the Queen Elizabeth Breast Unit providing screening services for 
its own and neighbouring primary care trusts has increased this proportion of screen 
detected cancers in this study group to 35%. The significant positive impact of the 
screening program can be seen in the effect that the mode of diagnosis has on disease 
free survival (fig 3.25). The screen detected cancers had a five year disease free 
survival of 93% compared to 72% for the symptomatic cancers (p=0.001). This 
improved outcome is due to the fact that 53% of cancers detected by the NHSBSP are 
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15mm or less and may not have been detected by clinical examination(The 
Information Centre, 2008). 
3.3.2 Pathological Features.  
The histological types of breast cancers in the study group (table 3.3) was 
representative of the tumour types expected with 85% of the cancer being non-special 
type ductal carcinomas. The improved survival outcome of special type cancers  in 
comparison to non-special type ductal cancers is well documented (Ellis I.O., 1992) 
and this has also been shown in this study group, 91% vs. 73% respectively (p = 
0.041) (fig 3.26)  
 
The majority of breast cancers diagnosed were grade 2 cancers (48%) with grade 1 
and grade 3 cancers representing 28% and 14% of the cases (table 3.4). Grade of 
cancer is an important prognostic factor and is used as one of the components of the 
Nottingham Prognostic Index (NPI).  The significant effect of grade on survival is 
shown in the survival curves plotted (fig 3.27). 
 
The tumour size was recorded in each case and there was a wide range of size found 
from 1mm to 190mm. The cancers were divided into size groups according to the 
TNM staging system (table 3.5). The majority of the tumours in the group were T1 
cancers (<20mm). This group includes the small screen detected cancers. Again the 
size of the tumour is known to be an important independent prognostic factor and this 
was demonstrated in this study group with the larger T3 tumours having a 
significantly poorer outcome compared to the smaller T1 tumours. (fig. 3.28) 
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Though not used in the NPI, lympho-vascular vessel space invasion (VSI) is 
recognised as an independent prognostic indicator. The presence of VSI is important 
when making decisions regarding adjuvant therapy. The results of this study show 
that VSI was seen in 26% of the cancers (table 3.6). The presence of VSI had a 
significant detrimental effect on survival, the 5 year survival of patients with VSI in 
the tumour was 59% compared with 84% in the group without (p=<0.001) (fig. 3.29).  
 
Lymph node status is established as the single most significant prognostic factors in 
invasive breast cancers (Carter C.L., 1989). The lymph node status was available on 
205 of the cancers in the group. As expected the presence of lymph node metastases 
had a significant effect on survival. The 5 year survival decreased as the burden of 
nodal disease increased. Node negative patients had a 5 yr survival of 89% compared 
with 64% with 1-3 nodes involved and 44% in those with more than 3 nodes involved 
(table 3.7). The survival curves (fig. 3.30) illustrate the significant relationship of 
node status and recurrence. 
 
The Nottingham Prognostic Index (NPI) was plotted for all of the cases where the 
components (tumour grade, size and node status) were available. The results show the 
expected distribution of cases between the NPI groups (table 3.8) and the predictive 
value of NPI group on overall survival (fig 3.31). 
 
The type of surgery performed was recorded in all cases; the operation recorded was 
the definitive surgical procedure, i.e. the final operation performed. There are a 
number of patients whom may initially have undergone breast conserving surgery but 
due to involved margins, mammographically invisible disease or multi-focal disease 
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went on to have a completion mastectomy. There has always been a wide variation in 
the rates of breast conserving surgery compared to mastectomies between different 
breast units. This is not necessarily related to the pathological features of the cancers 
presenting to the unit (Caldon et al., 2005), but more related to patient choice and 
communication with patients. The mastectomy rate at the QEH breast unit in 1999 
was 52% (table 3.9, Fig 3.32).   
 
During the follow-up period any incidences of disease recurrence were recorded 
irrespective as to whether the recurrences lead to a patient death. There were 50 
patients who suffered a recurrence of their disease (table 3.10). The most common site 
of recurrence was local to the primary tumour 34%. This group included recurrence in 
the same breast (if breast conserving surgery had been the initial treatment), chest 
wall recurrence and local lymphatic recurrence. It did not include cancers of the 
contralateral breast which were recorded as a second primary breast cancer. Bone 
metastases 28% was the next most common site followed by lung 16%, liver 14%, 
brain 6% and 1 case of a choroid metastases. The time between diagnosis and 
recurrence of disease was also recorded (fig. 3.33) and showed a diminishing 
incidence of recurrence as the time from diagnosis increases. This does not quite 
follow the bimodal curve of recurrence well established by previous large studies 
(Romano D., 2008). In the bimodal model there is a peak of incidence of recurrence in 
the after 24 months with a second broader peak after 60 months. In this study there 
was a high incidence of recurrence in year 1 compared with year 2 but the numbers 
are small in each group (13 cf 11 respectively). With greater numbers the group may 
become representative of the bimodal model.  
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In summary the pathological feature of this study group conformed to expectations 
and standards set by previous studies in breast cancer. The correlations of these 
pathological features are shown in table 3.11. This table shows that there is a 
significant relationship between all the pathological feature listed and 5 year survival.  
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3.3.3 The Receptor Status.  
3.3.3.1 Estrogen receptor.  
We determined the ER status of 196 cancers using IHC. There were problems with 
some very small cancers cutting out of the blocks reducing the numbers of results 
available. In this study group 71% of the patients had ER positive tumours (table 
3.12). It has been long established that ER status is an important factor in breast 
cancer correlating to pathological features and overall survival. In this study group ER 
positive tumours were significantly related to low grade tumours (p=<0.001), smaller 
tumours (p=0.024), negative VSI (p=<0.001), node negative tumours (p=0.006) (table 
3.14) and increased overall survival (p=<0.001) (fig. 3.34). These results all agree 
with previously published work (Fisher et al., 1988, Grann et al., 2005, Aaltomaa et 
al., 1991) and it is now widely agreed that ER status in an independent prognostic 
marker of disease outcome. Our results also demonstrated a significant relationship 
between ER positive and PR positive cancers (p=<0.001), this is not surprising as 
progesterone receptors expression is induced by estrogen (Schultz et al., 2003a). This 
study showed an inverse correlation between ER positive and HER2 positive tumours 
(p= 0.011). This is well recognised and described in previous studies, (Ciocca, 1992, 
Witton, 2003) though it is suggested that this relationship or predictive power of ER 
status on Her2 status is more apparent in the elderly patients and less significant in 
those younger patients (Huang, 2005). Along with an inverse correlation with HER2 
the ER results also showed a similar relationship with EGFR (p=<0.001). This agrees 
with previous studies demonstrating this correlation. (Zeillinger, 1993, Klijn, 1994)  
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3.3.3.2 Progesterone receptor.  
PR status was determined in 195 of the sample cases. Of these cases 132 (68%) of the 
cancers were PR positive (table 3.15). As described above there is a strong correlation 
between ER expression and PR expression. As the PR gene transcription is regulated 
by oestrogen PR expression is considered to be a marker of functioning ER (Horwitz, 
1978).  
PR expression is known to be strongly associated with ER expression and other 
positive predictive markers this study has shown like wise; PR expression is 
significantly associated with low grade (p=<0.001), negative VSI (p=0.003),  lower 
NPI group (p=<0.001) (table 3.17), and an increased 5 year survival (p= 0.001) (fig 
3.35). When considering PR correlation with other receptors it is clear that it is 
significantly associated with ER (p=<0.001) and like ER it is also negatively 
correlated to HER-2 (p=< 0.001) and EGFR (p=<0.001) (table 3.17).  
 
3.3.3.3 Combined ER and PR  
In this study it was shown that the majority of the tumours were ER/PR double 
positive (66%) or ER/PR double negative (27%) (table 3.18). The impact of this on 
survival is clearly seen on the survival curves with the double negative tumours doing 
poorly (fig. 3.36). The other 2 groups ER+ve/PR-ve (5.1%) and ER-ve/PR+ve (1.6%) 
are too small to attach and significance to. In larger studies it has been suggested that 
PR positive ER positive cancers are more responsive to hormonal therapy and hence 
have a better outcome when compared to PR negative ER positive cancers. This again 
is based on the theory of the PR representing a functioning ER signalling 
system.(Bardou, 2003)    
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3.3.3.4 HER-2. 
In this study we have shown that HER2 is over expressed in 26% of the cases it was 
technically possible to assess (table 3.19). The literature published on this is varied 
suggesting that over expression of HER2 occurs in 10-30% of invasive breast cancers 
(Ciocca, 2006). Though the assumption that we made regarding the samples scoring 2 
(assigning them as HER2 negative,) may have reduced slightly the proportion of 
cancer we classified as HER2 positive, we still have reported an over expression rate 
greater that that seen in some other studies. There now has been a revision of the 
expected rates of HER expression in an unselected group of cancers bases on UK 
audit data (Walker et al., 2008). See below;  
 
 
Table 3.37: data of HER2 positivity in unselected cases  (FISH, fluorescence in situ hybridisation; 
IHC, immunohistochemistry) 
Due to the historic variations in HER2 results between laboratories and the 
recognition of the importance of accurate reporting for the selection of patients for 
adjuvant Herceptin there are now a number of guidelines to reduce this variation. 
These include guidance on sectioning, staining and scoring as well as audit and 
quality assurance testing (Walker et al., 2008). Despite these efforts, it is accepted that 
there always will be a degree of regional variation in HER2 expression.  
 
2006 audit (15 689 cases) 2007 audit (17 270 cases) 
IHC score (% positivity): 
  
    2+ 18% (range 7 to 41%) 19% (range 1 to 38%) 
    3+ 13% (range 7 to 22%) 11% (range 4 to 20%) 
FISH positive 24% of 2+ 19% of 2+ 
Total HER2 positive 17% 15% 
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As with the previous receptors, we then assessed the correlation of HER2 expression 
with the other pathological features of the tumours (table 3.20 & 3.21). We have 
shown the over expression of HER2 was significantly associated with tumours of a 
higher grade (p=0.001) and vessel space invasion. (p=0.04), but not with tumour size 
(p=0.075), or nodal involvement (p=0.233), this is in agreement with previously 
published work (Huang, 2005, Sjorgen, 1998). As would be expected and because we 
had shown a significant correlation between HER2 over expression and grade we also 
demonstrated that HER2 over expression was also significantly related to tumours in a 
poorer prognostic group (p=0.002) (table 3.21). 
 
It is widely reported that HER2 over expression is inversely associated with ER/PR 
expression.(Gago, 2006) Our study agrees with these results, we demonstrated a 
significant inverse relationship between HER2 expression with ER (p=0.011) and PR 
(p=<0.001) status. In our study we found no relationship between HER2 and the other 
type 1 growth factor receptor EGFR (table 3.21).  
 
It is generally accepted that HER2 over expression is a marker of increased tumour 
aggressiveness (Pawlowski, 2000) and in many studies HER2 over-expression has 
been related to a poorer overall survival (Sjorgen, 1998). In this study however, 
though we showed a significant relationship between HER2 and markers of poorer 
outcome (high grade, high NPI and ER negative tumours), we have not shown a 
significant relationship between HER2 over expression and overall 5 yr survival. As 
seen in fig 3.37, the 2 survival curves do begin to diverge after 20 months and though 
there appears to be a trend towards poorer survival this is not significant. (p=0.1). We 
did however demonstrate a significant result between HER2 expression and disease 
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free survival at 5 yrs. (p=0.009). This disparity in results may be due to the length of 
time the patients were followed up. If the follow up time was extended to 7 yrs then 
we may possibly have seen a significant difference in overall survival.  
 
It has been suggested by earlier studies that HER2 expression is important in the 
prediction in response to adjuvant treatment (Payne, 2008). Studies have shown that 
HER2 status expression favours response to certain anthracycline containing 
chemotherapy regimens (Pritchard, 2006). It has also been suggested that HER2 
positive ER positive breast cancers may be resistant to endocrine (tamoxifen) 
treatment, (Gago, 2006) but it is accepted that currently these trials are insufficient to 
allow HER2 to influence choice of endocrine adjuvant therapy (Prowell, 2006). In our 
study group we compared the survival curves of the ER+/HER2+, ER+/HER2-, ER-
/HER2+ and ER-/HER2- sub groups. Though the ER+ sub groups were of a 
reasonable size (HER2 +ve 27 patients, HER2 -ve 111 patients,) (table 3.22) we were 
unable to show a difference in survival between the groups (fig. 3.38). As all the ER+ 
patients would have received Tamoxifen based adjuvant therapy we would agree that 
the HER2 status appears not to affect their response. Though in the ER- group there 
does seem to be a trend towards poorer outcome in the HER+ compared to HER- 
group the numbers are too small to be significant. In one study recently published a 
lower rate of HER2 positivity was seen in the ER positive group (13.3%) compared to 
19.5% in this study. Again a correlation was seen with high grade, nodal involvement 
and ER/PR negative tumours. A poorer survival (-7.5% at 5 years) was identified but 
this was confined to the lymph node positive sub-group (Purdie et al., 2010).     
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3.3.3.5 EGFR. 
The assessment for the expression of EGFR was completed in 203 cases. We found in 
our study 19 (9.4%) of the cancers expressed EGFR (table 3.23). The published rate 
of EGRF expression seen using IHC in the literature varies widely from 14-91% 
(Klijn, 1994) The higher rates of expression quoted are predominantly from earlier 
studies where the proportion of the small low grade tumours was very low (1.8% 
grade I cancers) (Zeillinger, 1993). Our study had 28% grade I cancers and this 
inclusion of predominantly screen detected cancers may account for the lower rates of 
EGFR expression.  
 
It is widely reported that EGRF expression is a marker of more aggressive disease in 
the in-vitro setting but many in vivo studies have reported contradictory results. Some 
of these studies confirm the relationship between EGFR receptor expression and 
aggressive disease and some are unable to demonstrate this link. (Klijn, 1992, 
Rampaul, 2005) In these studies it appears that the studies quoting the higher rates of 
expression on EGFR were less likely to show significant associations with poorer 
outcomes.  
 
In this study we have demonstrated a significant association between EGFR 
expression and tumours of a high grade: 1 out of 53 grade I tumours compared to 10 
out of 38 grade III tumours (p=0.004). We were also able to demonstrate an 
association between EGFR expression and increased tumour size (p=0.009). Some 
studies have managed to demonstrate this relationship with grade and size (Zeillinger, 
1993), but others have not (Klijn, 1994). Though it appears that EGFR expression is 
associated with larger more poorly differentiated tumour we found that there was no 
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significant association between EGFR and lymph node involvement (p=0.331). This 
concurs with the majority of the published data (Nieto, 2007a). We were however 
able to show a significant relationship between EGFR expression and the NPI group. 
Only 2 of the 82 patients in the good and moderate prognostic groups expressed 
EGFR compared to 17 of the poorer prognostic group. (p=0.034) (tables 3.24 & 3.25). 
 
When we compared EGFR expression with the expression of ER and PR we found 
that the majority (17/19) of tumours expressing EGFR were ER and PR negative 
(p=<0.001). There were only 2 cases where EGFR expression existed with ER and PR 
expression. Interesting both of these cases, compared to many of the other EGFR 
patients, did very well and were still disease free after 7 years. This relationship 
between positive EGFR expression and steroid receptor negative tumours has been 
previously demonstrated (Klijn, 1994, Zeillinger, 1993). As mentioned many studies 
have failed to show a link between EGFR expression and overall survival. In this 
study we found that the five year survival for the EGFR positive group of patients was 
47% in comparison to 82% in the EGFR negative group. When the survival curves 
(fig. 3.39) were plotted this difference was highly significant (p=<0.001).   
 
As EGFR plays a vital role in HER2 activation we analysed the sub group of HER2 
positive patients (n54) and their EGFR status. In this group 47 (87%) of the patients 
were EGFR negative and 7 (13%) of the patients were EGFR positive. It was shown 
that there was no significant correlation between HER2 and EGFR expression. When 
the survival of these two groups of patients was analysed it was demonstrated that all 
7 (100%) of the HER2 positive/EGFR positive patient died of disease recurrence 
within 5 years of diagnosis. This is compared to only 8 (17%) of the 47 HER2 
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positive/EGFR negative patients (p=<0.001). These results demonstrate, even in this 
small sample, the significance of co-expression of HER2 and EGFR on disease 
outcome (fig. 3.40). When considering these results it is logical to assume that dual 
therapy with anti-HER2 (Trastuzumab) and anti-EGFR (Gefitinib) would improve the 
outcome of these HER2 positive cancers. Unfortunately early phase I-II studies are 
not supporting this.(Arteaga, 2008). A new dual inhibitor of EGFR and HER2 
tyrosine kinases (Lapatinib) is now undergoing trials with some encouraging results 
(Medina, 2008).  
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3.3.4 Transcription factor expression in the study group. 
Where possible the transcription factor status of all of the tumours in the study group 
was ascertained. There were some technical problems with some of the samples 
predominantly being due to the lack of representative tissue in the blocks for some of 
the small tumours. 
 
3.3.4.1 STAT3. 
In this study 209 breast cancer samples were successfully analysed using IHC for the 
expression of STAT3. As described the samples were scored according to the cellular 
location of the STAT3 stain, nuclear vs. non-nuclear. Using this technique 56 (26.8%) 
of the cancers were positive for nuclear STAT3 (table 3.26). This rate of nuclear 
STAT3 is similar to the published rate seen using IHC of 23% (Clevenger, 2004).   
 
As discussed in section 1.3.2, STAT3 expression is considered a marker of more 
aggressive cancer cell morphology and behaviour but there has been little published 
work in the clinical setting. The results of the correlation of STAT3 are seen in tables 
3.27 and 3.28. In this study we have demonstrated a significant link between STAT3 
expression and the grade of the breast cancer. The expression of STAT3 increases 
with the increased grade of cancer. Our results show that 47% of Grade III cancers 
express nuclear STAT3 compared with 28% of Grade II cancers and only 7% of 
Grade I cancers (p=<0.001). As demonstrated in cell models over expression of 
STAT3 increases cell proliferation and its inhibition induces the converse (Burke, 
2001). In this study we have shown that STAT3 expression increases with increasing 
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tumour size, 18% of T1 (<20mm) tumours expressed nuclear STAT3 compared with 
39% on T2 and T3 (>20mm) tumours (p=0.004).  
 
The role of up-regulation of STAT3 and the invasive potential of breast cancer is not 
clear. Some studies have suggested that STAT3 inhibition decreases invasiveness in 
cell lines (Selander et al., 2004a). Other studied have show the opposite with a 
decrease in invasiveness and a negative correlation between STAT3 expression and 
lympho-vascular invasion (Dien et al., 2006).  
 
In this showed that there is a there is a relationship between STAT3 and VSI and also 
STAT3 and lymph node involvement. 38% of the breast cancers demonstrating VSI 
were STAT3 positive compared with 22% of cancers without VSI (p=0.034). Of the 
cases with lymph node involvement 37% were STAT3 positive compared with only 
20% of lymph node negative cases (p=0.015). These results are in agreement that 
Stat3 expression increases the tumours ability to metastasise. There is no current 
published work on the correlation of STAT3 with NPI group. It is logical to assume 
that as a significant relationship between STAT3, tumour grade, size and nodal status, 
which constitute NPI score was shown, we will see this relationship continue with 
NPI. This study did indeed demonstrate this relationship. Our results showed that 9% 
of tumours in the excellent and good (NPI<3.3) prognostic groups were STAT3 
positive compared to 40% of tumours in the moderate and poor (NPI>3.3) prognostic 
groups (p=<0.001). 
 
As described earlier STAT3 phosphorylation provides possible pathway for non-
classical ER signalling. It is therefore important to ascertain if there is a relationship 
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between ER and STAT3 expression in breast cancers. Our results show that there is a 
significant relationship between ER and STAT3 expression. When we analysed the 
ER positive cancers 22% of them were STAT3 positive this compares with 42% of 
ER negative cancers (p=0.003). It is not surprising that there is an increase in nuclear 
STAT3 in the ER negative cancers. It is likely that an ER positive cancer is being 
regulated by the classical ER pathway and therefore STAT3 will not be elevated. ER 
negative cancers however will grow through other stimulatory pathways such as 
EGFR, HER2 and IGF receptors. All of these pathways induce the phosphorylation of 
STAT3 and its shuttling to the nucleus (Gritsko et al., 2006b), hence we see an 
increase in nuclear STAT3 in these ER negative cancers. These results agree with 
other studies which described this relationship between ER and STAT3 (Yeh et al., 
2006b). Though STAT3 is more common in ER negative cancer we were interested to 
ascertain if it was important in ER positive cancers. As discussed earlier ER positive 
cancers which become resistant to anti-estrogen treatment may escape this inhibition 
by utilising non-classical pathways. The survival of the ER positive cancers split by 
the STAT3 expression was analysed, there was no difference in survival between the 
2 groups analysed. STAT3 expression does not help identify the ER positive cancers 
which become resistant to tamoxifen and relapse. These results infer that if a cancer is 
proliferating via a STAT3 mediated non-classical ER pathway its outcome is no 
worse than those proliferating via the classical pathway.    
 
There is little published data on the relationship between STAT3 expression and PR 
expression. It can however be assumed that because of the very significant 
relationship between ER and PR co-expression we would see a similar relationship 
between PR and STAT3 as we did with ER and STAT3. This study data showed that 
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when analysed 20% of PR positive cancers were positive for STAT3 compared to 
40% of PR negative cancers (p=0.003). This findings do contradict that of another 
study but in that study there was a massive discrepancy between ER expression and 
PR expression (Yeh et al., 2006b).  
 
There were 2 indications for the analysis of HER2 and its relationship with STAT3, 
firstly HER2 signalling activity involves STAT3 phosphorylation (Fernandes et al., 
1999) and STAT3 activity may up-regulate the expression of HER2 (Qian et al., 
2006). In this study group we determined the combined HER2 and STAT3 status of 
208 cancers. Of the HER2 negative cancers (n154) 25% were STAT3 positive and in 
the HER2 positive group (n54) 31% on the tumours were STAT3 positive (table 
3.29). There was no statistical difference between these two groups (p=0.38). This 
shows that, though an in-vivo mechanism has been shown for the up-regulation of 
HER2 via activation of STAT3, this is not apparent in this clinical study.  
 
As STAT3 is an important component of HER2 signalling, we were interested to see 
if the presence of STAT3 in the HER2 positive group would affect outcome for the 
patients. The 5 year overall survival of the HER2 positive patients in this study group 
was 70%. We assess the co-expression of HER2 and STAT3 in 218 patients. Of the 
64 HER2 positive cases 27 (42%) co-expressed STAT3 (table 3.29). The 5 year 
survival of this group was 53%, this is compared to 77% in the HER2 positive STAT3 
negative group (table 3.30). The survival curves show a trend to poorer survival but 
the data did not reach statistical significance (p=0.098) (fig 3.43). This failure to reach 
significance may be due to the smaller numbers in this sub group. If these results on 
further investigation are found to be significant then there would be a considerable 
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impact on the use of Herceptin in the management of these patients. These results 
suggest that anti HER2 therapy may only be effective in the STAT3 positive group of 
patients as it is these patients who are suffering the negative outcome of being HER2 
positive.   
 
It is known that EGFR is a potent activator of STAT3 phosphorylation (Real et al., 
2002). It was therefore expected that a significant relationship between the EGFR 
positive cancers and STAT3 would be demonstrated, though other studies had failed 
to do so (Diaz et al., 2006a). This studies results showed that 52% (10/19) of the 
EGFR positive cancers were STAT3 positive compared to only 24% (43/181) of the 
EGFR negative cancers, this result was statistically significant (p=0.007). From this 
result EGRF expression does correlate with STAT3 activation in a clinical setting. 
The finding of STAT3 activation in EGFR negative cancers suggests that this 
phosphorylation is also under the control of other receptor activated tyrosine kinases. 
Unfortunately due to the small numbers in the EGFR positive sub group (n19) the 
survival curves for the STAT3 positive and STAT3 negative groups did not reach 
statistical significance.  
 
The survival of the above sub-groups has already been discussed but one of the 
primary aims of this study was to ascertain if STAT3 expression affected overall 
patient outcome. There have been a number of studies which have looked at outcome 
following treatment for advanced or recurrent disease with adjuvant or palliative 
chemotherapy dependent on STAT3 expression. These studies suggest that patients 
with tumours over-expressing STAT3 have a poorer response to chemotherapy for 
recurrent disease (Diaz et al., 2006a). As mentioned in chapter 1.3.2 one study 
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suggested a survival advantage in the over expression of STAT3 in node negative 
tumours (Dolled-Filhart et al., 2003b). In this study group, when overall survival was 
analysed, a divergence of the survival curves after 2 years was noticed. At 5 year, 
though there was a trend towards a poorer survival in the STAT3 positive group, this 
result was not statistically significant (fig. 3.41). When the study group with regards 
to disease recurrence was analysed, it was found that there was a correlation between 
STAT3 positive cancers and recurrence of disease. The results showed that 35% of 
the STAT3 positive patients developed disease recurrence compared with 20% of 
STAT3 negative patients (p=0.049). When disease free survival was considered, an 
earlier split in the curves was shown this demonstrated that the STAT3 positive group 
were at a significantly higher risk of earlier disease recurrence (p=0.04) (fig 3.42). 
These results have not been shown before in a large unselected group of breast 
cancers. 
 
As these results have shown that STAT3 may be related to disease outcome we were 
interested to see if STAT3 status was useful in identifying those breast cancer patients 
with good prognostic group tumour who do poorly. Previous studies have suggested 
that in a sub-group of node negative breast cancers nuclear STAT3 expression was 
associated with an increased disease free survival (Dolled-Filhart et al., 2003b). The 
survival impact of STAT3 status on node negative cancers was analysed. The node 
negative breast cancer patients usually fall into the better prognostic groups, many of 
whom are not offered adjuvant chemotherapy. In this group of 123 patients 23 
(18.6%) were STAT3 positive (table 3.31). The STAT3 positive cancers had a 
reduction in 5 year survival compared to the STAT3 negative cancers (78.3% vs. 
94%). When the survival curves were plotted this result was significant (p=0.017) 
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(fig. 3.44). These results show that STAT3 expression may be a marker of poorer 
prognosis in those patients with node negative tumours.  
To see if the overall predictive value of STAT3 remained significant when the effect 
of grade and nodal status, the 2 most significant pathological predictive markers, were 
considered a Cox regression analysis was performed. In this analysis unfortunately the 
predictive value of STAT3 was not significant. Although we have shown that STAT3 
status is significantly associated with disease recurrence it is not a significant 
independent predictor of disease free survival. 
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3.3.4.2 Sp1 
The Sp1 expression was ascertained in 208 of the cancers. As discussed in chapter 
1.3.3 Sp1 transcription factor is implicated in many of the important gene 
transcriptions associated with breast cancer, it was expected that results would show 
Sp1 expression to some degree in the majority of samples tested. What was 
discovered was the vast majority, (91%,) of the samples showed a degree of IHC 
staining for Sp1 i.e. only 8.7% of samples had no staining (score 0). The majority of 
positive samples could be divided into 3 groups, those with weak cytoplasmic staining 
(score 1) n39 (18.8%), those with strong cytoplasmic staining (score 2) n 83 (38.9%) 
and those with strong cytoplasmic and nuclear staining (score 3) n 68 (32.7%) (table 
3.32). There is little published data relating to either the prevalence or cellular 
location of Sp1 in clinical breast cancer samples, therefore there are no comparisons 
to make with other studies. In the assessment of other solid tissue tumours the nuclear 
expression of Sp1 has been reported as 54% in gastric cancers (Zhang et al., 2005a), 
31% in colorectal cancers (Maurer et al., 2007) and 45% of pancreatic cancers (Jiang 
et al., 2008).  As Sp1 is consider to be functioning predominantly at the DNA level 
both in the transcription of ERα and ERα induced gene transcription (deGraffenried et 
al., 2002, Khan et al., 2007), we thought it reasonable that we should consider the 
samples with strong nuclear staining as having higher than usual Sp1 expression and 
activity i.e. Sp1 positive. Our over-expression / nuclear expression rate of 32.7% in 
breast cancer is therefore in a similar range to that of other solid tissue tumours.   
 
Due to the important role of Sp1 with ERα in both its expression and activity we 
hypothesised that there would be a relationship between Sp1 positive tumours and 
“good” prognostic features such as low grade, node negative and smaller tumours 
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which are a feature of ER positive disease. These results were unable to show any 
relationship between these pathological features and Sp1 expression (tables 3.33 & 
3.34). There was no correlation between Sp1 over-expression and tumour grade, 
tumour size, VSI, nodal status, or NPI group. In other solid tissue tumours over 
expression of Sp1 has been correlated with markers of poor prognosis such as tumour 
depth, TMN stage and rate of angiogenesis in gastric cancers (Zhang et al., 2005a, 
Wang et al., 2005) and high grade, stage and lymph node metastasis in pancreatic 
cancers (Jiang et al., 2008). It may be that in these cancers the SP1 transcription factor 
up-regulates pro-metastatic genes which are not as evident in the predominantly ER 
driven breast cancers.    
 
The study’s results showed that only 19% of ER negative cancers over expressed Sp1 
compared with 37% of ER positive cancers (p=0.015). Though there is an association 
with ER and Sp1 positive cancers there are obviously a proportion of ER positive 
cancers which do not over-express Sp1. These tumours are a demonstration that 
though Sp1 is essential for ERα gene transcription (deGraffenried et al., 2002) normal 
levels of Sp1 are adequate for ER expression. When the tumour samples which did 
not demonstrate any Sp1 IHC staining (score 0), 8.7% of the study group were looked 
at, 10 of the 18 cancers were still ER positive. These tumours must still have a degree 
of functioning Sp1 which was not evident on our IHC assay.  
 
It has been shown that PR expression is a measure of functioning ER stimulation. It is 
now know that the PR gene contains 2 regions that rely on Sp1 sites to confer this 
estrogen responsiveness (Schultz et al., 2003a). As an association between ER 
expression and Sp1 positive cancers had been demonstrated a similar relationship 
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between Sp1 and PR expression was expected. This study however was unable to 
demonstrate a significant relationship between these SP1 and PR. The lack of this 
significant relationship may be due to fact that the PR gene transcription does not rely 
on a single estrogen response element but on the co-operative interaction of numerous 
transcription factors and cis elements working together.  
 
There is no published evidence that Sp1 action may play a role in the expression of 
either EGFR or HER2. It is then expected that our results failed to show a correlation 
between Sp1 and EGFR or HER2, (p=0.544 and p=0.257 respectively).  
 
This study aimed to investigate if Sp1 transcription factor expression could be used as 
an indication of prognosis in invasive breast cancer. The successful treatment of ER 
positive breast cancer relies on both adequate surgery and also the use of adjuvant 
endocrine manipulation. The aim of the adjuvant endocrine therapy may be estrogen 
depravation (aromatase inhibitors) or alteration to ER response to estrogen (SERMs). 
It has been shown that on recurrence 25% of these ER positive tumours have lost ER 
expression(Kuukasjarvi et al., 1996).  
 
It was therefore hypothesised that Sp1 over-expression may decrease the loss of ER 
expression and therefore improve survival in this group. In our analysis of overall 
survival there appeared to be a trend towards improved survival in the Sp1 positive 
group 86.6% c.f. 74.6% in the Sp1 negative group but this failed to reach statistical 
significance (p=0.83) (fig. 3.46). When looking at the survival curves this separation 
of the curves appeared only after 2 years of follow-up. When the sub-group of 
patients alive after 2 years was analysed, 98% of the Sp1 positive group were alive 
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after 5 years compared with 82% of the Sp1 negative group. This relationship was 
significant (p=0.005) (fig 3.47). If this improved outcome was due to the maintenance 
of estrogen responsiveness in the ER positive cancers then one would expect to find a 
more impressive difference when the survival of ER positive sub-group was analysed. 
This however was not evident in the sub-group analysis where Sp1 lost its significant 
affect on survival. The ER negative group did show a separation of the curves after 2 
years but with a trend towards improved survival in the SP1 negative group but this 
did not reach statistical significance due to the loss on many ER negative patients in 
the first 24 months reducing the group numbers. It therefore appears that in this study 
the prognostic affect of Sp1 status after 2 years is independent of the ER status of the 
cancer.  
 
It is important to consider the recurrences that occur after 2 years. The bi-phasic 
nature of breast cancer recurrence in well know with the majority of recurrences 
occurring in the first 24 months but then a second significant peak of recurrences 
between 36 and 60 months. With the introduction of aromatase inhibitors it was 
considered that the aromatase inhibitors would be more effective in reducing the 
second peak of later recurrences, this gave rise to the “switching” strategies. 
Switching is where a patient is given 24 months tamoxifen then switched to an 
aromatase inhibitor. Two large trials were conducted into this strategy the TEAM/IES 
trial comparing Tamoxifen and Exemestane both as five year mono-therapy and a 
switched arm, and the BIG 1-98 comparing Tamoxifen and Letrazole as a switched 
strategy. The IES study did show a reduced disease recurrence in the arm that 
switched to exemestane for tamoxifen after 2 years compared with 5 years of 
tamoxifen (Coombes et al., 2007) and this did translate into a modest survival benefit. 
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Again in the BIG 1-98 trial there was an advantage in switching from tamoxifen to 
Letrazole but neither of these studies showed an advantage of the switching over 5 
years of AI treatment (Joerger and Thürlimann, 2009). There have also been studies 
into extending adjuvant anti-oestrogen beyond 5 years. The MA 17 study, which is a 
double blind randomised control study into the use of a further 2 years of letrazole 
following 5 years of tamoxifen, suggests that there is a significant reduction in 
recurrence and death in the node positive sub-group, and a trend towards significant 
improvement in outcome in all patients (Ingle et al., 2006).  
 
Though this study is not designed to ascertain if SP1 expression could identify patents 
that would benefit from switching or extended therapy it would be interesting to 
consider this with extended follow up data.        
 
The impact of Sp1 expression on survival in breast cancer has not been published 
previously and therefore these results cannot be corroborated by other studies. The 
previously discussed studies in gastric, pancreatic and colon cancers have all shown 
the converse association of Sp1 expression with prognosis (Zhang et al., 2005a, Jiang 
et al., 2008, Maurer et al., 2007). 
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3.3.4.3 NFκß  
208 cancer specimens were successfully assessed for the expression of NFκß. As with 
STAT3 and Sp1 the IHC scoring of the samples was based upon the presence and 
location of the stain. Our results show that 44.7% of the samples did not show any 
staining for NFκß, 40.4% of the patients exhibited cytoplasmic staining for NFκß and 
14.9% of the samples had nuclear staining (table 3.35). Previous studies have 
demonstrated that nuclear localisation is a marker of activation of NFκß (Biswas et 
al., 2004) therefore it was these cancers with positive nuclear stain that were 
considered as NFκß positive. The rate of nuclear expression demonstrated in this 
study, 14.9%, compares closely to the published rate of 13% seen in studies using a 
similar IHC technique (Buchholz et al., 2005).  
 
NFκß expression was then compared to pathological markers (tables 3.36 & 3.37) and 
demonstrated a significant correlation between NFκß positive tumours and higher 
pathological grade. Our results show that only 8.7% of grade I tumours expressed 
nuclear NFκß compared with 31.3% of grade III tumours (p=0.001). There was a 
significant relationship between NFκβ and tumour size, 9% of tumours <20mm were 
NFκß positive compared with 33% of larger tumours (p=0.014). There was no 
correlation between node status of tumour or the presence of vessel space invasion 
and NFκß. Only 6.9% of the good prognostic tumours expression NFκß compared to 
20.4% of the poorer prognostic tumours. This correlation with higher grade, larger 
and poorer prognostic tumours is not widely reported in the published literature with 
some studies unable to demonstrate a correlation between NFκß and clinical stage of 
the disease (Buchholz et al., 2005). When the pro-proliferative and anti-apoptotic 
action of NFκß is considered (Biswas et al., 2003), it is unsurprising that this 
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correlation with higher grade and larger tumours was found. As discussed later there 
is known association between NFκß and hormone receptor negative tumours and as 
already shown in this study these ER and PR negative tumours tend to be the higher 
grade and poorer prognostic cancers.  
 
Our data agrees with the link between NFκß expression and ER negative cancers (Van 
Laere et al., 2007a, Biswas et al., 2000, Biswas et al., 2004). The results have shown 
that 10.9% of ER positive cancers are NFκß positive compared with 28% of ER 
negative cancers (p=0.006). It has also been suggested that the ER expression may be 
down regulated as an effect of EGFR activation of NFκß (Van Laere et al., 2007a). A 
significant relationship between nuclear NFκß and EGFR expression was shown with 
36.8% of EGFR positive cancers expressing nuclear NFκß compared with only 13.2% 
of EGFR negative cancers (p=0.007).  
 
Following the significant association between NFκß, grade, tumour size and ER 
negative tumours a relationship between NFκß and disease outcome was expected to 
be shown. In this study however we found no relationship between NFκß and disease 
outcome. The 5 year overall survival for the NFκß positive group was 76.7% 
compared to 79.1% in the NFκß negative group (p=0.77) (fig 7.25).  
 
In-vitro studies have shown that NFκß activation is associated with resistance to anti-
oestrogens (Zhou et al., 2007) and inhibition of NFκß enhances sensitivity of resistant 
tumours to Tamoxifen (deGraffenried et al., 2004). Previous patient studies have also 
suggested that NFκß status identifies a sub set of ER positive cancers that are at a high 
risk of disease recurrence (Zhou et al., 2005). When the subset of ER positive cancers, 
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who would have received tamoxifen as adjuvant treatment was analysed, NFκß status 
had no impact on disease recurrence or overall survival.  
It has been suggested in some studies that activation of NFκß is linked to resistance to 
neo-adjuvant chemotherapy (Montagut et al., 2006a) and activation of the NFκß / bcl-
2 pathway decreased pathological response to doxorubicin based chemotherapy 
(Buchholz et al., 2005). A sub group of patients with a high nodal burden which were 
likely to have received chemotherapy were selected, analysis of this group showed no 
difference in disease outcome related to the NFκß status (fig 3.48.)  
 
Though some significant relationships between NFκß and various pathological 
features have been shown, its expression does not seem to have an impact on patient 
outcome. 
 
 
3.3.5 Summary of the discussion.  
 
This clinical study has yielded some significant results. It has show that STAT3 
expression appears to correlate with poorer outcome of disease. It has shown that SP1 
expression is associated with decreased disease recurrence after 2 years and it 
suggests that IHC expression of NFκβ has no relationship to disease outcome.  
 
There have been many studies of varying quality into potential prognostic markers in 
cancer. Due to the issue with many of these initial studies failing to fulfil their 
suggested potential the National Cancer Institute – European Organisation for 
Research and Treatment of Cancer  (NCI-EORTC) developed a set of criteria that 
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these studies should be judged against, the REMARK criteria (McShane et al., 2005) 
(see table 3.38). 
INTRODUCTION 
    1. State the marker examined, the study objectives, and any pre-specified hypotheses. 
MATERIALS AND METHODS 
Patients 
    2. Describe the characteristics (e.g., disease stage or co-morbidities) of the study patients, 
including their source and inclusion and exclusion criteria.  
    3. Describe treatments received and how chosen (e.g., randomized or rule-based). 
Specimen characteristics 
    4. Describe type of biological material used (including control samples) and methods of 
preservation and storage. 
Assay methods 
    5. Specify the assay method used and provide (or reference) a detailed protocol, including 
specific reagents or kits used, quality control procedures, reproducibility assessments, quantisation 
methods, and scoring and reporting protocols. Specify whether and how assays were performed 
blinded to the study endpoint.  
Study design 
    6. State the method of case selection, including whether prospective or retrospective and 
whether stratification or matching (e.g., by stage of disease or age) was used. Specify the time period 
from which cases were taken, the end of the follow-up period, and the median follow-up time.  
    7. Precisely define all clinical endpoints examined. 
    8. List all candidate variables initially examined or considered for inclusion in models. 
    9. Give rationale for sample size; if the study was designed to detect a specified effect size, 
give the target power and effect size.  
Statistical analysis methods 
    10. Specify all statistical methods, including details of any variable selection procedures and 
other model-building issues, how model assumptions were verified, and how missing data were 
handled.  
    11. Clarify how marker values were handled in the analyses; if relevant, describe methods 
used for cut point determination. 
RESULTS 
Data 
    12. Describe the flow of patients through the study, including the number of patients included 
in each stage of the analysis (a diagram may be helpful) and reasons for dropout. Specifically, both 
overall and for each subgroup extensively examined report the numbers of patients and the number of 
events.  
    13. Report distributions of basic demographic characteristics (at least age and sex), standard 
(disease-specific) prognostic variables, and tumour marker, including numbers of missing values.  
Analysis and presentation 
    14. Show the relation of the marker to standard prognostic variables. 
    15. Present univariate analyses showing the relation between the marker and outcome, with 
the estimated effect (e.g., hazard ratio and survival probability). Preferably provide similar analyses 
for all other variables being analyzed. For the effect of a tumour marker on a time-to-event outcome, 
a Kaplan–Meier plot is recommended.  
    16. For key multivariable analyses, report estimated effects (e.g., hazard ratio) with 
confidence intervals for the marker and, at least for the final model, all other variables in the model.  
    17. Among reported results, provide estimated effects with confidence intervals from an 
analysis in which the marker and standard prognostic variables are included, regardless of their 
statistical significance.  
    18. If done, report results of further investigations, such as checking assumptions, sensitivity 
analyses, and internal validation.  
DISCUSSION 
    19. Interpret the results in the context of the pre-specified hypotheses and other relevant 
studies; include a discussion of limitations of the study.  
    20. Discuss implications for future research and clinical value. 
Table 3.38: The “REMARK” criteria for reporting tumour marker prognostic studies(McShane et al., 
2005).  
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When considering this study and the remark criteria I would hope that it will satisfy 
most of the recommendations. In the introduction the rational for the chosen markers 
and hypothesis has been made clear. In the methods and materials the patient group 
has been defined the tumour material explained, the IHC methods described including 
the scoring systems, the end points defined and the power of the sample size 
calculated. In the results the demographics and other disease specific variable have 
been illustrated and correlation with known prognostic markers and disease end points 
made using recommended statistical tests. In the discussion the findings have been 
compared with other published works and the implications for further work discussed. 
 
 
3.3.6 Critique of the methodology and suggestions for improvements to the 
clinical study. 
 
I consider the basic methodology behind this study to be sound. The case selection is 
unbiased and the follow up data thorough. The protocols used for the standard 
receptor expression ER, PR, HER2 and EGFR are well validated. The development of 
the staining and scoring protocols for the novel transcription factors followed 
accepted methodology. An area of discussion within this study is the issue of inter and 
intra observer variation. In this study over 1400 slides were assessed and scored; this 
was conducted jointly by an experienced breast pathologist and me with discussion 
and agreement over borderline cases at the time of assessment. We were blinded to 
the other case details and reported results by case number alone. To improve the 
validity of this area of the study it would have been ideal to have the slides scored 
independently by 2 pathologists and where discrepancies arose a third pathologist 
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could be consulted. Slides could have also been re-assessed at a later time point by the 
same pathologists. This method would have allowed the intra and inter observer 
variability to have been assessed using a k-test. It may have also improved the 
consistency of the sample scoring.  
To improve the efficiency of sample scoring the newer method of tissue micro arrays 
could have been considered. The construction of a micro array involves tissue cores of 
0.6 mm in diameter from regions of interest in paraffin-embedded tissues such as 
clinical biopsies or tumour samples. These tissue cores are then inserted in a recipient 
paraffin block in a precisely spaced, array pattern. Sections from this block are cut 
using a microtome, mounted on a microscope slide and then analyzed by any method 
of standard histological analysis. Each microarray block can be cut into 100 – 500 
sections, which can be subjected to independent tests. These tissues micro-arrays are 
cumbersome to produce but allow analysis of multiple markers on a set of cancers. 
There are some issues in their use such as the representative nature of small cores of 
heterogeneous tumours requiring more than one sample per tumour to be analysed.   
 
When the sub-group analysis has been undertake the sample size of the groups 
becomes too small to generate statistical significance. To account for this the initial 
sample group would have had to been doubled in size and covered 2 years worth of 
cancers presenting to this unit or cancer samples from a second unit could have been 
recruited.  
 
With all of the issues raise above the constraints of funding and time were of a 
limiting factor.     
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4 The Cell Model Experiment. 
The results of the clinical study undertaken into the use of transcription factors as 
prognostic markers in breast cancer suggested that out of the three factors studied 
STAT3 was potentially the most significant. The clinical study showed that STAT3 
over expression was significantly associated with disease recurrence at 5 years this 
was more significant in the node negative i.e. “good” prognosis cancers. It was shown 
that STAT3 expression was associated with ER negative cancers and EGFR positive 
cancers. As a direct result of these finding it was thought to be important to go on and 
study the effect of estrogen stimulation and EGF stimulation on the activation of 
STAT3. To do this it was decided to use 3 cell line models.  
 
The aim of this section of the study was to ascertain the effect of estrogen and EGF 
stimulation on cells of differing receptor expression. The hypothesis based upon what 
is known about STAT3 stimulation is that EFG will stimulate STAT3 
phosphorylation but estrogen will have no effect.   
   
4.1. Methodology of cell model experiment  
The cell line study was conducted in the department of Surgery and Reproductive 
Sciences at the University of Newcastle upon Tyne. The experiments were performed 
in the flow cytometry facility under the supervision of Dr Brian Shenton.  
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4.1.1 Selected Cell lines 
The following 3 cell lines were selected for the cell models. The selections were made 
due to the receptors expressed and the documented response to oestrogen and EGF 
stimulation. The cell lines were provided by the Flow Cytometry Group, under the 
direction of Dr B.K. Shenton, Department of Surgery and Reproductive Sciences, 
University of Newcastle upon Tyne, where these cell lines were routinely cultured 
and used for experimental purposes.  
4.1.1.1 MCF7 Breast Cancer cell line. 
This cell line was derived from a malignant pleural effusion in a Caucasian patient 
with ductal carcinoma of the breast in 1970 (Soule, 1973). This cell line was of 
epithelial type cultured as an adherent monolayer. It has been documented to express 
ER, PR, and  very low levels of EGFR (Hall et al., 1990, Imai et al., 1982a) and be 
sensitive to tamoxifen. MCF 7 is HER2 negative (Bacus et al., 1990). The doubling 
time of this cell line is 29 hours in ideal conditions. This cell line is routinely used in 
this lab and was initially purchased from the European Collection of Animal Cell 
Cultures (ECACC, Salisbury, Wiltshire, UK.) 
 
 
 
 
 
 
 
Fig. 4.1: MCF7 cells in culture (x400) (courtesy of ATCC) 
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4.1.1.2 SKBr  -3 Breast Cancer cell line. 
SKBr-3: again this cell line was derived from a 43 year old female patient’s malignant 
pleural effusion in 1975 (Trempe, 1976). It was of an adherent epithelia monolayer 
type. It has been show to be ER, PR negative, HER-2 and EGFR positive (Karlin et 
al., 2005) and tamoxifen resistant SKBr3 has a doubling time of between 19 and 29 
hours depending on density rates of seeding. It was used in this lab and a sample was 
originally sourced from the American Type Culture Collection (ATCC, Manassas, 
Virginia, USA.) 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2: SK-BR-3 cells in culture (x400) (courtesy of ATCC) 
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4.1.1.3 MDA-MB-231. 
MDA-MB-231: established in 1973 from a pleural effusion. The cells grew as an 
epithelial type monolayer. Under the microscope they had a spindle shape 
morphology (Cailleau et al., 1978). They are documented to be ER-ve and PR-ve 
(Cailleau et al., 1978), EGFR+ve (Hall et al., 1990), HER-2 negative (Lewis et al., 
1993) and tamoxifen resistant. The doubling time of MDA-MB-231 is 28.1hr ± 1.2 
(Watanabe et al., 2001) This cell line routinely used in this lab was originally sourced 
from the European Collection of Animal Cell Cultures (ECACC, Salisbury, Wiltshire, 
UK.) 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3: MDA-MB-231 cells in culture (x400) (courtesy of ATCC) 
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4.1.2 Cell Culture 
4.1.2.1 Cell lines and basic cell culture.  
In the Department of Surgery and Reproductive Sciences, University of Newcastle 
upon Tyne, breast cancer cell lines are routinely cultured for the purpose of 
experimentation. Cell lines, when originally sourced, were tested for mycoplasma 
then frozen down in aliquots to provide a bank of original cells that could be returned 
to as a fresh stock for each individual experiment. The aim of this was to prevent 
phenotypic drift due to excessive passaging of the cells. For this cell model adherent 
cell lines were cultured in Complete Dulbecco’s Medium in 150cm3 cell culture flasks 
(Corning Ltd, High Wycombe, UK). The flasks were incubated at 37
o
C with 5% CO2 
in a humidified environment. The medium was changed over the cells ever 72 hours. 
When the cells reached the target of 80-90% confluence the flasks were stripped, the 
resulting cells were then re-suspended, frozen for storage or used for experimentation.  
 
4.1.2.2 Culture medium.  
Dulbecco’s Modified Eagle Medium (DMEM) containing 1000mg/l glucose, without 
pyruvate and phenol red (GIBCO Life Technologies, Paisley, UK) was used as the 
base medium for the MCF7 and MDA cell lines. McCoy’s 5a medium (Sigma, Pool, 
UK) was used as the base medium for the SKBr3 cell line. These media were 
supplemented with 10% heat in-activated FBS (Sigma) and the essential amino acid 
L-Glutamine 2mM. To this 50U/ml penicillin and 50μ/ml streptomycin (Sigma) was 
added. As the planned cell model required the assessment of the affects of growth 
factors a stripped medium devoid of these factors was required. To the base media 
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(DMEM or McCoy’s) 10% heat inactivated charcoal/dextran treated FCS (Hyclone, 
Perbio science Ltd Cheshire, UK) replaced the FBS usually added.  
4.1.2.3 Stripping of Cells.  
Once the cells had reached target confluence the culture medium was decanted and 
21ml of warm (37
o
C) Trypsin/EDTA (Sigma) was added to the flask. The flask was 
then returned to the incubator for 3-5 minutes until the cells had detached from the 
flask wall. The flask was then agitated to aid detachment, the resulting suspension 
decanted into a 30ml universal centrifuge tube (Bibby Sterilin Ltd, Staffs, UK), and 
spun at 1500 rpm (1230G) for 5 minutes. The pellet was then washed in 10ml DMEM 
for a further 5 minutes at 1500 rpm (1230G). The resulting pellet was the re-
suspended as required.  
4.1.2.4 Storage of cell lines.  
When not needed for active culture the cell lines were stored in cryo-stasis in liquid 
nitrogen. The cells were suspended in a freezing medium consisting of 80% complete 
DMEM (GIBCO), 10% heat inactivated FBS (Sigma) and 10% Dimethyl Sulphoxide 
(DMSO; Sigma). Following vortex mixing the suspension was transferred to 2ml 
cryogenic vials (Corning) in aliquots of 5x10
6
 cells in 1ml. The vials were initially 
placed in a -20
0
C freezer for 2 hours then into a -80
0
C freezer for a minimum of 4 
hours prior to transfer to liquid nitrogen storage. As required the cells could be 
returned to culture. The cells were defrosted in a water bath at 37
0
C. The suspension 
was then transferred to a 30ml universal centrifuge tube (Bibby,) and washed at 1500 
rpm (1230G) in 10 ml pre-warmed FBS. Once the DMSO had been removed by 
washing the cells were transferred to a culture flask along with 35ml of complete 
DMEM.  
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4.1.2.5 Cells required for slide culture.  
For the confirmation of cell receptor status with IHC cells were cultured on glass 
cover slips. Glass cover slips were sterilised in 70% ethanol (Sigma) for 5 minutes. 
The ethanol was poured off and the cover slips when dry were placed individually in 
6 well plates (Corning). 2ml of cell suspension (approx 2x10
5
 cells) in complete 
DMEM (GIBCO) was placed in each well and the plates returned to the incubator. 
The media was changed every 72hrs until an 80-90% cell confluence was reached.  
 
To fix the cells the media was decanted from the wells and 2ml of 1% 
paraformaldehyde (Sigma) added to each well. The plates were left to fix in the dark 
for 15 min, the formalin removed and the cover slips washed x2 in full media then 
4ml sterile PBS (Sigma). The cover slips were then transferred to a sterile petri dish 
then covered with PBS and stored in the dark at 4
0
C. 
 
4.1.2.6 Harvesting of Lymphocytes.  
To provide a control for the titration of flow cytometry antibodies lymphocytes from a 
healthy volunteer (Dr A Davison) were harvested. 5 ml of blood was taken into a 
EDTA tube. The blood was then transferred to a 30ml universal centrifuge tube 
(Bibby) and  mixed gently with 5ml of PBS. 10ml of Lymph-prep (Cedarlane, 
Ontario, Canada) was then pippetted as a layer on to of the blood/PBS mixture. The 
tube was then spun at 800G for 30 minutes in the centrifuge. The resulting cloudy 
layer of lymphocytes was carefully aspirated into to a fresh 30ml universal tube and 
then washed with an excess of PBS at 2500rpm. The resulting pellet was then re-
suspended in 2ml PBS for use.  
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4.1.2.7 Calculating cell numbers. 
Many of the experiment conducted require cells to be seeded at known concentrations 
and know volumes. To do this a method of cell counting has to be used. In this study 
cells were counted by using a haemocytometer. The haemocytometer is a counting 
chamber with grids of a known area and a chamber of a known depth. To calculate the 
number of cells in a solution the following method was used; 
 The cells were harvested washed and suspended in a known volume (usually 
1ml). 
 The suspension is then introduced into the counting chamber which is then 
placed onto the microscope.  
 The number of cells in 5 of the small grids is then counted.  
 The volume of the small grids = 0.04mm2 and 0.1mm deep = 0.004mm3 
 Total number of cells per ml =  x cells counted in 0.02mm3 (5x 0.004mm3)  
 x cells / 0.02 = y cells per mm3, there are 1000 mm3 in 1ml.  
 Total number of cells per ml = y cells x 1000.  
 
For example;  
 187 cells counted in 5 small grids.  
 Total number of cells per ml = (187/0.02 = 9350) x 1000 = 9,350,000 cells per 
ml.  
 
When the concentration of cells per ml is known then accurate numbers of cells can 
be used to see well plates for experimental purposes.  
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4.1.3 Flow Cytometry.  
The analysis of protein phosphorylation can be done by a number of techniques 
including western blot, ELISA or more recently flow-cytometry. It has been 
suggested that flow cytometry may have a number of advantages over western blot in 
these type of experiment. As will be explained flow cytometry allows the rapid 
analysis of single cells rather than a combined lysate of a population of cell in 
western. The flow cytometer is unique in analyzing single cells, rivalled only by 
microscopy techniques (which are limited in the number of the cells that can be 
analyzed). Westerns and ELISAs measure epitopes from whole populations of cells. 
Because flow cytometry acquires data for individual cells, the technique is inherently 
rich in statistical properties such as population means, medians, standard deviations, 
and coefficients of variation (Krutzik et al., 2004). When the protocol is refined flow 
cytometry allows the rapid assessment of multiple samples at multiple time points 
which would be difficult when using a western blot or ELISA technique and this 
specific advantage is important when conducting a time course experiment in 
triplicate. The laboratory that is under the supervision of Dr Shenton provided an 
important flow cytometry service to the University of Newcastle therefore I had 
access to both the facilities and expertise it offered. 
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Table 4.0: A comparison of Western Blot and Flow cytometry (Krutzik et al., 2004) 
 
4.1.3.1 Basics of flow cytometry.  
Flow cytometry is a sensitive experimental method which allows the simultaneous 
assessment of multiple properties of individual cells or particles. The flow cytometer 
is an instrument consisting of a fluid system, an optical system and a computer 
interface. The fluid system takes a suspension of cells and passes them under pressure 
rapidly through a flow chamber as single cells in a laminar flow stream. Within this 
flow chamber the stream of single cells is then “interrogated” by the beam from a 
laser. The optical systems consists of the laser and a series of dichroic mirrors and 
filters which separate, filter and direct the resulting light into a series of 
photomultiplier tubes (PMT). The role of the PMTs is to record the resulting light and 
convert this energy into an analogue or digital signal. The computer interface then 
takes these signals and translates them into graphical results in the form of dot plots or 
histograms that can be subsequently analysed and interpreted.   
Western Blot Flow Cytometry 
Population analysis 
       Obtain average value of multiple cells 
Single Cell analysis 
        Collects data for each individual cell 
Homogeneous sample 
     Limited to cultured or purified cells 
Heterogeneous cell types 
         Complex primary samples 
One parameter 
        Obtain data sets individually 
Multi-parameter 
         Correlate multiple markers 
simultaneously  
Large number of cells 
         Requires in vitro derived cultures of rare 
cells 
Small number – rare subsets 
         Direct analysis of rare cell types (i.e. DC) 
Time consuming for large sample sets 
        Not amenable to large screening efforts 
Rapid and Scalable 
         Performed in 96-well plates in parallel 
Protein size and Ab specificity 
         Ab selectivity for target is clearly visible 
Ab must be validated 
         Ab must have high affinity and selectivity 
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In this study 2 different flow cytometers were used, for the cell cycle and DNA 
analysis the FACscan was used (Becton and Dickinson, Oxford, UK) and for the 
STAT3 assessment a LSR II (BD) was employed. The FACscan contains 1 laser 
(Argon blue 488nm), 5 channel detection and uses analogue storage of 1024 channels 
of data which then interfaces with an Apple Macintosh computer using Cell Quest Pro 
(BD) software. The LSR II contains 4 lasers (HeCd 325nm UV, Solid State 405nm 
violet, Solid State 488nm blue and HeNe 633 red), 12 channel detection and uses 
digital storage of >250,000 channel levels, this then interfaces with a PC using 
FACSDIVA software (BD).  
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4.1.3.2 Light scatter.  
When a cell or particle intercepts a laser a number of things may happen. The beam 
may be stopped or it may be reflected of refracted at various angles (scattered). The 
cells or particles may auto-fluoresce or molecular dyes attached to the cells may 
fluoresce following excitation by the laser. The resulting scatter and fluorescence 
contain useful information which is then gathered and interpreted by the flow 
cytometer.  
 
 
 
     
               
 
 
 
Fig 4.4 Diagrammatic representation of the flow cell.  
 
Forward scatter (FSC) is the term ascribed to the diffracted light close to the angle of 
the interrogating laser, represented by the low angle scatter (fig 4.4). This FSC can be 
used to infer approximate information about the cell size as a property of the cells 
refractive index.   
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Side scatter (SSC) is the term ascribed to light which is reflected at angles closer to 
90
0
 from the incidental light source, high angle scatter (fig 4.4). This light is a 
measure of the cell’s reflective index as compared to its refractive index. The 
reflective index of a cell is dependent on a number of cellular properties such as the 
cells granularity, its shape and properties of the cell surface. Cell granularity is 
affected by its internal contents, cells with a complex of internal structures will have a 
high SCC.       
 
4.1.3.3 Fluorescence.  
As a florescent molecule is excited by energy from a laser its molecules and electrons 
move to a higher orbit (higher energy state). As they return to their rest state this 
energy absorbed is emitted at a particular wave length. Experimentally cells are 
deliberately “labelled” with fluorescent molecules. These molecules may be attached 
to the cell membrane, cytoplasm or nucleus; antibodies to specific cellular molecules 
can be conjugated to fluorochromic dyes.  
 
As a labelled cell passes though the flow chamber the resulting fluorescence is 
separated from the refracted and reflected light by an array of dichroic mirrors and 
band pass filters and focused onto specific PMTs. This light can then be analysed to 
ascertain the fluorescent properties of that cell.         
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Fig. 4.5: The arrangement of the laser and the detectors of the FACScan (BD) (Courtesy of Dr A. 
Davison, Department of Surgery, University of Newcastle upon Tyne.) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6: The arrangement of the 4 lasers and multiple PMTs of the LSR II (BD). (Courtesy of Dr A. 
Davison, Department of Surgery, University of Newcastle upon Tyne.) 
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4.1.3.4 Fluorescence Compensation.  
Flow cytometers are particularly useful as they allow the simultaneous measurement 
of multiple factors on the same cell. This is performed sometimes by labelling the cell 
with more than one fluorescent dye. This unfortunately raises the problem of cross 
over between the chosen dyes emission spectra. Two commonly used fluorochromic 
dyes are FITC and PE which have the similar absorbance of 495nm and emission 
spectra of  520nm and 576nm respectively, but as shown in fig 4.7 there is an overlap 
of their emission spectra.  
 
 
 
 
 
 
 
Fig.4.7: The absorption and emission spectra of FITC and PE.  
 
Due to the overlap of these two emission spectra it is logical to understand that a 
proportion of the FITC emission will be detected as PE emission and vice versa. If the 
two dyes are used to measure independent factors then this cross over will skew the 
results. The flow cytometer thus has to compensate for the proportion of each 
emission spectra incorrectly assigned to the wrong detector. This compensation is 
done by using the machines software and running compensation samples labelled with 
individual dyes.  
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Along with compensation there has to be standardisation of measurement by the flow-
cytometers to account for inter-machine and interval variations. This was done using 
fluorescent micro-bead standards (Spherotech Inc, Libertyville, Illinois, USA) at 
regular intervals as part of the flow cytometry department protocol. 
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4.1.4 Assessment of Cell Cycle.   
As cells grow, the DNA content in the nucleus passes through stages of replication. 
Flow cytometry can be used to determine the position of a cell along the path of 
replication from the G0/G1 phase via S phase to the G2/M phase. When this is applied 
to a population of cells we can determine the percentage of that population at each 
point on the cell replication pathway.    
 
 
 
 
 
 
 
Figure 4.8: The basic cell cycle. (Courtesy of The Biology Project, University of Arizona, USA)    
 
4.1.4.1 Synchronisation of cell lines. 
Prior to the assessment of cell cycle the cell lines under study have to be 
synchronised. This synchronisation of the cells aims to produce the majority of the 
cells in the G0/G1 phase. The process also removes the majority of the exogenous and 
secreted stimulating steroids. Synchronisation allows accurate observation of the 
effects of stimulation on the cell population.  
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Cells from standard cultures were stripped, washed and re-suspended in stripped 
media at a concentration of 2x10
5
 cells per ml. 6 well plates (Corning) were then 
seeded with 2ml of the suspension and placed in the incubator.  
 
Following 24 hours incubation to allow cell adhesion the media was aspirated and 
fresh stripped media applied, this process was repeated every 24 hours for 72 hours. 
Following 72 hours of culture in stripped media the cells was considered to be 
synchronised. The cells were then tested by cell cycle analysis.  
 
4.1.4.2 DNA staining.  
Propidium Iodide (PI; Sigma) is a fluorescent dye which can be excited by a 488nm 
Argon laser and emits on a range of wave lengths which can be detected by the Fl2 or 
FL3 PMTs. It irreversibly inter-calculates between the bases in DNA and RNA, 
therefore it is useful when assessing the DNA content of a cell. PI is not able to cross 
an intact cell membrane therefore to allow DNA staining the cell membrane has to be 
disrupted by the use of a detergent, in this case 5% Triton X-100 (BDH). To remove 
the RNA which PI also binds to RNAse A (Sigma) was added to the cell preparation.  
 
Cells, once synchronised in a 6 well plate, were stripped washed and re-suspended in 
350μml of PBS in 3ml FACS tubes (BD). To this 100μml of PI (0.25mg/ml) in 5% 
triton X-100 and 50μml of 1mg/ml RNAse A was added. Following mixing by vortex 
the cells are ready for analysis on the FACScan using pre-defined settings.    
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4.1.4.3 DNA analysis.  
Using Multi-cycle (Phoenix Flow Systems, San Diego, USA,) an initial dot plot was 
generated of FSC against FL2 area. This dot plot allowed the determination of intact 
cells and these intact cells were gated and plotted in a second dot plot of FL2 area 
against FL2 width. This plot was used to determine if a cell on the plot was truly a 
single cell in G2 or a doublet (2 single cells adhered to each other). A doublet will 
have the same fluorescence as a G2 cell but due to its increase overall size will have a 
prolonged time in flight across the flow chamber, FL2 width is a measure of time in 
flight across the chamber (fig 6.9). A gate was then drawn around the population of 
singlet cells and these cells were then plotted as a histogram of cell number against 
FL2 height (fig 6.9). From this histogram the Multi-cycle AV (Phoenix Flow 
Systems, San Diego, USA) software then fitted a cell cycle model to the plot and 
determines the percentage of the cell population in G1, S and G2 phases. Multi-cycle 
does this by calculating the area below each curve on the histogram, with each curve 
representing a stage of the cell cycle see fig 4.9. From the figure below it can be seen 
that the fluorescent channel with the highest number of events, the median channel 
fluorescence for the G2 population (shown in green) was double the fluorescence of 
the G1 population shown in red; this was representative of the doubling of the DNA 
content of the G2 population compared to the G1 population.      
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Fig. 4.9: SKBr3 cells stimulated with EGF (1x10
-8
). Left; dot plot of FL2-area over FL2 width showing 
the gated population (A) as the intact single cells. Right; histogram of FL2 height showing the G1 
population (red curve) the S population (blue curve) and the G2 population (green curve).   
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4.1.5 Assessment of Cell numbers.  
To determine the affect of treatments on cell lines it was necessary to be able to 
determine the numbers of live, dead and apoptotic cells within a population. This has 
been traditionally done using a haemocytometer and MTT assay. An MTT assay 
relies on the action of mitochondria in living cell reducing the Yellow MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) to purple 
formazan This water insoluble crystal is then liberates from the cells into a solution 
using acidified isopropanol. The absorption of this purple solution cen then be 
measured using a spectrometer. As this reduction reaction only takes place in living 
cells then the degree of absorption is proportional to the number of live cells. This 
technique doesn’t take account of the variability within a heterogeneous cell 
population or provided information on the apoptotic population. To overcome these 
issues flow cytometry uses differences within a cells’ membrane during healthy 
growth, apoptosis and cell death.      
 
4.1.5.1 Detection of apoptosis and dead cells.  
Apoptosis is defined as the process of programmed cell death. As opposed to necrosis, 
which is cell death due to an external insult, apoptosis is a normal physiological 
process to maintain homeostasis in a multi-cellular organism. This process is a 
pathway of events which include loss of plasma membrane asymmetry and 
attachments, condensation of the cytoplasm and nucleus and DNA cleavage. Loss of 
the cellular membrane integrity is an early step in this process, it is characterised by 
the translocation of some of the phospholipids from the internal leaf of the membrane 
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to the external leaf, this event exposes those phospholipids to the extra-cellular 
environment. The phospholipid Phosphatidylserine (PS) is one of these molecules.  
 
Annexins are a large group of intra and extra cellular proteins. Annexin V is a 36-kDa 
protein which binds specifically to the PS phospholipid via a calcium dependent 
mechanism. Annexin V can be conjugated to various fluorochromic dyes such as 
FITC and Phycoerythrin (PE). As the externalisation of PS is an early event in 
apoptosis, these conjugated dyes to Annexin provide an accurate identification of cells 
in early apoptosis using flow cytometry.  
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Fig. 4.10: A diagrammatic representation of the externalisation of PS in early apoptosis and the 
specific binding of PE labelled Annexin V.(Courtesy of BD Biosciences, Ca, USA) 
 
 
The addition of a vital dye to this assay allows the detection of dead cells. 7-Amino-
actinomycin (7-AAD) is a vital dye that intercalates within double stranded DNA 
binding strongly to the GC rich areas. It is a fluorescent dye which can be excited 
using a 488nm argon laser. 7-AAD is unable to penetrate an intact cell membrane 
which makes it useful in the identification of dead cells and cells in late apoptosis. 
The combination of both these stains can identify three populations of cells.  
 
Cell Fluorescence Cell Status 
Annexin V-PE negative & 7-AAD negative Healthy cell 
Annexin V-PE positive & 7-AAD negative Early apoptosis 
Annexin V-PE positive & 7-AAD positive Late apoptosis / Dead cell 
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4.1.5.2 Calculating cell numbers. 
Flow count beads are used for the calculation of cell numbers. The beads are 10μm 
polystyrene particles which fluoresce in a range of 525nm to 700nm when excited by 
a 488nm argon laser. The beads are provided in an aqueous solution at 1006/μl 
concentration (Flow-count Fluorospheres; Beckman Coulter). These beads are easily 
identified on a FSC-height vs. FL2 dot plot due to their low FSC and high FL2 values. 
By adding a know volume of a set concentration of beads to the sample, cell 
concentrations can by calculated thus; 
 
Total No. Beads in Assay    X   No. Cell Events    =       No. Cells/ml 
        No. Bead Events 
4.1.5.3 Protocol for Live / Apoptotic / Dead staining.  
The Proliferation studies were conducted using the Annexin V-PE Apoptosis 
Detection Kit I (BD Pharmingen). Cells stripped from the 6 well plates with 2ml of 
cool trypsin were placed in 3ml FACS tubes (BD) and washed twice. The pellet was 
then re-suspended in 100μml of full media and incubated at 370C for 30 minutes. This 
allowed the repair of any cell membrane damage cause in the stripping and washing 
process. The cells were then pelleted and re-suspended in 100μml of Annexin V 
binding Buffer (BD). To this suspension 5μml of Annexin V-PE and 5μml of 7-AAD 
was added and the sample mixed by vortex. The tubes were the placed in the dark at 
room temperature for 15 minutes. Once the staining was complete 400μml of the 
Annexin V binding buffer and 10μml of Flow-count beads (Beckman Coulter) were 
added to the tube and the sample analysed within 1 hour.  
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4.1.5.4 Analysis of proliferation studies.  
The proliferation samples were run on the FACScan (BD) using pre-set parameters. 
The tubes were thoroughly mixed by vortexing prior to analysis to evenly distribute 
the cells and beads throughout the solution.  Initially a Dot plot of FSC vs. SCC was 
generated and a parameter is drawn around the intact cells and the bead population 
(fig 4.11). 
 
 
 
 
  
 
 
 
 
 
Fig. 4.11: FSC vs SSC plot of MCF7 cells, P1 gated around intact cells, P2 gated around Bead 
population. 
 
A second dot plot of Annexin-PE vs. 7-AAD was gated to P1 and from this the 3 
population of cells, live cells, apoptotic calls and dead cells (fig 4.12). The software 
then provided a results table with the numbers of each of the cell populations and the 
total number of beads (fig 4.13). By applying the formula described above, accurate 
cell numbers and percentage in each stage of proliferation was calculated.    
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Fig. 4.12: Annexin V PE vs 7AAD plot showing the 3 populations of cells, Q1 population Annexin +ve 
7AAD –ve apoptotic cells, Q2 population Annexin +ve 7AAD +ve necrotic/dead cells (note the 2 
vertical population of G1 and G2 cells) and Q3 Annexin and 7AAD negative cells which are alive. 
 
 
 
 
 
 
 
Fig.4.13: Figure showing the numbers and % of the 3 cell populations (Q1, Q2,Q3) and the total 
numbers of counter beads (P2).   
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4.1.6 Titration of Oestrogen concentration. 
Previously in this lab many stimulation experiments have been run analysing the 
affects of oestrogen on cell lines. The optimum concentration of oestrogen for 
stimulation of ER positive MCF7 cells is 10
-9
M. These growth rate experiments were 
carried out by Dr A Davison on MCF7 cell lines at various E2 concentrations as part 
of his work towards his PHD thesis. Many other studies have considered 10
-9
M to be 
the physiological concentration of estrogen required to stimulate ER positive cells 
(Alyea and Watson, 2009, Natoli et al., 1983, Stoica et al.).  
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4.1.7 Titration of EGF concentration. 
To ascertain the optimum concentration of EGF required for maximum stimulation of 
the cell lines under investigation the following titration experiment was performed. 
Recombinant EGF (Sigma) was reconstituted with 0.01M HCl to produce a stock 
concentration of 1x10
-4
M, this stock was then used to produce the test solutions. 1 ml 
of 1 x 10
5
/ml of MDA-231 breast cancer cell line were seeded into 6 well plates. 
These were synchronised in stripped media SDMEM for 72 hours (see 4.1.4.1).The 
following 6 well plates were then set up in triplicate: 
 
 
 
 
 
 
The plates were then incubated at 37
0
C for 96 hours with the test media changed 
every 48 hours. At the following time points each triplicate was stripped and assessed 
for proliferation and cell cycle (see 4.1.4 & 4.1.5). Time points 0hr, 24hr, 48hr, 72hr, 
96hr. 
Plate 1 Control DMEM 
Plate 2 Control DMEM and 0.01M HCl 
Plate 3  EFG 10
-7
 
Plate 4 EGF 10
-8 
Plate5 EGF 10
-9 
Plate 6 EGF 10
-10 
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4.1.7.1 Results of EGF titration.  
The results for each test at each time point were plotted.   
  
Cell proliferation results: 
 
 
 
 
 
 
 
 
 
Fig. 4.14: Graph showing live cell numbers for each treatment over time course in hours. 
 
 
 
 
 
 
 
 
 
Fig 4.15: Graph showing % population of live cells for each treatment over time course in hours. 
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Fig.4.16: Graph showing % dead cells for each treatment over time course in hours. 
 
Results of Cell Cycle analysis; 
 
 
 
 
 
 
 
 
 
Fig. 4.17: Graph showing % cell population in G1 phase for each treatment over time course in hours. 
 
  
221 
 
MDA EGF titration
S phase %.
0
5
10
15
20
25
30
24 48 72 96
Time point.
%
S
control
control Hcl
10-7
10-8
10-9
10-10
MDA EGF titration
G2 phase %.
0
5
10
15
20
25
30
35
24 48 72 96Time point. 
G
2
%
control
control Hcl
10-7
10-8
10-9
10-10
 
 
 
 
 
 
 
 
Fig. 4.18: Graph showing % cell population in S phase for each treatment over time course in hours. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.19: Graph showing % of cell population in G2 phase for each treatment over time course in 
hours. 
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4.1.7.2 Analysis of EGF titration. 
The results of this titration demonstrated that although the percentage of the 
population in each phase at each time point did not significantly differ, an EGF 
concentration of 10
-8
M induced the highest proliferation. There was an obvious 
problem with the 72 hour control time point which was probably due to a technical 
error. The percentage live cells and overall live cell numbers fell off after 96 hours 
which may have been due to overgrowth within the wells or lack of growth factors 
after 72 hours culture in stripped medium supplemented only with EGF.  
 
Following this time course experiment it was decided to use a test EGF concentration 
of 1x10
-8 
M. The 1x10
-8 
M concentration is equivalent to 123ng/ml, previous 
experimental papers on EGF stimulation of STAT3 have used concentration from 
10ng/ml (Grant et al., 2002, Li and Shaw, 2002, Selander et al., 2004b) to 100ng/m 
(Imai et al., 1982a, Garcia et al., 2001, Lo et al., 2005b). We therefore considered a 
1x10
-8 
solution to be adequate to maximally stimulate the cell lines and STAT3 
phosphorylation.  
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4.1.8 Titration of pY705 Stat3 Antibody.  
Stat3 is activated via tyrosine phosphorylation at Tyr705. To assess the effects of 
estrogen and EGF stimulation on Stat3 the assay used had to recognise the 
phosphorylated form of Stat3.  BD Biosciences Pharmingen (San Jose, USA.) produce 
a range of Phos-flow antibodies specifically for detecting phosphorylated signalling 
proteins using flow cytometry. Following failure in the testing of various other anti-
bodies and protocols the PE conjugated Anti-Stat3 pY705 antibody was used and the 
appropriate stain buffer and isotype control (IgG2a, κ) (see data sheet in appendix). 
 
Due to the transient and temporary nature of signalling protein phosphorylation it was 
a concern that any delay in the assessment of the pY705 Stat3 during the time course 
experiment may induce error in the experiment. This delay may occur due to the fact 
that at each time point during the experiment every triplicate cell sample had to be run 
for proliferation and cell cycle status as well as protein expression. It was decided that 
during the time course experiment the protein assessment samples would be snap 
frozen to preserve the phosphorylation status of the Stat3 to allow assessment at a 
later date. Using IHC we had demonstrated Stat3 expression in MCF7 cells.  
 
 
 
 
 
 
Fig. 4.20: MCF7 breast cancer cells stained for STAT3 using IHC. Cell show a strong cytoplasmic 
stain with some nuclear staining.(x400)   
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4.1.8.1 Protocol for pY705 Stat3 titration.  
Un-stimulated MCF7 cells were routinely cultured in 6 well plates. Lymphocytes 
were harvested as a control cell. The Stat3 antibody was titrated at volumes to cover 
the recommended 20μl test volume. Isotype control volumes were matched to 
antibody volumes.  
 
 
 
   
       
 
 
 
 
 
 
 
 
 
 
 
The staining and analysis protocol for the pSTAT3 experiment was based on the 
protocol provided on the technical data sheet (contained in appendix) for this specific 
antibody. Each tube was repeated in triplicate.  
Tube Number Cell type Antibody volume 
1 MCF7 Control (no antibody) 
2 MCF7 Antibody 5μl 
3 MCF7 Antibody 10μl 
4 MCF7 Antibody 15μl 
5 MCF7 Antibody 20μl 
6 MCF7 Antibody 30μl 
7 MCF7 Isotype 5μl 
8 MCF7 Isotype 15μl 
9 MCF7 Isotype 30μl 
10 Lymphocytes Control (no antibody) 
11 Lymphocytes Antibody 5μl 
12 Lymphocytes Antibody 10μl 
13 Lymphocytes Antibody 15μl 
14 Lymphocytes Antibody 20μl 
15 Lymphocytes Antibody 30μl 
16 Lymphocytes Isotype 5μl 
17 Lymphocytes Isotype 15μl 
18 Lymphocytes Isotype 30μl 
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Cells seeded in 6 well plates were stripped with 2ml cool trypsin. They were then 
washed twice with PBD at 2500rpm (2050G) for 5 minutes and then fixed with 2% 
paraformaldehyde/PBS for 30 minutes at 37
0
C. Following fixing the cells were 
washed again in PBS then frozen at -80
0
C. 
 
The cell samples were then defrosted at 37
0
C, washed again with PBS and then 
divided into three 3ml FACS tubes (BD). To allow the antibody to permeate the cells 
the cells were permeablised by the addition of 1ml cold 90% methanol for 30 minutes 
on ice. The samples were then washed twice at 2500 rpm (2050G) for 5 minutes with 
BD Pharmingen Stain Buffer. The appropriate volume antibody, isotype control or 
control PBS was then added to the tube and incubated for 30 minutes in the dark at 
room temperature. Following staining the sample was washed in stain buffer to 
remove unbound antibody then re-suspended in 500μl of stain buffer for analysis on 
the LSR II flow cytometer. 
 
Following analysis a dot plot of SSC-height vs. FITC-area identified the cell 
population. This gated population was then plotted as a FITC-height vs. FITC-area to 
distinguish single cells from doublets. The singlet population was then plotted as PE 
575/26 area vs. SSC- height to determine the specific cell fluorescence. The cell 
fluorescence was then plotted as a histogram on a log scale and the median channel 
fluorescence calculated (fig 4.21 & 4.22). In the cell model experiment, to ascertain 
the fluorescence shift specific to the binding of the STAT3 antibody we subtract the 
median channel florescence in the isotype control tube from the median channel 
fluorescence of the antibody tube to give the specific median channel shift.    
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Fig. 4.21: Un-stimulated MCF7 breast cancer cells stained with a stat3 isotype control with the median 
channel for the singlet population(black arrow) of 1259.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22:Un-stimulated MCF7 breast cancer cells stained with a stat3 antibody with the median 
channel for the singlet population of 2364 (black arrow).   
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Figure 4.21 and 4.22 show the histograms generated for the 2 tubes of MCF7 cells 
analysed on the flow cytometer. The first tube (fig 4.21) contains MCF7 cells stained 
with the isotype control which showed the non specific binding and fluorescence of 
the PE 575/26A dye. The second tube (fig 4.22) contained MCF7 cells stained with 
the STAT3 specific antibody. The difference in the median channel between these 2 
tubes was the median channel shift specific which is a measure of the pY705 
phospho-STAT3 expression in un-stimulated MCF7 cells. For example using these 2 
tubes the median channel shift would be 1095 channels (2364 – 1269)       
4.1.8.2 Results of pY705 Stat3 Titration.         
In this titration experiment the median shift was the difference between the antibody 
or isotype control and the control tube. The average median channel shift for the 
triplicate of each titration tube was then calculated then plotted a graph. 
 
    
 
 
 
 
 
 
 
Fig. 4.23: Graph showing the median channel shift see for each volume of antibody and isotype control 
in both MCF7 breast cancer cells and human lymphocytes. 
   
228 
 
4.1.8.3 Analysis of pY705 STAT3 titration.  
The results demonstrate that there was no specific binding of the isotype control in 
either of the tested cells. It appeared that the lymphocytes do demonstrate pY705 
Stat3 expression and this pStat3 was not saturated in this experiment. When the 
MCF7 curve was analysed it demonstrated the classical titration curve for pStat3 
antibody with a saturation point of 20μl and the curve reaching a plateau at this point 
(fig 4.23).  
 
This titration experiment confirmed that using our protocol for staining we were using 
a specific stain which saturated the sample at a volume identical to the manufacturer’s 
suggested test volume of 20μl. 
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4.1.9 The cell model time course experiment.  
 
The Stat3 analysis time course experiments were conducted with each of the 3 cell 
lines consecutively. Each cell line model followed the same protocol. There were 7 
treatments for each cell line; 
 
Treatment 1. Control:  Stripped DMEM only.  
 
Treatment 2. Control:  ETOH (20μl 100% ETOH in 19.98ml DMEM.)  
 
Treatment 3. Control:  HCl (20μl 0.01M HCl in 19.98ml DMEM.) 
 
Treatment 4. Control:  ETOH & HCl (20μl 100% ETOH & 20μl 0.01M HCl in 19.96 
ml DMEM) 
 
Treatment 5. Test E2: 10
-9
M E2 (20μl E2 10
-6
 stock in 19.98ml DMEM.)  
 
Treatment 6. Test EGF: 10
-8
 EGF (20μl 10-5 EGF stock in 19.98ml DMEM.) 
 
Treatment 7.  Test E2 & EGF: 10
-9
 E2 & 10
-8
 EGF (20μl E2 10
-6
 stock and 20μl 10-5 
EGF stock in 19.96ml DMEM)  
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6 well plates of the selected cell lines were set up in parallel for both the Stat3 
expression and for the cell cycle / live dead and apoptotic study. Each test point was 
conducted in triplicate. The cells were synchronised for 72 hours as described earlier. 
 
4.1.9.1 Stat3 expression assessment.  
87 wells of 200,000 cells were seeded for each experiment in 2ml of media. These 
represented the 7 treatments to be tested at 0hrs, 12hrs, 24hrs, 48hrs, and 72hrs. The 
test media was changed at 0hrs, 24hrs and 48hrs.  
 
The selection of time points for the analysis of STAT3 was based upon the fact that 
the phosphorylation of STAT3 is a relatively rapid event but the effect of pSTAT3 
induction of cell proliferation has a longer time course. Some studies have shown that 
in the inflammatory setting phosphorylation of STAT3 occurs maximally at 3 hours 
when cardiac cell are stimulated with IFN-γ (Wang et al., 2002). In breast cancer cell 
lines MCF7 cells show a peak in STAT3 phosphorylation at a 6h then 24h time point 
when stimulated by hypoxia (Lee et al., 2006). Other studies have shown that 
depending on cell line type stimulation with IL-6 causes a peak of phosphorylation at 
6-12hr or 24-48hrs. There is little published work on the time course of estrogen of 
EGF stimulated phosphorylation of STAT3 in breast cancer cell lines. It is hope that 
the selected time points in this study will detect these peaks in phosphorylation.  
 
The 6 well plates were then stripped at the appropriate time point and frozen for 
analysis as per the protocol above. Stat3 analysis was then conducted as per the 
protocol described above with an antibody test volume of 20μl. 
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4.1.9.2 Cell cycle, Live / Dead and apoptotic time course.  
66 wells of 100,000 cells were seeded for each experiment in 2 ml of media. These 
represented the 7 treatments to be tested at 0 hrs, 24hrs, 48 hrs and 72hrs, with the 
media changed every 24 hours,  
 
The wells were then stripped at the given time point and divided into 2 x 3ml FACS 
tubes. 1 tube was analysed for cell cycle using the protocol described above and the 
second tube was used to calculate the live/dead and apoptotic populations as per 
protocol described above.   
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4.1.9.3 Statistical analysis of cell model results. 
Each treatment at each time point was run in triplicate simultaneously. Cell numbers, 
cell cycle proportions and pSTAT3 median channel shifts were all calculated as a 
mean of the triplicates for each treatment and time point. The treatments were 
compared to the specific controls for that treatment i.e. estrogen to ethanol, EGF to 
HCl.  
 
The comparison of these means were made using a paired t-test, a result was 
considered significant with a p value of 0.05 or less. Statistical analysis was carried 
out using SPSS Statistical Software, 15.0 version. (SPSS, Inc, Chicago, IL, USA.)      
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4.2 Results of Cell Model.  
The results for the cell model experiments are presented for each cell line 
individually. For each cell line a conclusion table is shown for the cell number results, 
the cell cycle results and the STAT3 induction of expression results. Selected graphs 
are shown to illustrate significant trends or results. The raw data and statistical 
analysis for each experiment is contained in the appendix. All significant results are 
bases on a two sided t-test with significance level of 0.05 or less. The significant 
results are expressed when there is a significant difference between the treatments and 
the specific controls for the treatment at that time. To show these differences results 
are plotted on the bar charts for the treatments with the specific control  
 
4.2.1 MCF7 cell model results. 
4.2.1.1 Cell number results.  
The mean cell number of the triplicate experiments was compared to that of the 
treatment specific control using a using a paired t-test and significant values 
(p=<0.05) are shown in the tables. Where no significant difference no result is shown.   
Treatment \Time point 24 hours 48 hours 72 hours 
E2 ↑ Total cells 
↑Live cells 
↑ Total cells 
↑Live cells 
↑Apoptotic cells 
↑ Total cells 
↑Live cells 
EGF ■ ■ ■ 
E2 & EGF ■ ↑ Total cells 
↑Live cells 
↑Apoptotic cells 
↑ Total cells 
↑Live cells 
 
Table 4.1: Table showing the significant results for the MCF7 cell number experiment. Significant 
increase. Significant decrease. (p=0.05) 
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The following graphs illustrate these significant results.  
 
 
 
 
 
 
 
 
 
 
Fig 4.24: Graph showing the mean total cell numbers of E2 stimulated MCF7 cells. * = significant 
difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
Fig 4.25: Graph showing the mean live cell numbers of E2 stimulated MCF7 cells. * = significant 
difference compared to control. 95% CI bars shown. 
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Fig 4.26: Graph showing the mean apoptotic cell numbers of E2 stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.27: Graph showing the mean total cell numbers of E2and EGF stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
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Fig 4.28: Graph showing the mean live cell numbers of E2 and EGF stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
Fig 4.29 Graph showing the mean live cell numbers of E2 and EGF stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
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4.2.1.2 Cell cycle results. 
The mean of the triplicate % populations between the treatments and controls were 
compared. This table shows the significant increases (in red) and decreases (in blue) 
of the % population in the G1, S and G2 phases for the MCF7 cell model. 
 
 
 
 
 
Table 4.2: Table showing the results of the MCF7 cell cycle experiment. . Significant increase. 
Significant decrease. (p=0.05) 
The following graphs illustrate these significant results. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.30: Graph showing the mean G1 % of E2 stimulated MCF7 cells. * = significant difference 
compared to control. 95% CI bars shown.  
Treatment \Time point 24 hours 48 hours 72 hours 
E2 
↓G1, ↑S↑G2 ↓G1 ↓G1, ↑S↑G2 
EGF 
↓G1, ↑S ↑S ↑S 
E2 & EGF 
↓G1, ↑S↑G2 ↓G1, ↑S  ↑S↑G2 
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Fig 4.31 Graph showing the mean S % of E2 stimulated MCF7 cells. * = significant difference 
compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
Fig 4.32 Graph showing the mean G2 % of E2 stimulated MCF7 cells. * = significant difference 
compared to control. 95% CI bars shown. 
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Fig 4.33: Graph showing the mean G1 % of EGF stimulated MCF7 cells. * = significant difference 
compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
Fig 4.34: Graph showing the mean S % of EGF stimulated MCF7 cells. * = significant difference 
compared to control. 95% CI bars shown. 
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Fig 4.35: Graph showing the mean G1 % of combined E2 and EGF stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.36: Graph showing the mean S % of combined E2 and EGF stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
  
241 
 
 
 
 
 
 
 
 
 
Fig 4.37: Graph showing the mean G2 % of combined E2 and EGF stimulated MCF7 cells. * = 
significant difference compared to control. 95% CI bars shown. 
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4.2.1.3 STAT3 expression results. 
This table shows the change in pSTAT3 expression when measured as a significant 
change in median channel shift for each treatment at each time point when compared 
to its specific control. Where there is no significant difference no result is shown.   
 
Treatment \ Time point 12 Hr 24 Hr 48 Hr 72 Hr 
E2 
■ ■ ↑ ■ 
EGF 
↑ ■ ↑ ■ 
E2 and EGF 
■ ■ ■ ■ 
 
Table 4.3: Table showing the significant results for the MCF7 STAT3 induction experiment. Significant 
increase. Significant decrease. (p=0.05) 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.38: Graph showing the mean median channel shift of pSTAT3 in MCF7 cells with E2 stimulation. 
* = significant difference compared to control. 95% CI bars shown. 
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Fig 4.39:Graph showing the mean median channel shift of pSTAT3 in MCF7 cells with EGF 
stimulation. * = significant difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.40:Graph showing the mean median channel shift of pSTAT in MCF7 cells with E2 and EGF 
stimulation. No significant difference compared to control. 95% CI bars shown. 
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To illustrate the effect of the increased stimulation of STAT3 phosphorylation by 
EGF alone compared to estrogen and EGF two of the histograms plotted are shown 
below. 
 
 
 
 
 
 
 
 
Fig 4.41Histogram of pSTAT3 expression in MCF7 cells stimulated with EGF after 48hrs. The black 
arrow (single cells) shows a median channel fluorescence of 2920. 
 
 
 
 
 
 
 
 
 
Fig 4.42 Histogram of pSTAT3 expression in of MCF7 cells stimulated with estrogen and EGF after 
48hrs. The black arrow (single cells) shows a median channel fluorescence of 756. 
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The 2 histograms above clearly show the inhibiting effect on pSTAT3 expression of 
the addition of estrogen to EGF stimulation in MCF7 breast cancer cells.  
To demonstrate the effect of the treatment on the induction of pSTAT3 a graph 
showing the ratio change of the pSTAT3 induction for the treatment compared to its 
specific control at each time point.  
 
 
 
 
 
 
 
 
 
 
 
Fig 4.43 Graph showing ratio of median channel shift for pSTAT3 induction in MCF7 cells. 
4.2.1.4 Summary of results for MCF7 cell model experiment.  
The results for the cell numbers and cell cycle have shown that MCF7 cell were 
stimulated to grow and divide by estrogen and to a lesser extent EGF. The pSTAT3 
results have shown that EGF stimulation causes a biphasic increase in the expression 
of phosphorylated STAT3 at 12 and 48 hours. Estrogen does appear also to have a 
small affect at 48 hours. The addition of E2 to EGF stimulation appears to inhibit 
EGF ability to stimulate pSTAT3 expression both at 12 and 48 hours. 
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4.2.2 SKBr3 cell model results. 
4.2.2.1 Cell number results.  
This table shows the significant changes in the numbers of total, live, apoptotic and 
dead cells over time for each of the treatments when compares to their control at that 
time point. Where there is no significant difference no result is shown.  
Treatment \Time point 24 hours 48 hours 72 hours 
E2 
■ ■ ■ 
EGF 
■ ■ 
↑ Total cells 
↑Live cells 
E2 & EGF 
■ ■ 
↑ Total cells 
↑Live cells 
 
Table 4.4: Table showing the significant results for the SKBr3 cell number experiment. Significant 
increase. Significant decrease. (p=0.05) 
The following graphs represent these significant results.  
 
 
 
 
 
 
 
 
 
 
Fig 4.44: Graph showing the mean total cell numbers of EGF stimulated SKBr3 cells. * = significant 
difference compared to control. 95% CI bars shown. 
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Fig 4.45: Graph showing the mean live cell numbers of EGF stimulated SKBr3 cells. * = significant 
difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.46: Graph showing the mean total cell numbers of E2 and EGF stimulated SKBr3 cells. * = 
significant difference compared to control. 95% CI bars shown. 
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Fig 4.47: Graph showing the mean live cell numbers of E2 and EGF stimulated SKBr3 cells. * = 
significant difference compared to control. 95% CI bars shown. 
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4.2.2.2 Cell cycle results. 
This table shows the significant increases (in red) and decreases (in blue) of the mean 
% population in the G1, S and G2 phases for the SKBr3 cell model experiment. 
Where there is no significant difference no result is shown.  
Treatment \Time point 24 hours 48 hours 72 hours 
E2 
■ ■ ■ 
EGF 
■ ↑S ↓G1 ■ 
E2 & EGF 
■ ■ ■ 
 
Table 4.5: Table showing the results of the SKBr3 cell cycle experiment. . Significant increase. 
Significant decrease. (p=0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.48: Graph showing the mean G1 % of EGF stimulated SKBr3 cells. * = significant difference 
compared to control. 95% CI bars shown. 
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Fig 4.49: Graph showing the mean S % of EGF stimulated SKBr3 cells. * = significant difference 
compared to control. 95% CI bars shown. 
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4.2.2.3 STAT3 expression results. 
This table shows the change in pSTAT3 expression when measured as a significant 
change in median channel shift for each treatment at each time point when compared 
to its specific control. Where there is no significant difference no results is shown. 
 
 
 
 
 
Table 4.6: Table showing the significant results for the SKBr3 STAT3 induction experiment. Significant 
increase. Significant decrease. (p=0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.50: Graph showing the mean median channel shift of pSTAT3 in SKBr3 cells with EGF 
stimulation. * = significant difference compared to control. 95% CI bars shown.  
Treatment \ Time point 12 Hr 24 Hr 48 Hr 72 Hr 
E2 
■ ■ ■ ■ 
EGF 
■ ↑ ■ ↑ 
E2 and EGF 
■ ↑ ■ ↑ 
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Fig 4.51: Graph showing the mean median channel shift of pSTAT3 in SKBr3 cells with E2 and EGF 
stimulation. * = significant difference compared to control. 95% CI bars shown. 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.52: Histogram of pSTAT3 expression in SKBr3 cells stimulated with EGF after 72hrs. The black 
arrow (single cells) shows a median channel fluorescence of 1212. 
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Fig 4.53: Histogram of pSTAT3 expression in SKBr3 cells stimulated with E2 and EGF after 72hrs. 
The black arrow (single cells) shows a median channel fluorescence of 1110. 
 
The 2 histograms above shows that, unlike MCF7 cells, the addition of E2 to EGF 
stimulation does not inhibit STAT3 phosphorylation in SKBr3 cells. Again to show 
this a ratio of the median channel shift of treatment vs. control was plotted 
 
 
 
 
 
 
 
 
 
 
Fig 4.54: Graph showing ratio of median channel shift for pSTAT3 induction in SKBr3 cells. 
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4.2.2.4 Summary of results for SKBr3 cell model experiment.  
The results for the cell cycle have shown that SKBr3 cells were stimulated to grow 
and divide by EGF with a decrease in the G1 population and an increase in S phase 
population at 48 hours. The STAT3 results have shown that EGF stimulation in 
SKBr3 cells again causes a biphasic increase in the expression of phosphorylated 
STAT3 this time at the 24 and 48 hour time point. Estrogen has no affect on STAT3 
expression in this cell line. The addition of E2 to EGF stimulation in this cell line 
appears not to inhibit EGF ability to stimulate STAT3 expression especially at the 72 
hour point unlike theMCF7 cell line. 
 
 
4.2.3 MDA 231 cell model results. 
After the analysis of the cell model results, and despite running the same cell model 
twice, we have been unable to ascertain and significant differences in cell number, 
cell cycle or STAT3 expression. The reasons for this are postulated in the discussion 
of results.  
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4.2.4 Summary of the cell line experiment. 
The table below is shown to summarise the overall effect on STAT3 phosphorylation 
of stimulation with estrogen, EGF and combined stimulation on the 2 cell lines MCF7 
and SKBr3. 
 
 Cell Line Receptor Status Stimulation. 
Cell Line ER EGFR E2 EGF E2&EGF 
MCF7 Positive Weak ↑ ↑ 0 
SKBr3 Negative Positive 0 ↑ ↑ 
 
Table 4.7: Table showing the stimulation of STAT3 phosphorylation in MCF7 and SKBr3 cell lines 
following treatment with E2, EGF or combined E2 and EGF.  
 
The overall results showed that in the ER positive EGFR weak MCF7 cells estrogen 
and EGF alone resulted in an increase in STAT3 phosphorylation whereas combined 
stimulation did not increase STAT3 phosphorylation. These results were different 
from the ER negative EGFR positive SKBr3 cells where estrogen had no effect on 
STAT3 phosphorylation and EGF and combined estrogen and EGF increased STAT3 
phosphorylation.  
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4.3. Discussion of cell model results. 
The aim of the cell model study was to delineate the role of E2 and EGF stimulation 
on levels of STAT3 phosphorylation. To do this we selected the ER positive EGFR 
negative MCF7 cell line and compared its response to the ER negative EGFR positive 
cell lines MDA-231 and SKBr3. Overall stimulation of growth of the cell line was 
assessed using analysis of cell numbers and changes to the cell cycle populations. 
Changes in STAT3 phosphorylation was assessed by looking at significant increases 
in the median channel shift in florescence caused by E2 or EGF stimulation and 
combined stimulation when compared to the controls.  
4.3.1 Cell line stimulation.  
When considering the MCF7 cell line, we expected that upon stimulation with E2 and 
with the combination of E2 and EGF that the cell line would grow and proliferate. 
This stimulation would be represented by an increase in overall cell numbers and an 
increase in the live cell population. We would also see the cells progressing though a 
change in the DNA with a decrease in the G1 population compared with an increase 
in the S phase population and eventually a rise in the G2 population as the cell prepare 
to divide.  
 
Table 4.1 shows the results for the MCF cell number experiment. In this estrogen 
sensitive breast cancer cell line, stimulation with estrogen caused a significant 
increase in total cell number and in the live cell number at all time points when 
compared to the ETOH control (fig 4.25 & 4.25). At the 48 hour time point with the 
estrogen stimulation there was also a significant increase in the apoptotic cell 
population (fig 4.26,) this was an indication of increased cell turnover.  
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The combined stimulation with estrogen and EGF also lead to an increase in total and 
live cell numbers at the 48 and 72hr time point (fig 4.27 & 4.28) and the apoptotic 
cells at 48hrs (fig 4.29). This would be predominantly a result of the estrogen 
stimulation due to the very low level if EGFR present in MCF7 cells.   
 
The results for the cell cycle experiment are shown in table 4.2. These results show 
that stimulation with estrogen did result in a significant decrease in the G1 % 
population at the 24, 48 and 72 hour time point, the decrease in comparison to the 
ETOH control is shown in fig 4.30. This decrease in G1 % population was matched 
with the associated increase in the S phase proportion at the same time points, at 48 
hours this increase did not quite reach statistical significance though the trend can be 
seen in fig. 4.31. The results also showed a significant increase in the G2 % 
population at the 24 72 hour time point (fig 4.32).  
 
Stimulation with EGF did appear to decrease the initial G1 % population and increase 
the S phase % population at 24, 48 and 72 hours. Though only small (fig 4.33 & 4.34) 
the changes did appear to be significant. MCF7 is classical thought to be EGFR 
deficient but studies have shown low levels of functional EGFR below the lower 
limits for IHC detection (Imai et al., 1982b). This apparent stimulation in cell cycle 
was not reflected in a significant change in the cell numbers (table 4.1)   
 
The combined stimulation with E2 and EGF showed similar results to the E2 alone 
stimulation with a decrease in G1 % population and an increase in S phase % 
population at all time points (fig 4.35 & 4.36). The G1 % drop at 72 hours though not 
statistically significant due to the slightly larger 95% CI became more obvious when 
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plotted on the graph (fig 4.35). Once again we also saw a significant increase in G2 % 
at the 24 and 72 hours time points (fig 4.37). 
 
These results demonstrated that the MCF7 cell line was stimulated by E2 alone and 
E2 combined with EGF. Work in MCF7 cells has shown that in optimum stimulated 
conditions 85% of the cells had a mean cell cycle length of 21.3 hrs with cells passing 
through G2M phase in 3 hours (Taylor et al., 1983). These results have shown that a 
G2 % population increase within occurred the first 24 hours.  
 
The cell number results, for the SKBr3 cell line (table 4.4), has shown that E2 
stimulation had little effect on the cell line. Stimulation with EGF and combined EGF 
and estrogen caused an increase in total and live cell numbers at most of the time 
points (fig 4.44 – 4.47) but these increases did not become statistically significant 
until the 72 hr time point. 
 
The cell cycle results have shown that E2 and the combined E2 and EGF stimulation 
had no significant effect on the % population in each phase (table 4.5). There was a 
significant decrease in G1 % and increase in S phase % at the 48 hour time point with 
EGF stimulation, indicating that the cell were moving though the cell cycle towards 
division (fig 4.48 & 4.49).    
 
Though these results were not as impressive as hoped with regard to the increase in 
cell numbers and the progression through to G2 phase of the cell cycle they did 
indicate that SKBr3 was undergoing stimulation by EGF. Though previous work has 
shown that 72 hours is a sufficient length of time to show this progression through the 
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cell cycle it appears that the cells used in this model had a slower than expected 
growth rate. With prolonged culture beyond 72 hours this progression may well have 
been evident. Other studies have documented a longer proliferation time with the drop 
in G1 population proportion not evident until 4-6 days and similar difficulties in 
showing an increase in the G2 population proportion (Ingrid et al., 1997).  
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4.3.2 STAT3 induction.  
The results of the STAT3 induction are presented as absolute differences of mean 
median channel shift between the treatment and its control and as a ratio of this 
difference.  
 
When considering the MCF7 cell model we have shown that there is a significant 
increase in pSTAT3 when the cell line is stimulated with EFG (table 4.3). This 
appeared to be a biphasic response with a peak at 12 hours and a further peak at 48 
hours (fig 4.39 and fig 4.43). Though as discussed above MCF7 are classically 
thought to be EGFR negative these results show that pSTAT3 induction via an EGF 
mediated route requires only a very low level of EGFR receptor expression. This 
STAT3 induction despite low levels of EGFR has been reported before in MCF7 cell 
lines (Li and Shaw, 2002) and again in MDA-231 cell lines deficient in detectable 
EGFR (Selander et al., 2004a).  
 
The results of the EGFR positive SKBr3 cell model again, as demonstrated this bi-
phasic response to EGF stimulation in the activation of pSTAT3 (see table 4.6). In the 
SKBr3 cell model this response occurs slightly later at the 48 and 72 hour time point 
(fig 4.50 & 4.54).  
 
It has been suggested that STAT3 activation via EGF can occur via a rapid JAK 
mediated signal pathway with some studies demonstrating increases in nuclear 
STAT3 complexes after 30 min of treatment with EGF (Lo et al., 2005a). This rapid 
response has been termed “acute STAT3 activation” (Li and Shaw, 2002). A slower 
STAT3 response has been shown when starved cell lives have been re-suspended in 
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full serum and in this case it was suggested that this slower response was mediated via 
an IL6 pathway. There has been little published documentation of this bi-phasic 
response following continued EGF stimulation. The kinetics of this response may 
suggest that the first 12 hour peak is due to the phosphorylation of STAT3 which is 
constitutionally present in the cytoplasm whereas the second peak is due to an up 
regulation of the STAT3 gene itself. It has been shown that the STAT3 gene 
expression is up regulated by the sub-unit of the IL6 receptor gp130 (Ichiba et al., 
1998). Gp130 activation and up regulation occurs in response to EGF stimulation in 
breast cancer cells (Grant et al., 2002). It has also been shown that inhibition of gp130 
in breast cancer cell decreased STAT3 activation (Selander et al., 2004a). This 
provides a mechanism of up regulation of STAT3 gene expression via EGF 
stimulation which would account for this second peak seen in fig 4.50 and 4.54. It 
appears that EGF induction of STAT3 can be blocked by inhibition of the JAK with 
the pan-Jak inhibitor P6 but the joint EGFR/HER2 inhibitor used in clinical practice 
(Gefitinib) does not decrease EGF mediated STAT3 activation (Berishaj et al., 2007).  
 
ER activation is not classical considered as one on the predominate pathways of 
STAT3 activation. Our results in the MCF7 cell line have shown that though the 
initial acute phase of STAT3 activation is not present there is a delayed peak of 
pSTAT3 at the 48 hour time point. This ER activation of STAT3 has been 
demonstrated in other studies (Bjornstrom and Sjoberg, 2002) and it has been shown 
that the addition of Tamoxifen can inhibit this activation (Yeh et al., 2006b). This 
stimulation is likely not to be a direct activation of STAT3 by ER, seen with the acute 
EGF response, but activation via non-genomic cross talk as discussed in section 1.2.2. 
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This cross talk may be via G-protein coupling with EGFR receptors or the up 
regulation of Scr and MAPK pathways (Wong et al., 2002b). 
 
The results of the SKBr3 model showed that when the cell line is deficient in ER there 
is no STAT3 activation upon stimulation with estrogen (table 4.6). This result, though 
expected, is important as we have shown that EGFR expression below detectable 
levels in the MCF7 cell line is adequate for STAT3 stimulation, the converse in the 
SKBr3 cell line with ER was not true.       
 
An interesting and novel finding in our results is the inhibition of EGF pSTAT3 
induction when the cells were stimulated with EGF in combination with estrogen (see 
table 4.3). Though many experiments have been directed at the induction of STAT3 
with EGF or E2 little work has been published on the affect of dual stimulation. This 
inhibition of EGF pSTAT3 stimulation by estrogen was seen only in the ER positive 
MCF7 cell line. In the ER negative SKBr3 cell line the dual stimulation still results in 
the bi-phasic increase in STAT3 activation (table 4.6 & fig 4.50 & 4.54). The 2 
histograms plotted (fig 4.52 & 4.53) showed that there was no difference between the 
pSTAT3 median channel fluorescence at 72hrs in SKBR3 cells stimulated with EGF 
alone or EGF and estrogen combined. This is in contrast to the histograms (fig 4.41 & 
4.42) which showed the drop in pSTAT3 median channel fluorescence at 48hrs when 
MCF cells are stimulated with EGF and estrogen compared with EGF alone.     
 
There is no clear mechanism to account for this inhibition of EGF action on pSTAT 
when combined with E2 stimulation. There is some evidence that though ER can 
stimulate STAT3 activation it has also been shown that when MCF7 cell lines were 
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stimulated with IL6 the resultant STAT3 activation was inhibited by the addition of 
E2. It was also demonstrated that this inhibition could be reversed by the addition of 
Tamoxifen (Yamamoto et al., 2000a). It was suggested in this study that this 
inhibition was due to a direct interaction between ERα and STAT3. STAT3 action in 
Multiple Myeloma has been shown to be inhibited by PIAS3 (protein inhibitor of 
activated STAT3). Cell line experiments in Multiple Mylomas have shown that E2 
treatment increases the synthesis of PIAS3 (Wang et al., 2001). Both of these studies 
may supply a mechanism to explain the results seen in this work but further work is 
obviously necessary to clarify this interaction of dual stimulation.     
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4.3.3 The MDA-231 cell model. 
Unfortunately many difficulties were encountered with the MDA-231 cell line during 
culture. The cells were ascertained form in house stock and during the EGF titration 
experiment appeared to behave as expected with EGF stimulation. In the titration 
experiment the live cell numbers increased with stimulation and the cell moved 
through the G1, S and G2 cycle over the 96 hours. When the cell model experiment 
was conducted the same stock of MDA-231 was used but it became apparent on the 
analysis of the cell number and cell cycle data that they did not respond to any of the 
treatments with no difference between the controls and the treatments. We are 
currently at a loss as to the reasons for this but it is likely to be a technical problem 
with the culture of that stock of cells. It is unfortunate that these results are lacking as 
it would have been interesting to have seen the difference in STAT3 activation with 
this cell line and if they would respond in the same way to the SKBr3 cell line which 
had a similar receptor expression profile.      
 
4.3.4 Critique of the methodology and suggestions for improvements to the cell 
line models.  
Though this experiment has yielded some interesting results there were a number of 
metholodical issues that arose both in the running of the cell model and the analysis of 
the results. In this section I will identify some of those issues and offer suggestion on 
how this experiment could be developed and refined in the future.  
 
The basis of the cell model is sound, to ascertain the effects of the phosphorylation of 
STAT3 by estrogen and EGF it is sensible to have cell lines which have a different 
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expression of the 2 receptors for the hormones of interest i.e. one to act as a control 
for another. The MCF 7 line provided an ER positive line and the SKBr3 a strong 
EGFR positive ER negative line to allow this comparison. The fact that the MCF7 
line was also a low expresser of EGFR did lead to the interesting results seen with the 
co-stimulation with estrogen and EFG discussed above. To explore this further a truly 
ER positive EGFR negative line could be added in. A second option to provide a more 
thorough negative control would be the use of a receptor inhibition arm to the 
experiment. This would be provided by the use of tamoxifen as the estrogen control or 
Cetuximab (a monoclonal antibody against EGFR) as the EGF control.  
 
The second issue with the model was the time points of analysis. As explained in 
section 4.1.9.1 there is a variation in the phosphorylation pattern of STAT3 depending 
on the stimulation used and the cell line under stimulation. It is of concern that as this 
is a relatively fluid and transient processes the peak of phosphorylation may be 
missed with the time points chosen. To address this further optimisation experiments 
could be performed now it is know that EGF does stimulate STAT3 phosphorylation 
in SKBr3 cells. This experiment could be designed along the lines of a brief period of 
stimulation followed by the analysis of the cell population at rapid multiple time 
points i.e. 15 min 30 min 1hr 2hr 6hr etc. This would ensure that an earlier peak of 
phosphorylation was not missed in this cell model.  
 
There is a question of validity of the results seen using flow cytometry alone to assess 
STAT3 phosphorylation. Now flow cytometry is widely recognised for this purpose 
but at the time of the experiments there was less published experience in its use in this 
field. To further validate these results other methods could have been used alongside 
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the flow cytometry. These could have included western blot to ascertain a semi-
quantitative result for STAT3 phosphorylation or possibly the use of confocal 
fluorescence microscope which would allow the assessment of nuclear localisation of 
pSTAT3 in stimulated cells. 
 
Another point of discussion is the analysis of the results with regards to what values 
to use as the control points. There were two possible methods to do this one would be 
to compare the level of pSTAT3 with the time point zero result in the same stimulated 
arm of the experiment or to compare the level of pSTAT3 with the control un-
stimulated arm at each time point. It was decided that as STAT3 phosphorylation is a 
variable process then it was more valid to compare its level to the control arm at each 
time point, this was to take into account the possible natural fluctuation if pSTAT3 
levels across the time span of the experiment. I do however appreciate the arguments 
in favour of the other approach of going back to time point zero as the control value. 
This again could be addressed by the use of western blotting films at each time point 
to add more validity to this method.  
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5 Conclusion of the thesis. 
The two aims of this study were firstly to ascertain if the over expression of 
transcription factors STAT3 SP1 and NFKB in invasive breast cancer are related to 
the disease outcome and secondly to assess the role of estrogen and EGF in the 
induction of pSTAT3 in ER and EGFR positive and negative cell lines.  
 
Immunohistochemistry was used to determine the expression of the 3 transcription 
factors in 204 breast cancer samples in the study group. The study group selected was 
shown to be representative for the range of patient age and tumour types with regards 
to histology, grade and stage. The transcription factor “status” in the tumour was then 
compared to important pathological prognostic features and to overall patient 
outcome. 
 
The transcription factor STAT3 was over expressed in 27% of the cancers analysed. It 
was shown that nuclear expression of STAT3 was significantly associated with the 
poor prognostic markers of high grade, larger tumour size, vessel space invasion, 
node metastasis and a high NPI group. STAT3 expression was also significantly 
associated with ER and PR negative status but not to HER2 expression. STAT3 
nuclear expression was related to EGFR positive cancers.  
 
With regards to patient outcome we have shown that STAT3 over expression was 
significantly associated with disease recurrence but not with overall survival at 5 
years. Although STAT3 over expression was not shown to be an independent 
prognostic marker it was shown that it was a significant marker of poor survival in 
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node negative breast cancers. This sub-group of node negative patients may be being 
under treated with regards to adjuvant therapy with current management protocols. 
 
Sub-group analysis dependent on the HER2 status appeared to show that the dual 
positive cancers (HER2 +ve and STAT3 +ve) had a much poorer outcome than the 
HER2 +ve STAT3 -ve cancers. The significance of this was limited due to the size of 
these sub groups. These findings could have significant clinical importance if it is 
confirmed that the negative survival effect of HER2 positivity is only significant in 
the STAT3 positive patients. Anti HER2 (Herceptin) therapy may be more effectively 
targeted to these dual positive patients. This would target treatment to those with most 
to benefit; reducing the overall numbers of patient treated unnecessarily, which is 
important when considering the implications of Herceptin therapy.  A further study 
into STAT3 expression in HER2 receiving Herceptin could well identify that the 
population who benefit from Herceptin is the population which express STAT3. 
 
Nuclear or transcriptionally active SP1 was seen in 33% of the breast cancers tested. 
There were no significant correlations with any of the pathological features recorded 
but there was an association between SP1 and ER positive cancers. Though SP1 is an 
important transcription factor in the expression of ER it is not necessary for a tumour 
to have nuclear SP1 staining to express ER. Where SP1 does seem to be important is 
in the identification of patients who will suffer from a late disease recurrence. When 
survival after 2 years was plotted dependent on SP1 status, the only recurrences fell in 
the SP1 negative group of patients. This effect was independent of initial ER status. 
These results may allow the identification of patients with the risk of late recurrence 
to be targeted with further adjuvant treatments.  
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When testing our patient samples it was shown that nuclear localisation of NFKB was 
present in 15% of the group. This nuclear localisation was significantly associated 
with larger and higher grade cancers but not with node status. Due to the correlation 
with these larger more aggressive tumours there was also a relationship between 
nuclear NFKB and high NPI score. As in other studies a link between NFKB and ER 
negative tumours was shown. Despite these initial finding no link between NFKB 
expression and disease outcome was demonstrated. The sub group analysis failed to 
show any survival impact of NFKB expression, as of yet a there appears not to be a 
role for the IHC determined expression of NFKB in breast cancers.  
 
This IHC based clinical study has yielded some new and significant findings which 
may clinical and management implications. Further studies looking at STAT3 in 
HER2 positive cancers are needed determine if the initial trends seen in this study 
become significant with increased numbers of patients tested. Extended follow up in 
both the STAT3 and SP1 groups may yield significant late survival effects for each of 
these transcription factors and a larger cohort would allow more significant sub-group 
analysis.  
 
The cell model was designed to ascertain the effects of cell stimulation with estrogen, 
EGF or combined stimulation on the levels of phosphorylated STAT3. These results 
have confirmed that EGF stimulation in the EGFR rich cell line, SKBr3, results in an 
increase in STAT3 phosphorylation, it has also been shown that this is a bi-phasic 
response to EGF stimulation. These results have shown that, despite very low levels 
of expressed EGFR, the MCF7 cell line again exhibits a bi-phasic phosphorylation of 
STAT3 with EGF stimulation. 
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In the ER rich MCF7 cells it was shown that estrogen alone can increase STAT3 
phosphorylation and in the discussion we have proposed a mechanism to explain this. 
In this experiment the results suggested the novel finding that the addition of estrogen 
to EGF stimulation in the ER positive MCF7 cells there is an inhibition of STAT3 
phosphorylation. This inhibition did not occur in the ER negative SKBr3 cell line. It 
may be considered that ER stimulation of this predominantly ER driven cell line 
causes a preferential cell growth via an ER pathway rather than an EFGR/STAT3 
pathway i.e. the ER pathway overrides the EGFR/STAT3 phosphorylation. This could 
be important in a clinical setting when we consider an ER positive cancer which also 
has the potential for EGFR/STAT3 driven cell growth. If this cancer, currently driven 
via an estrogen stimulated ER pathway is then deprived of estrogen by an adjuvant 
therapy, such as aromatase inhibitor therapy, then they may be switch to an 
EGFR/STAT3 pathway of cell proliferation. This could cause and unexpected 
proliferation in tumour growth. 
 
These results generate many interesting hypothesis which deserve further 
investigation. The cell model experiment could be extended to include ER 
inhibition/blocking and EGFR inhibition. This may confirm firstly estrogen does 
inhibit EGF phosphorylation of STAT3 and whether or not this is via an ER mediated 
pathway.  
 
This hypothesis could also be tested in the clinical setting. Patients who do not have 
surgery for their tumour, undergoing primary endocrine therapy instead, provided a 
clinical setting to test this hypothesis. Samples of ER positive breast cancers which 
were treated with primary endocrine therapy (i.e. Letrazole) could be examined for 
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the levels of pSTAT3 before treatment and then at time points during the treatment. 
Some of these tumours will progress or recur after an initial response to primary 
endocrine therapy and if these tumours displayed an increase in pSTAT3 levels then 
this would add weight to the hypothesis that intervention with estrogen deprivation 
causes a shift to pSTAT3 mediated proliferation.  
 
This study has added to what is known about the role of STAT3, SP1 and NFKB 
expression in breast cancer patients and in so it has generated some important 
questions which should be the subject of further investigation. The cell model has 
raised the suggestion that estrogen deprivation may increase STAT3 mediated cell 
proliferation and the impact of this has been discussed.   
 
Breast cancer was one of the first tumours where biological markers were used to 
dictated treatment. With the increasing understanding of the molecular biology of 
breast cancer we have had a glimpse of the future of breast cancer management. That 
future is that upon presentation a patient’s tumour will be subjected to an entire panel 
of molecular markers which will identify the proliferative pathways in use by that 
cancer and future pathways available to that tumour. This will allow a bespoke 
package of adjuvant therapies to be tailored to the patient which will ensure the best 
possible outcome. Until this point we will always be faced with the patient who 
should have done well dying from their disease.    
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Sample size/power calculation formulae 
T Chadwick 20/03/09 
 
I have revised the calculation to look for the power available to detect the observed 
differences rather than what could be obtained with 80% power as this is a calculation made 
after the experiment. 
 
To illustrate we consider the alpha-ostrogen receptor with a sample group of 140 patients : 
 
70% of the sample is positive on this (of which approximately 83% survive) and 30% are 
negative. 
 
We need to define the following terms: 
 
Group 1: Postive 
m – sample size in group (98 [70% of 140]) 
p1 – survival proportion in group (0.83 – taken as the [rounded] midpoint of the range 
provided) 
 
Group 2: Negative 
n – sample size in group (42) 
p2 – survival (0.68) 
 
 
iv 
 
General 
phi = n/m (i.e. the ratio of group sizes = 3/7 = 0.429) 
delta = abs(p2-p1) (the absolute value of the difference in survival = 0.15) 
alpha = 0.05 (significance level) 
beta = 1 – power 
z_(1-alpha/2) = 1.96 (from normal distribution) 
p = (p1 + phi*p2)/(1+phi) 
 
Now to obtain the power which was available to detect the observed difference at the given 
significance level we use the following formula: 
 
z_(1-beta) = 
 
[delta*sqrt(m*phi) – z_(1-alpha/2)*sqrt(p*(1-p)*(1+phi))]/[sqrt(phi*p1*(1-p1)+p2*(1-p2))] 
 
and we then obtain the value of beta from normal distribution tables (from the z-score). 
 
[Note: to obtain a sample size first calculate m as shown below and then n = phi*m 
 
m =  
 
{[z_(1-alpha/2)*sqrt(p*(1-p)*(1+phi))+z_(1-beta)*sqrt(phi*p1*(1-p1)+p2*(1-
p2))]/[delta*sqrt(phi)]}^2] 
 
v 
 
Results 
 
Receptor p1 (m) p2 (n) z_(1-beta) Power 
alpha-o 0.83 (98) 0.68 (42) 0.0184258 51% 
EGFR 0.75 (70) 0.63 (70) -0.4285806 33% 
HER2 0.75 (35) 0.63 (105) -0.703246 24% 
 
Using rearrangements of the formula it can be shown that: 
 
alpha-o: 
There would be 80% power to detect a difference between 0.83 & 0.58 (or 0.68 & 0.91) – 
around 25% difference in survival [worst case] 
EGFR: 
There would be 80% power to detect a difference between 0.75 & 0.51 (or 0.63 & 0.85) – 
around 24% difference in survival [worst case] 
HER2: 
There would be 80% power to detect a difference between 0.75 & 0.47 (or 0.63 & 0.89) – 
around 28% difference in survival [worst case] 
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Data Sheet for pSTAT3 antibody. 
BD™ Phosflow Technical Data Sheet PE Mouse Anti-Stat3 (pY705)  
Product Information  Material Number: 612569  
Size: 50 tests  
Vol. per Test: 20 µl  
Clone: 4/P-STAT3  
Immunogen: Phosphorylated Human Stat3 (Y705) Peptide  
Isotype: Mouse IgG2a, .  
QC Testing: Human  
Tested in Development: Mouse  
Storage Buffer: Aqueous buffered solution containing BSA and =0.09% sodium azide.  
Description  
Stat proteins function as both cytoplasmic signal transducers and activators of transcription. 
Stat3 has been reported to be a 92kDa protein that is activated as a DNA binding protein 
through cytokines, such as IL-6, and growth factors, such as EGF. Stat3 activation occurs via 
tyrosine phosphorylation at Tyr-705. Tyrosine phosphorylation in response to cytokine 
stimulation is generally mediated by JAK1. Upon activation,Stat3 dimerizes, translocates to 
the nucleus, and binds DNA response elements thereby regulating gene expression. It has 
been reported that Stat3 binds to DNA as a homodimer, but it is also capable of binding as a 
heterodimer with Stat1. In addition to tyrosine phosphorylation, Stat3 is also phosphorylated 
at Ser-727 via the MAPK pathway. Stat3 is widely expressed and can bind to the sis-
inducible element (SIE) site from the c-fos promoter. This site is similar to the GAS element 
that is present in IFN-. induced genes. Thus, phosphorylation of Tyr-705 in Stat3 occurs in 
response to growth factors and cytokines, and is essential for normal transcription activity.  
vii 
 
This antibody is routinely tested by flow cytometric analysis. Other applications were tested 
at BD Biosciences Pharmingen during antibody development only or reported in the 
literature.  
Flow cytometric analysis of Stat3 (pY705). Human wholeblood was collected in the presence 
of heparin. Whole blood was either left unstimulated (unshaded) or stimulated (shaded) with 
recombinant human IL-6 (MN 550071) at 100 ng/mL for 15 min at 37 °C. Cells were lysed 
and fixed in a single step using BD™ Phosflow Lyse/Fix buffer (MN 558049) for 10 min at 
37 °C. Cells were then permeabilized in BD™ Phosflow Perm Buffer III (MN 558050) for 30 
min on ice or overnight at -20 °C. Cells were then washed twice in BD Pharmingen™ Stain 
Buffer (MN 554656) and stained with PE mouse anti-Stat3 (pY705) antibody (MN 612569) 
for 30 min at room temperature. Samples were analyzed on a BD FACSCalibur™ instrument.  
Preparation and Storage ; Store undiluted at 4° C and protected from prolonged exposure to 
light. Do not freeze.  
The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity 
chromatography.  
The antibody was conjugated with R-PE under optimum conditions, and unconjugated 
antibody and free PE were removed by gel filtration chromatography.  
Application  
Intracellular staining (flow cytometry) Routinely Tested 612569 Rev. 7 Page 1 of 2 
Suggested Companion Products  
Catalog Number Name Size Clone  
554656 Stain Buffer (FBS) 500 ml (none)  
558050 Perm Buffer III 125 ml (none)  
558049 Lyse/Fix Buffer 5X 250 ml (none)  
550071 Recombinant Human IL-6 10 µg (none)  
viii 
 
558595 PE Mouse IgG2a, . Isotype Control 50 tests MOPC-173  
Product Notices  
1.This reagent has been pre-diluted for use at the recommended Volume per Test. We 
typically use 1 X 10e6 cells in a 100-µl experimental sample (a test).  
2. Source of all serum proteins is from USDA inspected abattoirs located in the United States.  
Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute 
azide compounds in running water before discarding to avoid accumulation of potentially 
explosive deposits in plumbing.  
3. This conjugated product is sold under license to the following patents: US Patent Nos. 
4,520,110; 4,859,582; 5,055,556; European Patent No. 76,695; and Canadian Patent No. 
1,179,942.  
4. For fluorochrome spectra and suitable instrument settings, please refer to our 
Fluorochrome Web Page at www.bdbiosciences.com/pharmingen/colors.  
5. Please refer to www.bdbiosciences.com/pharmingen/protocols for technical protocols.  
References  
Bromberg J, Darnell JE. The role of STATs in transcriptional control and their impact on 
cellular function. Oncogene. 2000; 19:2468-2473.(Biology)  
Kazuroni I, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000; 37:1-11.(Biology)  
Liu KD, Gaffen SL, Goldsmith MA. JAK/STAT signaling by cytokine receptors. Curr Opin 
Immunol. 1998; 10(3):271-278.(Biology) 612569 Rev. 7 Page 2 of 2 
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 Table Showing the transcription factor IHC results.  
Pt number STAT3 status SP1 status  NFkB status 
99H00004 2 3 0 
99H00016 1 2 0 
99H00038 1 2 0 
99H00089 1 2 1 
99H00205 3 3 0 
99H00207 2 1 0 
99H00495 3 2 0 
99H00506 2 2 1 
99H00508 1 3 0 
99H00631 1 1 0 
99H00695 3 2 0 
99H00716 2 2 0 
99H00740 0 2 0 
99H00741 2 2 0 
99H00838 2 1 0 
99H00856 1 2 0 
99H00947 3 3 0 
99H00979 2 3 0 
99H01129 2 2 0 
99H01170 
 
3 
 99H01171 1 2 0 
99H01289 3 2 1 
99H01518 1 1 1 
99H01587 0 3 0 
99H01588 2 3 1 
99H01591 2 2 1 
99H01687 2 1 1 
99H01730 2 3 1 
99H01749 1 2 0 
99H01823 1 3 1 
99H01824 1 2 0 
99H01825 1 2 0 
99H01857 1 2 2 
99H01955 1 0 0 
99H01958 2 3 1 
99H01983 2 3 1 
99H01984 3 3 0 
99H02067 2 3 0 
99H02072 3 2 2 
x 
 
 
99H02089 3 3 1 
99H02180 1 3 2 
Pt number STAT3 status SP1 status  NFkB status 
99H02181 1 0 2 
99H02242 3 1 1 
99H02261 3 2 0 
99H02287 2 2 2 
99H02320 3 3 2 
99H02321 
 
3 2 
99H02326 2 3 1 
99H02463 1 3 1 
99H02483 1 3 2 
99H02506 3 1 1 
99H02705 
  
0 
99H02707 3 2 1 
99H02726 3 1 2 
99H02728 1 1 1 
99H02752 0 1 0 
99H02798 1 1 1 
99H02926 1 1 1 
99H03091 3 2 1 
99H03144 2 3 0 
99H03173 1 3 1 
99H03175 1 3 1 
99H03188 2 2 1 
99H03299 2 2 1 
99H03312 1 2 0 
99H03392 2 2 1 
99H03450 3 2 2 
99H03464 1 2 1 
99H03467 1 3 2 
99H03508 1 3 0 
99H03512 2 2 1 
99H03557 2 2 0 
99H03566 3 3 1 
99H03660 2 2 0 
99H03747 2 1 2 
99H03769 3 3 2 
99H03962 1 2 1 
99H03972 1 1 0 
99H03973 1 1 2 
xi 
 
99H03979 0 1 0 
99H03989 1 2 0 
99H04208 3 3 1 
99H04294 2 3 0 
Pt number STAT3 status SP1 status  NFkB status 
99H04345 1 2 1 
99H04346 3 3 2 
99H04347 1 3 2 
99H04439 2 2 0 
99H04440 1 3 1 
99H04533 3 2 1 
99H04542 2 2 0 
99H04545 1 1 1 
99H04613 1 1 0 
99H04642 1 2 2 
99H04737 1 3 0 
99H04746 2 3 0 
99H04750 1 2 0 
99H04776 3 1 2 
99H04840 1 3 0 
99H04943 2 3 1 
99H05020 3 3 0 
99H05032 3 2 2 
99H05033 1 2 0 
99H05071 1 2 1 
99H05222 3 2 1 
99H05234 3 3 1 
99H05235 2 3 2 
99H05275 2 3 0 
99H05281 3 3 1 
99H05342 
   99H05475 3 2 1 
99H05478 1 2 0 
99H05479 1 1 2 
99H05480 2 2 1 
99H05481 2 3 0 
99H05482 1 2 0 
99H05616 1 3 0 
99H05655 1 2 2 
99H05698 1 2 0 
99H05710 2 2 0 
99H05746 1 2 0 
99H05747 2 2 1 
xii 
 
99H05798 1 3 1 
99H05910 2 1 1 
99H05925 1 2 2 
99H05983 1 3 1 
99H05984 1 1 0 
Pt number STAT3 status SP1 status  NFkB status 
99H05993 2 3 0 
99H06041 
   99H06087 2 2 0 
99H06108 3 1 0 
99H06119 1 2 1 
99H06204 1 2 0 
99H06205 0 3 1 
99H06210 0 2 1 
99H06292 3 0 2 
99H06322 2 1 1 
99H06435 2 1 1 
99H06449 2 3 1 
99H06500 1 1 1 
99H06514 3 3 1 
99H06515 1 0 0 
99H06675 3 2 1 
99H06689 3 3 0 
99H06720 3 2 0 
99H06863 2 3 0 
99H06870 2 1 1 
99H06933 1 2 0 
99H07104 1 2 0 
99H07106 1 1 0 
99H07170 2 2 1 
99H07474 3 2 2 
99H07648 3 2 0 
99H07680 1 3 0 
99H07681 3 2 1 
99H07785 
 
3 
 99H07917 3 2 2 
99H07923 1 3 0 
99H07968 2 3 0 
99H08028 1 2 0 
99H08029 2 3 0 
99H08143 2 1 1 
99H08179 2 1 1 
99H08242 2 0 2 
xiii 
 
99H08345 3 3 0 
99H08405 1 1 1 
99H08416 1 1 1 
99H08417 3 1 
 99H08428 1 0 0 
99H08494 3 3 0 
Pt number STAT3 status SP1 status  NFkB status 
99H08512 3 0 1 
99H08758 1 0 1 
99H08780 1 1 0 
99H08790 2 2 
 99H08791 1 
 
0 
99H08893 2 0 0 
99H08908 2 1 0 
99H08909 3 1 0 
99H08988 
   99H09139 3 2 1 
99H09157 1 0 0 
99H09318 2 2 1 
99H09334 0 0 1 
99H09335 3 3 1 
99H09336 3 2 0 
99H09344 1 0 1 
99H09354 1 2 1 
99H09357 1 2 2 
99H09530 0 2 0 
99H09567 3 1 0 
99H09633 2 2 0 
99H09650 3 2 0 
99H09662 2 3 1 
99H09749 3 0 0 
99H09754 
 
3 0 
99H09796 2 3 0 
99H09797 2 2 0 
99H09798 1 3 0 
99H09799 1 
 
1 
99H09892 3 0 
 99H09909 3 
 
1 
99H09992 1 2 1 
99H10000 2 
 
1 
99H10049 2 0 1 
99H10050 1 1 1 
99H10066 0 0 1 
xiv 
 
 
Scoring:  
STAT3/SP1  0 = no stain. 
  1 = weak cytoplasmic 
  2 = strong cytoplasmic 
  3 = nuclear stain 
 
NFkB  0 = negative. 
  1 = cytoplasmic. 
  2 = nuclear. 
 
 
 
 
 
 
99H10069 3 2 1 
99H10080 3 3 
 99H10223 2 0 0 
99H10254 1 2 1 
99H10607 2 3 0 
99H10731 2 1 1 
99H10757 3 0 1 
Pt number STAT3 status SP1 status  NFkB status 
99H10805 1 2 2 
99H10820 3 3 1 
99H10993 2 
 
2 
99H10995 3 3 2 
99H11009 1 2 1 
xv 
 
MCF7 cell model results. 
Table showing cell cycle results for MCF7 model at 24 hr 
MCF7 24hr cell cycle 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
G1 % 64.87 .55 65.77 1.00 65.20 1.05 61.57 1.74 43.00 2.91 54.67 .81 43.13 1.08 
S1 % 25.03 1.31 25.23 1.44 24.43 1.64 26.33 .25 41.00 3.83 31.83 1.06 40.97 .50 
G2 % 9.89 1.07 9.23 1.07 10.82 1.12 11.60 1.25 17.53 1.46 12.63 .67 15.47 .74 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
G1 % E F G E F G E F G E F G  E G  
S1 %     A B C D F A B C D A B C D F 
G2 %     A B C D F B A B C D 
xvi 
 
Table showing cell cycle results for MCF7 model at 48 hr 
 
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
G1 % 75.73 .81 75.87 1.59 75.20 1.71 74.03 1.66 63.10 3.03 70.30 .78 58.83 .68 
S1 % 14.67 .51 14.30 1.25 15.50 .69 15.57 1.62 24.33 1.29 19.47 .68 27.33 .55 
G2 % 9.18 .97 9.98 .75 9.79 1.09 10.12 .42 11.76 1.72 10.09 .79 12.03 .74 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
G1 % E F G E F G E G E G  E G  
S1 %     A B C D F A B C D A B C D F 
G2 %        
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each 
significant pair, the key of the smaller category appears under the category with larger mean. 
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Table showing cell cycle results for MCF7 model at 72 hr 
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
G1 % 78.97 1.31 83.10 2.25 76.00 2.72 79.20 1.35 57.57 .86 68.87 .31 59.90 1.95 
S1 % 14.17 1.07 10.90 .61 15.30 1.61 13.57 .75 28.77 1.24 19.80 .82 25.80 .52 
G2 % 6.46 3.19 6.35 1.89 9.10 .63 7.96 1.26 12.73 .84 11.83 .90 13.63 1.77 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
G1 % E F G C E F G E F G E F G  E G  
S1 % B  B  A B C D F A B C D A B C D F 
G2 % 
 
    A B A B A B D 
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Table showing cell number results for MCF7 cell model at 24 hrs. 
 
 
Treatment 
 
control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Total cell number 250507.30 9609.77 211684.20 32534.48 246017.37 29489.04 237636.53 20391.91 340886.63 25414.40 221182.13 27871.51 318000.47 45185.67 
Live cell numbers 216364.07 16707.30 192566.23 28506.76 218421.47 23217.06 208670.10 17879.77 306571.97 27599.18 183134.50 23390.85 282468.03 34087.29 
Apoptotic cell 
number 
23717.67 11387.04 11391.50 1068.31 19562.43 5275.38 21511.23 7111.63 26435.83 4152.21 28061.10 3765.39 22548.20 4646.52 
Necrotic cell 
numbers 
10425.57 2181.43 7726.47 3706.75 8033.43 2115.38 7455.17 1405.81 7878.83 2005.49 9986.50 1814.27 12984.23 6633.12 
 
Comparisons of Column Means
a
 
 Treatment 
 control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Total cell number     A B C D F  B F 
Live cell numbers     A B C D F  B F 
Apoptotic cell number        
Necrotic cell numbers        
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Table showing cell number results for MCF7 cell model at 48 hrs. 
Cell number experiment MCF7 cell model 48 hrs.  
 
Treatment 
 
control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Total cell number 302353.57 17179.11 231227.30 17489.02 292603.33 17641.71 294220.43 11772.73 359475.43 3424.97 321437.23 24100.95 395157.90 44842.96 
Live cell numbers 249450.20 8992.41 194783.20 14087.03 229105.40 9484.81 234436.17 14625.57 297432.13 7119.80 237296.40 19756.67 306846.70 37463.95 
Apoptotic cell 
number 
39763.20 7405.86 25847.13 4609.12 51715.63 10608.31 49061.10 3696.05 48761.73 4246.18 70070.30 5504.11 69058.70 3907.42 
Necrotic cell 
numbers 
13140.13 3717.57 10597.00 1732.78 11782.30 972.20 10723.17 853.40 13281.53 440.20 14070.57 1184.55 19252.57 7920.10 
 
Comparisons of Column Means
a
 
 Treatment 
 control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Total cell number B    B B A B C D F 
Live cell numbers     B C D F  A B C D F 
Apoptotic cell number   B B B A B D E A B D E 
Necrotic cell numbers        
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Table showing cell number results for MCF7 cell model at 48 hrs. 
Cell number experiment MCF7 cell model 72 hrs.  
 
Treatment 
 
control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Total cell number 362706.97 33721.44 320731.73 14603.48 406544.90 30109.14 268498.87 13584.50 519558.67 60619.59 338801.20 32127.14 390903.87 14674.72 
Live cell numbers 334375.03 33057.23 285957.50 17567.77 362757.80 34477.82 242801.07 15787.51 488513.47 62125.13 296671.63 29766.71 357767.50 10179.01 
Apoptotic cell 
number 
19724.77 2505.02 29279.70 8214.56 36001.93 6516.10 19321.30 2947.57 23913.17 1404.66 36307.97 7805.45 26539.40 6348.80 
Necrotic cell 
numbers 
8607.13 1419.83 5494.50 1133.15 7785.20 2521.21 6376.47 1283.53 7131.97 231.72 5821.63 285.88 6597.00 466.47 
 
Comparisons of Column Means
a
 
 Treatment 
 control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Total cell number   D  A B C D F G  D 
Live cell numbers   D  A B C D F G  D 
Apoptotic cell number        
Necrotic cell numbers        
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Table Showing pSTAT3 median channel shift at 12 hr time point MCF7 cell model.  
 
 
Treatment 
 
Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median 
Channel Shift 
1081.33 35.92 1007.33 53.16 829.00 222.54 948.00 142.52 1491.33 412.54 1579.67 146.65 1324.33 187.40 
 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift     C C D  
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
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Table Showing pSTAT3 median channel shift at 24 hr time point MCF7 cell model.  
 
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
1791.00 198.20 1689.67 590.14 1719.33 569.83 1429.00 237.99 1739.00 371.69 2165.33 185.77 1827.00 229.97 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift        
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
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Table Showing pSTAT3 median channel shift at 48 hr time point MCF7 cell model.  
 
 
48 hr median channel shift.  
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
327.00 169.68 824.00 103.32 525.00 238.70 1227.67 170.50 1669.33 420.64 1968.67 295.06 1558.67 163.40 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift    A A B C A B C D A C 
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
. 
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Table Showing pSTAT3 median channel shift at 72 hr time point MCF7 cell model.  
 
  
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
199.00 90.93 1503.33 211.52 1368.67 133.72 1271.67 191.28 928.33 203.04 1432.33 336.85 1544.67 311.07 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift  A A A A A A 
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
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SKBr3 Results 
Table showing Cell cycle results of SKBr3 cell model 24 hrs. 
 
 treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
G1 % 76.80 4.94 73.06 3.64 71.09 3.82 76.72 2.75 73.86 3.29 80.53 3.98 82.34 2.54 
S % 15.81 3.85 14.58 1.56 16.50 8.26 15.01 2.58 17.32 2.37 10.64 5.00 10.74 1.67 
g2per 7.39 1.72 12.36 3.97 12.41 6.33 8.27 3.21 8.83 3.01 8.82 2.91 6.92 1.33 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
G1 %       C 
S %        
g2per        
xxvi 
 
Table showing Cell cycle results of SKBr3 cell model 48 hrs. 
 
 
 treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
G1 % 75.13 3.98 74.98 3.49 76.08 2.30 75.61 1.28 74.95 3.34 62.79 3.43 68.93 5.14 
S % 18.15 3.12 16.53 3.88 16.11 4.13 18.56 4.24 20.84 2.41 30.05 5.04 26.87 5.39 
g2per 6.72 3.17 8.48 2.18 7.81 2.00 5.84 3.86 4.22 1.11 7.17 2.55 4.20 1.58 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
G1 % F F F F F   
S %      B C  
g2per        
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each 
significant pair, the key of the smaller category appears under the category with larger mean. 
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Table showing Cell cycle results of SKBr3 cell model 72 hrs. 
 
 
 treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
G1 % 75.65 8.52 72.16 1.23 72.15 2.99 70.29 2.40 73.28 .97 66.73 2.37 64.20 .81 
S % 16.37 5.35 14.90 4.05 17.32 4.79 18.10 4.75 15.28 4.45 20.90 3.04 22.58 5.03 
g2per 7.99 3.75 12.94 2.95 10.52 2.26 11.61 3.25 11.45 4.45 12.37 2.68 13.22 4.88 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
G1 % G       
S %        
g2per        
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each 
significant pair, the key of the smaller category appears under the category with larger mean. 
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Table showing Cell number results of SKBr3 cell model 24 hrs. 
 
 
Treatment 
 
control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Total cell number 56248.86 3444.04 66674.99 8420.38 50226.10 3606.74 69801.20 18321.43 71441.13 17146.10 83110.74 8774.53 89106.84 9511.83 
Live cell numbers 34344.13 2107.95 45619.15 1000.61 25876.87 3967.23 46946.58 13185.64 45574.93 21099.68 56487.98 9281.08 69804.20 8891.96 
Apoptotic cell 
number 
4427.36 507.13 7761.66 7062.48 8471.04 3230.62 11949.05 11134.96 13976.91 8383.77 13956.02 9820.20 6580.49 827.29 
Necrotic cell 
numbers 
17477.37 5443.51 13294.18 2608.79 15878.19 1972.48 10905.57 2926.49 11889.29 2685.08 12666.75 2416.87 12722.16 943.98 
 
Comparisons of Column Means
a
 
 Treatment 
 control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Total cell number       C 
Live cell numbers       A C 
Apoptotic cell number        
Necrotic cell numbers        
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Table showing Cell number results of SKBr3 cell model 48 hrs. 
 
 
Treatment 
 
control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Total cell number 78402.38 22123.94 101230.00 22694.97 81870.08 12245.07 86239.26 3400.86 86125.53 14226.44 80602.23 2389.74 105195.51 17858.58 
Live cell numbers 46320.63 10940.14 67113.66 11801.91 51691.18 11979.73 62561.31 5796.85 62130.96 14181.12 55666.12 2643.13 80864.52 11887.86 
Apoptotic cell 
number 
21166.50 9817.26 20540.11 8775.43 17776.25 4904.28 14740.21 5083.95 16601.96 641.42 11988.40 2509.13 8269.80 2591.63 
Necrotic cell 
numbers 
10915.25 1605.86 13576.23 2837.98 12402.65 1817.04 8937.74 384.71 7392.60 725.93 12947.71 4347.79 16061.18 4921.03 
 
Comparisons of Column Means
a
 
 Treatment 
 control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Total cell number        
Live cell numbers       A 
Apoptotic cell number        
Necrotic cell numbers        
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Table showing Cell number results of SKBr3 cell model 72 hrs. 
 
Treatment 
 
control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Total cell number 53498.71 5678.67 67042.75 3159.85 48724.23 5880.16 62576.76 3522.12 85311.62 12330.50 95236.67 8728.56 99208.98 10007.34 
Live cell numbers 44885.28 4016.57 55357.45 4759.58 35323.70 4778.49 50958.14 2549.43 61657.69 14894.20 77514.55 9117.51 81494.60 9310.35 
Apoptotic cell 
number 
2779.83 379.61 4679.78 3037.71 6938.54 1120.13 4341.51 822.05 14599.80 3651.71 7475.17 1000.08 5642.46 809.49 
Necrotic cell 
numbers 
5833.60 2538.72 7005.53 604.77 6461.99 1270.99 7277.11 569.38 9054.13 667.33 10246.95 2908.28 12071.93 2166.27 
 
Comparisons of Column Means
a
 
 Treatment 
 control ETOH HCl ETOH&HCl E2 EGF E2&EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Total cell number     A C A B C D A B C D 
Live cell numbers     C A C D A B C D 
Apoptotic cell number     A B C D F G   
Necrotic cell numbers       A C 
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Table showing SKBr3 cell model pSTAT3 induction median channel shift 12 hr.  
 
 
SKBr3 pSTAT median channel shift 12 hr 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
1063.00 65.82 879.00 53.51 798.33 20.55 714.33 94.94 751.67 133.81 904.67 166.49 822.33 146.77 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift D       
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
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Table showing SKBr3 cell model pSTAT3 induction median channel shift 24 hr.  
 
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
1239.67 242.92 1267.67 255.63 1153.67 10.97 878.33 150.04 1661.33 204.71 1806.00 15.62 1448.67 72.70 
 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift     C D A B C D D 
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
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Table showing SKBr3 cell model pSTAT3 induction median channel shift 48 hr.  
 
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
817.33 181.51 1048.67 65.90 967.33 35.53 994.00 203.03 1136.33 95.09 1203.33 167.16 910.00 162.08 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift        
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
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Table showing SKBr3 cell model pSTAT3 induction median channel shift 72 hr.  
 
SKBr3 pSTAT median channel shift 72 hr 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 
Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation Mean 
Standard 
Deviation 
Median Channel 
Shift 
494.00 38.11 606.00 50.32 569.33 170.37 541.00 138.43 513.67 40.46 961.33 71.84 946.00 148.16 
 
 
Comparisons of Column Means
a
 
 Treatment 
 Control ETOH HCl ETOH & HCl E2 EGF E2 & EGF 
 (A) (B) (C) (D) (E) (F) (G) 
Median Channel Shift      A B C D E A B C D E 
Results are based on two-sided tests assuming equal variances with significance level 0.05. For each significant pair, 
the key of the smaller category appears under the category with larger mean. 
a. Tests are adjusted for all pairwise comparisons within a row of each innermost subtable using the Bonferroni 
correction. 
 
 
